User Image Cart Icon 0 Search Image
  • Home > Blog > Rapamycin (Mtor Inhibition)

Rapamycin (Mtor Inhibition)

  1. Mechanism of action of the immunosuppressant Rapamycin
  2. Rapamycin in transplantation: a review of the evidence
  3. Rapamycin: Clinical Results and Future Opportunities1
  4. Targets for cell cycle arrest by the immunosuppressant Rapamycin in yeast
  5. The target of Rapamycin (TOR) proteins
  6. Solubilization of Rapamycin
  7. Rapamune (Sirolimus, Rapamycin): an overview and mechanism of action.
  8. Total synthesis of Rapamycin
  9. Activity of Rapamycin (AY-22, 989) against transplanted tumors
  10. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
  11. SDZ RAD, a new Rapamycin derivative: pharmacological properties in vitro and in vivo
  12. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase
  13. Regulation of cellular growth by the Drosophila target of Rapamycin dTOR
  14. Bench to bedside: the development of Rapamycin and its application to stent restenosis
  15. Rapamycin (AY-22, 989), a new antifungal antibiotic II. Fermentation, isolation and characterization
  16. Two TOR complexes, only one of which is Rapamycin sensitive, have distinct roles in cell growth control
  17. Rapamycin (AY-22, 989), a new antifungal antibiotic I. Taxonomy of the producing streptomycete and isolation of the active principle
  18. The Rapamycin-sensitive signal transduction pathway as a target for cancer therapy
  19. A mammalian protein targeted by G1-arresting Rapamycin–receptor complex
  20. Rapamycin inhibits vascular smooth muscle cell migration.
  21. TOR mutations confer Rapamycin resistance by preventing interaction with FKBP12-Rapamycin
  22. Isolation of a protein target of the FKBP12-Rapamycin complex in mammalian cells
  23. Rapamycin selectively represses translation of the” polypyrimidine tract” mRNA family
  24. Phosphorylation of the translational repressor PHAS-I by the mammalian target of Rapamycin
  25. Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update.
  26. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
  27. Elucidating TOR signaling and Rapamycin action: lessons from Saccharomyces cerevisiae
  28. Biosynthesis of erythromycin and Rapamycin
  29. Blood distribution of Rapamycin.
  30. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of Rapamycin
  31. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of Rapamycin
  32. Studies on the mechanism of resistance to Rapamycin in human cancer cells
  33. A Rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus
  34. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations.
  35. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1
  36. Structure of the FKBP12-Rapamycin complex interacting with binding domain of human FRAP
  37. Expression and disruption of the Arabidopsis TOR (target of Rapamycin) gene
  38. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro
  39. The biosynthetic gene cluster for the polyketide immunosuppressant Rapamycin
  40. Mammalian target of Rapamycin (mTOR): pro-and anti-apoptotic
  41. SDZ RAD, a new Rapamycin derivative: synergism with cyclosporine
  42. Rapamycin (AY-22, 989), A NEW ANTIFUNGAL ANTIBIOTIC III. IN VITRO AND IN VIVO EVALUATION
  43. RAFT1: a mammalian protein that binds to FKBP12 in a Rapamycin-dependent fashion and is homologous to yeast TORs
  44. p53/p21CIP1 cooperate in enforcing Rapamycin-induced G1 arrest and determine the cellular response to Rapamycin
  45. Raptor, a binding partner of target of Rapamycin (TOR), mediates TOR action
  46. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase
  47. The principal target of Rapamycin‐induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain.
  48. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases
  49. The immunosuppressant Rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation
  50. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells
  51. TOR kinase domains are required for two distinct functions, only one of which is inhibited by Rapamycin
  52. inhibition of cell cycle progression by Rapamycin induces T cell clonal anergy even in the presence of costimulation
  53. Revised NMR assignments for Rapamycin
  54. Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation.
  55. Absorption and intestinal metabolism of SDZ-RAD and Rapamycin in rats
  56. Rapamycin resistance tied to defective regulation of p27Kip1.
  57. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/Rapamycin complex
  58. Targeted disruption of p70s6k defines its role in protein synthesis and Rapamycin sensitivity
  59. Target of Rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression
  60. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus
  61. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins
  62. SIROLIMUS (Rapamycin)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATION: Similar Efficacy and Different Toxicity Compared with Cyclosporine: 1, 2
  63. Inhibitors of mammalian target of Rapamycin as novel antitumor agents: from bench to clinic
  64. Cytoplasmic–nuclear shuttling of FKBP12-Rapamycin-associated protein is involved in Rapamycin-sensitive signaling and translation initiation
  65. A protein kinase B-dependent and Rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification
  66. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability
  67. A chemical genomics approach toward understanding the global functions of the target of Rapamycin protein (TOR)
  68. Mechanism of metabolic control: target of Rapamycin signaling links nitrogen quality to the activity of the Rtg1 and Rtg3 transcription factors
  69. Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a Rapamycin-sensitive pathway
  70. inhibition of human B lymphocyte cell cycle progression and differentiation by Rapamycin
  71. Mammalian target of Rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on …
  72. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or Rapamycin.
  73. Cyclosporin A, FK506 and Rapamycin: more than just immunosuppression
  74. Rapamycin inhibits human adipocyte differentiation in primary culture
  75. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells
  76. inhibition of T and B lymphocyte proliferation by Rapamycin.
  77. Target of Rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation
  78. Partitioning the transcriptional program induced by Rapamycin among the effectors of the Tor proteins
  79. Rapamycin (AY-22, 989), A NEW ANTIFUNGAL ANTIBIOTIC IV. MECHANISM OF ACTION
  80. Control of translation by the target of Rapamycin proteins
  81. Control of Ser2448 phosphorylation in the mammalian target of Rapamycin by insulin and skeletal muscle load
  82. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of Rapamycin mediated by a protein kinase B signaling pathway
  83. Serum‐stimulated, Rapamycin‐sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI
  84. Rapamune®(RAPA, Rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle …
  85. Regulation of Ribosome Biogenesis by the Rapamycin-sensitive TOR-signaling Pathway in Saccharomyces cerevisiae
  86. Enhancement of human platelet aggregation and secretion induced by Rapamycin.
  87. A Rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1
  88. Biochemical correlates of mTOR inhibition by the Rapamycin ester CCI-779 and tumor growth inhibition
  89. The mammalian target of Rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism
  90. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via Rapamycin (mTOR)‐dependent signaling
  91. Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites
  92. Immunopurified mammalian target of Rapamycin phosphorylates and activates p70 S6 kinase α in vitro
  93. The principal Rapamycin-sensitive p70 (s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by Rapamycin-insensitive kinase kinases.
  94. Direct inhibition of the signaling functions of the mammalian target of Rapamycin by the phosphoinositide 3‐kinase inhibitors, wortmannin and LY294002.
  95. The Rapamycin-binding domain governs substrate selectivity by the mammalian target of Rapamycin
  96. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells
  97. Interaction of RAFT1 with gephyrin required for Rapamycin-sensitive signaling
  98. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells
  99. Suppression of B cell activation by cyclosporin A, FK506 and Rapamycin
  100. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins
  101. Rapamycin and FK506 binding proteins (immunophilins)
  102. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis
  103. On the chemistry and high field nuclear magnetic resonance spectroscopy of Rapamycin
  104. Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and Rapamycin
  105. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, Rapamycin and cyclosporin A
  106. Activated mammalian target of Rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors
  107. inhibition of the mammalian target of Rapamycin sensitizes U87 xenografts to fractionated radiation therapy
  108. Atomic structure of the Rapamycin human immunophilin FKBP-12 complex
  109. The FKBP12-Rapamycin-binding domain is required for FKBP12-Rapamycin-associated protein kinase activity and G1 progression
  110. A novel pathway regulating the mammalian target of Rapamycin (mTOR) signaling
  111. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the Rapamycin target mTOR
  112. Mammalian target of Rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
  113. Rapamycin: a bone sparing immunosuppressant?
  114. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of Rapamycin
  115. Mechanism of action of Rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells
  116. Preclinical evaluation of a new potent immunosuppressive agent, Rapamycin.
  117. Early clinical experience with a novel Rapamycin derivative
  118. Antitumor activity of the Rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination …
  119. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of Rapamycin (mTOR) signaling
  120. Total synthesis of Rapamycin and demethoxyRapamycin
  121. Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway
  122. Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and Rapamycin in rat adipocytes
  123. Synergistic interactions of cyclosporine and Rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro.
  124. Interaction between FKBP12-Rapamycin and TOR involves a conserved serine residue.
  125. Comparison of acute Rapamycin nephrotoxicity with cyclosporine and FK506
  126. Refined structure of the FKBP12–Rapamycin–FRB ternary complex at 2.2 Å resolution
  127. Immunosuppressants FK506 and Rapamycin function as reversal agents of the multidrug resistance phenotype
  128. Regulation of the cell integrity pathway by Rapamycin-sensitive TOR function in budding yeast
  129. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells
  130. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease1
  131. Hyperlipidemia in renal transplant recipients treated with sirolimus (Rapamycin)
  132. Effects of Rapamycin on Ryanodine Receptor/Ca2+-Release Channels From Cardiac Muscle
  133. Conversion to Rapamycin immunosuppression in renal transplant recipients: report of an initial Experience1
  134. Global and specific translational control by Rapamycin in T cells uncovered by microarrays and proteomics
  135. Synergistic effects of cyclosporine and Rapamycin in a chronic nephrotoxicity model1
  136. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells
  137. Total synthesis of (-)-Rapamycin using an Evans-Tishchenko fragment coupling
  138. FKBP12-Rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions
  139. Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein.
  140. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle
  141. FKBP12-Rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction
  142. Modulation of transcription of rRNA genes by Rapamycin
  143. The effect of Rapamycin on kidney function in the Sprague-Dawley rat.
  144. Organization of the biosynthetic gene cluster for Rapamycin in Streptomyces hygroscopicus: analysis of the enzymatic domains in the modular polyketide synthase
  145. Growth-dependent translation of IGF-II mRNA by a Rapamycin-sensitive pathway
  146. Effects of Rapamycin in experimental organ allografting.
  147. Metabolic and autocrine regulation of the mammalian target of Rapamycin by pancreatic β-cells
  148. Predominant nuclear localization of mammalian target of Rapamycin in normal and malignant cells in culture
  149. Effect of nitrogen source on biosynthesis of Rapamycin by Streptomyces hygroscopicus
  150. Rapamycin‐sensitive phase of 3T3‐L1 preadipocyte differentiation after clonal expansion
  151. The mammalian target of Rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus
  152. Rapamycin eluting stent: the onset of a new era in interventional cardiology
  153. Efficacy of sirolimus (Rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled …
  154. B cell receptor-associated protein α4 displays Rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A
  155. The immunosuppressant Rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites
  156. Regulation of translational effectors by amino acid and mammalian target of Rapamycin signaling pathways: possible involvement of autophagy in cultured …
  157. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and Rapamycin.
  158. … vascular smooth muscle cell DNA synthesis. inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of Rapamycin by …
  159. Mammalian target of Rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and …
  160. Influence of cyclosporin, tacrolimus and Rapamycin on renal function and arterial hypertension after renal transplantation
  161. Antifungal activities of Rapamycin and its derivatives, prolylRapamycin, 32-desmethylRapamycin, and 32-desmethoxyRapamycin
  162. Rapamycin inhibits macropinocytosis and mannose receptor–mediated endocytosis by bone marrow–derived dendritic cells
  163. Pharmacokinetics of Rapamycin.
  164. The immunosuppressant Rapamycin represses human immunodeficiency virus type 1 replication
  165. Treatment with Rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement.
  166. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured …
  167. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model
  168. Total synthesis of Rapamycin via a novel titanium-mediated aldol macrocyclization reaction
  169. Cyclosporin A, FK-506, and Rapamycin: pharmacologic probes of lymphocyte signal transduction
  170. Enhancement of the antifungal activity of Rapamycin by the coproduced elaiophylin and nigericin
  171. … X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and Rapamycin
  172. Mammalian target of Rapamycin-dependent phosphorylation of PHAS-I in four (S/T) P sites detected by phospho-specific antibodies
  173. Rapamycin induces apoptosis in monocyte-and CD34-derived dendritic cells but not in monocytes and macrophages
  174. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple Rapamycin-sensitive steps
  175. Clinical development of mammalian target of Rapamycin inhibitors
  176. Identification of an 11-kDa FKBP12-Rapamycin-binding domain within the 289-kDa FKBP12-Rapamycin-associated protein and characterization of a critical serine …
  177. COMBINED COSTIMULATION BLOCKADE PLUS Rapamycin BUT NOT CYCLOSPORINE PRODUCES PERMANENT ENGRAFTMENT1
  178. Effect of amino acids on Rapamycin biosynthesis by Streptomyces hygroscopicus
  179. Rapamycin antifungal action is mediated via conserved complexes with fkbp12 and tor kinase homologs incryptococcus neoformans
  180. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes.
  181. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate Rapamycin cytotoxicity.
  182. … autophagy and activation of lysosome-dependent proteolysis in C2C12 myotubes through a mammalian target of Rapamycin-independent signaling pathway
  183. Control of PHAS-I by insulin in 3T3-L1 adipocytes: synthesis, degradation, and phosphorylation by a Rapamycin-sensitive and mitogen-activated protein …
  184. Stress-activated protein kinase-2/p38 and a Rapamycin-sensitive pathway are required for C2C12 myogenesis
  185. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR
  186. Rapamycin (sirolimus, rapamune).
  187. Organisation of the biosynthetic gene cluster for Rapamycin in Streptomyces hygroscopicus: analysis of genes flanking the polyketide synthase
  188. Rapamycin selectively inhibits angiotensin II–induced increase in protein synthesis in cardiac myocytes in vitro: potential role of 70-kD S6 kinase in angiotensin II …
  189. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of Rapamycin-dependent signaling pathway
  190. Resistance to Rapamycin: a novel anticancer drug
  191. Carbon source nutrition of Rapamycin biosynthesis in Streptomyces hygroscopicus
  192. Osteoblastic differentiation is enhanced by Rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells
  193. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of Rapamycin phosphorylation site
  194. The Rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats
  195. Regulation of translation elongation factor‐2 by insulin via a Rapamycin‐sensitive signalling pathway.
  196. The FKBP12‐Rapamycin‐associated protein (FRAP) is a CLIP‐170 kinase
  197. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor
  198. Molecular characterization of a plant FKBP12 that does not mediate action of FK506 and Rapamycin
  199. Synergistic effect of Rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis.
  200. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver
  201. Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of Rapamycin (mTOR)-mediated downstream signaling
  202. Evidence that phosphorylation of human Upfl protein varies with intracellular location and is mediated by a wortmannin-sensitive and Rapamycin-sensitive PI 3-kinase …
  203. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of Rapamycin sensitive signaling
  204. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, Rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase …
  205. cAMP-and Rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells
  206. A Rapamycin-selective 25-kDa immunophilin
  207. FKBP12‐Rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol‐4 kinase activity.
  208. Pharmacokinetics and safety of single oral doses of sirolimus (Rapamycin) in healthy male volunteers
  209. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and Rapamycin in 3T3-L1 adipocytes: evidence for the involvement …
  210. The TOR (target of Rapamycin) signal transduction pathway regulates the stability of translation initiation factor eIF4G in the yeast Saccharomyces cerevisiae
  211. Heat capacity changes and hydrophobic interactions in the binding of FK506 and Rapamycin to the FK506 binding protein
  212. Attenuation of mammalian target of Rapamycin activity by increased cAMP in 3T3-L1 adipocytes
  213. Rapamycin specifically interferes with the developmental response of fission yeast to starvation.
  214. CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant Rapamycin.
  215. Incorporation of acetate, propionate, and methionine into Rapamycin by Streptomyces hygroscopicus
  216. … Virus 1 Envelope Glycoprotein Complex-induced Apoptosis Involves Mammalian Target of Rapamycin/FKBP12-Rapamycin–associated Protein–mediated p53 …
  217. The efficacy and toxicity of Rapamycin in murine islet transplantation. In vitro and in vivo studies.
  218. Rapamycin partially prevents insulin resistance induced by chronic insulin treatment
  219. Rapamycin potentiates transforming growth factor β-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells
  220. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (Rapamycin), mycophenolate mofetil and leflunomide
  221. Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an atypical PKC complex
  222. Prolongation of renal allograft survival in a large animal model by oral Rapamycin monotherapy.
  223. The effect of a high‐fat meal on the oral bioavailability of the immunosuppressant sirolimus (Rapamycin)
  224. Intracellular sensing of amino acids in Xenopus laevis oocytes stimulates p70 S6 kinase in a target of Rapamycin-dependent manner
  225. SIROLIMUS (Rapamycin) HALTS AND REVERSES PROGRESSION OF ALLOGRAFT VASCULAR DISEASE IN NON-HUMAN PRIMATES1
  226. The isolation, synthesis and characterization of an isomeric form of Rapamycin
  227. Effects of cyclosporin, FK506, and Rapamycin on graft-vessel disease
  228. … translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin: role of mammalian target of Rapamycin, protein kinase b, and …
  229. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.
  230. A Unified Total Synthesis of the Immunomodulators (−)-Rapamycin and (−)-27-DemethoxyRapamycin: Assembly of the Common C (1− 20) Perimeter and Final …
  231. Mechanism of the combination immunosuppressive effects of Rapamycin with either cyclosporine or tacrolimus
  232. The antimicrobial activities of cyclosporine, FK506, and Rapamycin
  233. Molecular cloning of a membrane-associated human FK506-and Rapamycin-binding protein, FKBP-13.
  234. Contrasting impacts of immunosuppressive agents (Rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during …
  235. … new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12: prevention by the immunosuppressant drugs FK506 and Rapamycin
  236. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and Rapamycin in man and rat.
  237. Rapamycin Inhibits α1-Adrenergic Receptor–Stimulated Cardiac Myocyte Hypertrophy but Not Activation of Hypertrophy-Associated Genes: Evidence for Involvement …
  238. FK506 and Rapamycin: novel pharmacological probes of the immune response
  239. Target of Rapamycin
  240. Mutagenesis of the Rapamycin producer Streptomyces hygroscopicus FC904
  241. The effect of Rapamycin on T cell development in mice
  242. The effects of Rapamycin in murine peripheral nerve isografts and allografts
  243. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to Rapamycin
  244. A putative sirolimus (Rapamycin) effector protein
  245. Rapamycin: In Vitro Profile of a New Immunosuppressive Macrolide.
  246. The Upregulation of p27Kip1 by Rapamycin Results in G1 Arrest in Exponentially Growing T-Cell Lines
  247. Generation of novel Rapamycin structures by microbial manipulations
  248. Consensus guidelines for therapeutic drug monitoring of Rapamycin: report of the consensus panel
  249. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and Rapamycin on coronary endothelial function
  250. Convergence of the target of Rapamycin and the Snf1 protein kinase pathways in the regulation of the subcellular localization of Msn2, a transcriptional …
  251. FKBP-Rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line.
  252. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral Rapamycin
  253. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by Rapamycin-insensitive pathways in skeletal muscle …
  254. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and Rapamycin
  255. Studies on the chemistry of Rapamycin: novel transformations under Lewis-acid catalysis
  256. Rapamycin on trial
  257. Effects of Rapamycin on cultured hepatocyte proliferation and gene expression
  258. Therapeutic monitoring of Rapamycin: a new immunosuppressive drug.
  259. Chlamydia trachomatis Mip‐like protein has peptidylprolyl cis/trans isomerase activity that is inhibited by FK506 and Rapamycin and is implicated in initiation of …
  260. MID1 and MID2 homo-and heterodimerise to tether the Rapamycin-sensitive PP2A regulatory subunit, alpha 4, to microtubules: implications for the clinical …
  261. Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells.
  262. Rapamycin prevents the onset of insulin‐dependent diabetes mellitus (IDDM) in NOD mice
  263. Sensitive and specific quantification of sirolimus (Rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry
  264. … LYMPHOCYTES MAY DISTINGUISH CYCLOSPORINE EFFECT IN RENAL TRANSPLANT RECIPIENTS RECEIVING A CYCLOSPORINE+ Rapamycin REGIMEN1
  265. Rapamycin, a potential disease-modifying antiarthritic drug.
  266. The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a Rapamycin-sensitive point immediately …
  267. Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of Rapamycin
  268. Treatment of autoimmune uveoretinitis in the rat with Rapamycin, an inhibitor of lymphocyte growth factor signal transduction
  269. Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat.
  270. lnterleukin-2-mediated elimination of the p27 Kipl cyclin-dependent kinase inhibitor prevented by Rapamycin
  271. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and Rapamycin
  272. Ultraviolet-induced phosphorylation of p70S6K at Thr389 and Thr421/Ser424 involves hydrogen peroxide and mammalian target of Rapamycin but not Akt and atypical …
  273. Toxicity of Rapamycin–a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat.
  274. L-Asparaginase inhibits the Rapamycin-targeted signaling pathway
  275. The Rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity
  276. The Target of Rapamycin Signaling Pathway Regulates mRNA Turnover in the Yeast Saccharomyces cerevisiae
  277. Protein kinase activity and identification of a toxic effector domain of the target of Rapamycin TOR proteins in yeast
  278. inhibition of in vitro immunoglobulin production by Rapamycin.
  279. Rapamycin inhibits corneal allograft rejection and neovascularization
  280. Base catalyzed degradations of Rapamycin
  281. Rapamycin inhibits the generation of graft-versus-host disease-and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic …
  282. The immunosuppressive macrolides FK-506 and Rapamycin act as reciprocal antagonists in murine T cells.
  283. Rapamycin: FK506’s fraternal twin or distant cousin?
  284. Substrate specificity for the human rotamase FKBP: a view of FK506 and Rapamycin as leucine-(twisted amide)-proline mimics
  285. Structure-activity studies of Rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP …
  286. Rapamycin reduces hybridoma cell death and enhances monoclonal antibody production
  287. A novel FK506-and Rapamycin-binding protein (FPR3 gene product) in the yeast Saccharomyces cerevisiae is a proline rotamase localized to the nucleolus.
  288. p70s6k integrates phosphatidylinositol 3-kinase and Rapamycin-regulated signals for E2F regulation in T lymphocytes
  289. DIFFERENTIAL EFFECTS OF CYCLOSPORINE A, METHYLPREDNISOLONE, MYCOPHENOLATE, AND Rapamycin ON CD154 INDUCTION AND REQUIREMENT …
  290. Target of Rapamycin proteins and their kinase activities are required for meiosis
  291. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line.
  292. inhibition by Rapamycin of PDGF-and bFGF-induced human tenon fibroblast proliferation in vitro.
  293. New process control strategy used in a Rapamycin fermentation
  294. Tacrolimus-Rapamycin combination therapy for experimental autoimmune uveoretinitis
  295. Serotonin Activates S6 Kinase in a Rapamycin-Sensitive Manner inAplysia Synaptosomes
  296. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of Rapamycin in mitogen-stimulated and transformed cells
  297. Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin-and Rapamycin-sensitive pathways
  298. Phosphate, ammonium, magnesium and iron nutrition of Streptomyces hygroscopicus with respect to Rapamycin biosynthesis
  299. Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and Rapamycin sensitivity domains.
  300. Growth of Streptomyces hygroscopicus in rotating-wall bioreactor under simulated microgravity inhibits Rapamycin production
  301. Structure of Rapamycin: an NMR and molecular‐dynamics investigation
  302. 40-O-(2-Hydroxyethyl)-Rapamycin Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in Rats
  303. The Drosophila p70s6k homolog exhibits conserved regulatory elements and Rapamycin sensitivity
  304. Structure-activity studies of nonmacrocyclic Rapamycin derivatives
  305. Gene disruption and replacement in the Rapamycin-producing Streptomyces hygroscopicus strain ATCC 29253
  306. Production of synergistic but nonidentical mechanisms of immunosuppression by Rapamycin and cyclosporine.
  307. A Unified Total Synthesis of the Immunomodulators (−)-Rapamycin and (−)-27-DemethoxyRapamycin: Construction of the C (21− 42) Perimeters
  308. Design and Synthesis of a Rapamycin-based high affinity binding FKBP12 ligand
  309. Synthetic investigations of Rapamycin. 2. Synthesis of a C (22)-C (42) fragment
  310. The immunosuppressant Rapamycin, alone or with transforming growth factor-b, enhances osteoclast differentiation of RAW264. 7 monocyte-macrophage cells in the …
  311. Origin and true nature of the starter unit for the Rapamycin polyketide synthase
  312. … , p70 S6 kinase and glycogen synthase kinase-3 activity in L6 muscle cells: evidence for the involvement of the mammalian target of Rapamycin (mTOR) pathway in the …
  313. Impaired phosphate handling of renal allografts is aggravated under Rapamycin‐based immunosuppression
  314. … in stereochemical communication: a strategy for the stereospecific synthesis and stabilization of the triene substructure of Rapamycin through sulfone substitution
  315. TACROLIMUS (FK506) AND SIROLIMUS (Rapamycin) IN COMBINATION ARE NOT ANTAGONISTIC BUT PRODUCE EXTENDED GRAFT SURVIVAL IN CARDIAC …
  316. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and Rapamycin.
  317. Raf/MAPK and Rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells
  318. Rapamycin INDUCES TRANSFORMING GROWTH FACTOR-β PRODUCTION BY LYMPHOCYTES1
  319. Insulin release and suppression by tacrolimus, Rapamycin and cyclosporin A are through regulation of the ATP‐sensitive potassium channel
  320. … kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by Rapamycin: evidence that wortmannin …
  321. The Pipecolate‐Incorporating Enzyme for the Biosynthesis of the Immunosuppressant Rapamycin—Nucleotide Sequence Analysis, Disruption and Heterologous …
  322. Graft-versus-host disease prevention by Rapamycin: cellular mechanisms
  323. Regulation of both glycogen synthase and PHAS-I by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and Rapamycin …
  324. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography–electrospray tandem mass spectrometry
  325. Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and Rapamycin.
  326. Isolation of two immunosuppressive metabolites after in vitro metabolism of Rapamycin.
  327. p-Glycoprotein-mediated transport of a fluorescent Rapamycin derivative in renal proximal tubule
  328. Expression, enzyme activity, and subcellular localization of mammalian target of Rapamycin in insulin-responsive cells
  329. Insulin regulation of glucose-6-phosphate dehydrogenase gene expression is Rapamycin-sensitive and requires phosphatidylinositol 3-kinase
  330. Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival
  331. Molecular cloning of a 25-kDa high affinity Rapamycin binding protein, FKBP25.
  332. The immediate precursor of the nitrogen-containing ring of Rapamycin is free pipecolic acid
  333. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin)
  334. A novel ring contraction of Rapamycin
  335. Prolongation of canine pancreatic islet allograft survival with combined Rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related.
  336. inhibition of liver, kidney, and intestine regeneration by Rapamycin
  337. Ig receptor binding protein 1 (α4) is associated with a Rapamycin-sensitive signal transduction in lymphocytes through direct binding to the catalytic subunit of protein …
  338. … of the International Society for Heart and Lung Transplantation working formulation for heart transplant biopsy specimens. Rapamycin Cardiac Rejection Treatment …
  339. Effect of Rapamycin on the cyclosporin A–resistant CD28-mediated costimulatory pathway
  340. Lack of change of cancellous bone volume with short-term use of the new immunosuppressant Rapamycin in rats
  341. Studies towards the total synthesis of Rapamycin: A convergent and stereoselective synthesis of the C22 C32 carbon framework
  342. Rapamycin and wortmannin enhance replication of a defective encephalomyocarditis virus
  343. … factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of Rapamycin
  344. … acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by Rapamycin, and is independent …
  345. Effect of p27 deficiency and Rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model
  346. The effect of dexamethasone, cyclosporine, and Rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and …
  347. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect
  348. Complete amino acid sequence of the FK506 and Rapamycin binding protein, FKBP, isolated from calf thymus
  349. Effects of Rapamycin, cyclosporin A, and dexamethasone on interleukin 5‐induced eosinophil degranulation and prolonged survival
  350. Microbial conversion of Rapamycin
  351. Therapeutic blood levels of sirolimus (Rapamycin) in the allografted rat
  352. Effect of Rapamycin on the expression of the IL‐2 receptor (CD25)
  353. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts.
  354. β-Agonists regulate Na, K-ATPase via novel MAPK/ERK and Rapamycin-sensitive pathways
  355. Assessment of cell‐signaling pathways in the regulation of mammalian target of Rapamycin (mTOR) by amino acids in rat adipocytes
  356. Beneficial effects of cyclosporine and Rapamycin in small bowel ischemic injury
  357. Routine clinical monitoring of sirolimus (Rapamycin) whole-blood concentrations by HPLC with ultraviolet detection
  358. inhibition by Rapamycin of P‐glycoprotein 170‐mediated export from normal lymphocytes
  359. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood Rapamycin concentrations
  360. THE METABOLIC IMPACT OF Rapamycin (SIROLIMUS) IN CHRONIC CANINE ISLET GRAFT RECIPIENTS1
  361. Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes.
  362. Dominant mutations confer resistance to the immunosuppressant, Rapamycin, in variants of a T cell lymphoma
  363. Effects of cyclosporine and Rapamycin on immunoglobulin production by preactivated human B cells
  364. Facile synthesis of the “tricarbonyl” subunit in the immunosuppressant Rapamycin
  365. Effects of FK506 and Rapamycin on excitation‐contraction coupling in skeletal muscle fibres of the rat.
  366. Involvement of a Rapamycin-sensitive pathway in CD40-mediated activation of murine B cells in vitro
  367. Degradation of Rapamycin: synthesis of a Rapamycin derived fragment containing the tricarbonyl and triene sectors
  368. Calcineurin inhibitor‐induced chronic nephrotoxicity in liver transplant patients is reversible using Rapamycin as the primary immunosuppressive agent
  369. EFFECT OF TACROLIMUS (FK506) AND SIROLIMUS (Rapamycin) MONO-AND COMBINATION THERAPY IN PROLONGATION OF RENAL ALLOGRAFT …
  370. Efficacy of Rapamycin and FK 506 in prolonging rat hind limb allograft survival.
  371. Distinct repression of translation by wortmannin and Rapamycin
  372. Evidence that Rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes.
  373. Determination of Rapamycin in whole blood by HPLC
  374. Total synthesis of Rapamycin
  375. Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition.
  376. Uncoupling p70s6 kinase activation and proliferation: Rapamycin-resistant proliferation of human CD8+ T lymphocytes
  377. Exogenous shikimic acid stimulates Rapamycin biosynthesis inStreptomyces hygroscopicus
  378. Ryanodine receptors from rabbit skeletal muscle are reversibly activated by Rapamycin
  379. Synthetic studies toward Rapamycin: a solution to a problem in chirality merger through use of the Ireland reaction
  380. The nature of the starter unit for the Rapamycin polyketide synthase
  381. Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (Rapamycin)
  382. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a Rapamycin derivative
  383. USE OF ANTI-CD25 MONOCLONAL ANTIBODY IN COMBINATION WITH Rapamycin TO ELIMINATE CYCLOSPORINE TREATMENT DURING THE INDUCTION …
  384. Loss of ypk1 function causes Rapamycin sensitivity, inhibition of translation initiation and synthetic lethality in 14-3-3-deficient yeast
  385. Acute effects of Rapamycin on glomerular dynamics: a micropuncture study in the rat
  386. Cyclosporine, FK506, and Rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells.
  387. The cyclohexane moiety of Rapamycin is derived from shikimic acid in Streptomyces hygroscopicus
  388. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of Rapamycin but develop an …
  389. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with Rapamycin
  390. Degradative studies on the tricarbonyl containing macrolide Rapamycin
  391. The potential role of Rapamycin in pediatric transplantation as observed from adult studies
  392. Comparison of the effects of FK-506, cyclosporin A and Rapamycin on IL-2 production.
  393. Insulin-stimulated kinase from rat fat cells that phosphorylates initiation factor 4E-binding protein 1 on the Rapamycin-insensitive site (serine-111)
  394. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and Rapamycin.
  395. Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells
  396. Effect of Rapamycin on rat aortic ring vasomotion.
  397. … cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of Rapamycin
  398. Rapamycin blocks sexual development in fission yeast through inhibition of the cellular function of an FKBP12 homolog
  399. Simultaneous on-line extraction and analysis of sirolimus (Rapamycin) and ciclosporin in blood by liquid chromatography–electrospray mass spectrometry
  400. Both Rapamycin-sensitive and-insensitive pathways are involved in the phosphorylation of the initiation factor-4E-binding protein (4E-BP1) in response to insulin in rat …
  401. Compared to mycophenolate mofetil, Rapamycin induces significant changes on growth factors and growth factor receptors in the early days postkidney …
  402. Mammalian RAFT1 kinase domain provides Rapamycin-sensitive TOR function in yeast.
  403. Conversion from liquid to solid Rapamycin formulations in stable renal allograft transplant recipients
  404. Secretion of FK506/FK520 and Rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans
  405. Side effects of Rapamycin in the rat
  406. The effect of Rapamycin on single ENaC channel activity and phosphorylation in A6 cells
  407. Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries …
  408. Measurement of Rapamycin in whole blood using reverse-phase high-performance liquid chromatography.
  409. Regulation of the Rapamycin and FKBP-target 1/mammalian target of Rapamycin and cap-dependent initiation of translation by the c-Abl protein-tyrosine kinase
  410. Rapamycin stimulates viral protein synthesis and augments the shutoff of host protein synthesis upon picornavirus infection.
  411. Two discrete regions of interleukin-2 (IL2) receptor β independently mediate IL2 activation of a PD98059/Rapamycin/wortmannin-insensitive Stat5a/b serine …
  412. The tyrosine89 residue of yeast FKBP12 is required for Rapamycin binding
  413. Assignment of the human FKBP12-Rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization
  414. Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression
  415. Rapamycin: personal algorithms for use based on 250 treated renal allograft recipients.
  416. Rapamycin INHIBITS DEVELOPMENT OF OBLITERATIVE AIRWAY DISEASE IN A MURINE HETEROTOPIC AIRWAY TRANSPLANT MODEL1
  417. The immunosuppressant Rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo
  418. Estrogen and Rapamycin effects on cell cycle progression in T47D breast cancer cells
  419. The effects of the immunosuppressant Rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast
  420. Deletion of rapQONML from the Rapamycin gene cluster of Streptomyces hygroscopicus gives production of the 16-O-desmethyl-27-desmethoxy analog
  421. Rapamycin may prevent post-transplant lymphoma
  422. … π-face selectivity in anti aldol reactions of E-enol borinates from chiral alkoxymethyl ketones: stereocontrolled synthesis of a C24-C32 polyol subunit of Rapamycin
  423. … of MAP kinases, pp90rsk and pp70‐S6 kinases in mouse mast cells by signaling through the c‐kit receptor tyrosine kinase or FcϵRI: Rapamycin inhibits activation of …
  424. Intramolecular hydrogen transfer reactions of o-(bromophenyl) dialkylsilyl ethers. Preparation of Rapamycin-d1
  425. … 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of Rapamycin, Ly294002, and wortmannin on …
  426. Rapamycin dissociates p70S6K activation from DNA synthesis stimulated by bombesin and insulin in Swiss 3T3 cells
  427. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells
  428. Rapamycin: immunosuppression, hyporesponsiveness, and side effects in a porcine renal allograft model.
  429. Effect of cyclosporine, mycophenolic acid, and Rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study
  430. Single-channel activity of the Ca2+-dependent K+ channel is modulated by FK506 and Rapamycin
  431. Use of Rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on …
  432. Failure of Rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase
  433. Rapamycin inhibits proteasome activator expression and proteasome activity
  434. ASSOCIATION OF GLUCOCORTICOIDS AND CYCLOSPORIN A OR Rapamycin PREVENTS E-SELECTIN AND IL-8 EXPRESSION DURING LPS-AND TNFα …
  435. The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor Rapamycin
  436. Sirolimus (Rapamycin) in clinical transplantation
  437. Rapamycin inhibits didemnin B‐induced apoptosis in human HL‐60 cells: Evidence for the possible involvement of FK506‐binding protein 25
  438. Siloxanes: versatile templates for acyclic stereocontrol. Synthesis of the C27-C33 segment of Rapamycin
  439. Dose-dependent pharmacokinetics of Rapamycin-28-N,N-dimethylglycinate in the mouse
  440. Interstitial pneumonitis associated with sirolimus (Rapamycin) therapy after liver transplantation
  441. The relationship of blood concentrations of Rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model.
  442. … -severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and Rapamycin
  443. … hydration contributions to the thermodynamics of ligand binding by proteins. Enthalpy and heat capacity changes of tacrolimus and Rapamycin binding to FK506 …
  444. Selective epimerization of Rapamycin via a retroaldol/aldol mechanism mediated by titanium tetraisopropoxide
  445. inhibition of proliferation but not erythroid differentiation of J2E cells by Rapamycin
  446. The 14-3-3 proteins positively regulate Rapamycin-sensitive signaling
  447. Systemic toxicity following administration of sirolimus (formerly Rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes
  448. Oral administration of Rapamycin and cyclosporine differentially alter intestinal function in rabbits
  449. p70 S6 kinase sensitivity to Rapamycin is eliminated by amino acid substitution of Thr229.
  450. High‐Sensitivity sequencing of large proteins: Partial structure of the Rapamycin‐fkbp12 target
  451. Renal effects of Rapamycin in the spontaneously hypertensive rat
  452. Effects of immunosuppressants FK506 and Rapamycin on the heterooligomeric form of the progesterone receptor
  453. Sirolimus (Rapamycin, Rapamune®) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model: correlation with blood levels and the …
  454. The effect of Rapamycin on renal function in the rat: a comparative study with cyclosporine
  455. Efficient Removal of Pipecolinate from Rapamycin and FK506 by Reaction with n-Bu4N+ CN−
  456. Rapamycin resistance in ataxia-telangiectasia.
  457. Regulation of ribosomal S6 kinase 2 by mammalian target of Rapamycin
  458. Induction of differentiation of human myeloid leukemia cells by immunosuppressant macrolides (Rapamycin and FK506) and calcium/calmodulin-dependent kinase …
  459. Lipophilic benzamide and anilide derivatives as high-performance liquid chromatography internal standards: application to sirolimus (Rapamycin) determination
  460. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with Rapamycin
  461. … by insulin and insulin-like growth factor-I: glycogen synthase activation is antagonized by wortmannin or LY294002 but not by Rapamycin or by inhibiting …
  462. Pharmacokinetics of Rapamycin: single-dose studies in the rabbit.
  463. Preferential production of Rapamycin vs prolylRapamycin by Streptomyces hygroscopicus
  464. Successful myoblast allotransplantation in mdx mice using Rapamycin
  465. A second type-I PKS gene cluster isolated from Streptomyces hygroscopicus ATCC 29253, a Rapamycin-producing strain
  466. Pediatric utilization of Rapamycin for severe cardiac allograft rejection
  467. An application of the suárez reaction to the regiospecific and stereospecific synthesis of the C28-C42 segment of Rapamycin
  468. Immunopharmacology of Rapamycin
  469. Manipulation of the Rapamycin effector domain. selective nucleophilic substitution of the C7 methoxy group
  470. High performance liquid chromatographic isolation, spectroscopic characterization, and immunosuppressive activities of two Rapamycin degradation products
  471. Antifungal Rapamycin analogues with reduced immunosuppressive activity
  472. … localization of the human α4/IGBP1 gene, the structure of which is closely related to the yeast TAP42 protein of the Rapamycin-sensitive signal transduction pathway
  473. Antagonistic roles for CTLA-4 and the mammalian target of Rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen …
  474. inhibition by Rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC‐6 cells in culture
  475. Insulin stimulation of muscle protein synthesis in obese Zucker rats is not via a Rapamycin-sensitive pathway
  476. Stability of sirolimus (Rapamycin) in whole blood
  477. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl)Rapamycin and cyclosporine in blood with electrospray-mass spectrometric …
  478. Cytokine and alloantibody networks in long term cardiac allografts in rat recipients treated with Rapamycin.
  479. FK506 and Rapamycin modulate the functional activities of human peripheral blood eosinophils
  480. Sirolimus (Rapamycin) potentiates cyclosporine in prevention of acute lung rejection
  481. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells
  482. FAP1, a homologue of human transcription factor NF‐X1, competes with Rapamycin for binding to FKBP12 in yeast
  483. Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3’untranslated region.
  484. Effect of Rapamycin on morphological and functional parameters in the kidney of the rabbit
  485. Synthetic investigations of Rapamycin. 1. Synthesis of a C10-C21 fragment
  486. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of Rapamycin derivative (SDZ RAD) used alone and …
  487. Proton and nitrogen sequential assignments and secondary structure determination of the human FK506 and Rapamycin binding protein
  488. Abrogation by Rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and …
  489. FK506 binding protein 12 mediates sensitivity to both FK506 and Rapamycin in murine mast cells
  490. Post-translational reduction of cell surface expression of insulin receptors by cyclosporin A, FK506 and Rapamycin in bovine adrenal chromaffin cells
  491. Antiproliferative effect of Rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of …
  492. Effects of the combination of Rapamycin with tacrolimus or cyclosporin on experimental intimal hyperplasia
  493. Anisomycin and Rapamycin define an area upstream of p70/85S6k containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction.
  494. Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart …
  495. Studies towards the total synthesis of Rapamycin: Preparation of the C10 C17 carbon unit
  496. Effects of Rapamycin on apoptosis of rheumatoid synovial cells
  497. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under …
  498. Mean field analysis of FKBP12 complexes with FK506 and Rapamycin: Implications for a role of crystallographic water molecules in molecular recognition and …
  499. Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and Rapamycin, on hair growth initiation in …
  500. High performance liquid chromatographic isolation and spectroscopic characterization of three major metabolites from the plasma of rats receiving Rapamycin …
  501. Implication of alpha4 phosphoprotein and the Rapamycin-sensitive mammalian target-of-Rapamycin pathway in prolactin receptor signalling
  502. Effects of Rapamycin on human HLA-unrestricted cell killing
  503. cDNA Cloning of a human 5 kDa FK506 and Rapamycin binding protein
  504. Identification of a new metabolite of macrolide immunosuppressant, like Rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray …
  505. Evidence that Rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use.
  506. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides Rapamycin and FK506 inhibit progestin-and glucocorticosteroid receptor-mediated …
  507. CsA, FK506, corticosteroids and Rapamycin inhibit TNFα production by cultured PTEC
  508. Augmentation of SR Ca2+ release by Rapamycin and FK506 causes K+‐channel activation and membrane hyperpolarization in bladder smooth muscle
  509. Dihydroxylation of the triene subunit of Rapamycin
  510. Rituximab and Rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases
  511. Effect of single-dose Rapamycin-based immunosuppression on the development of cardiac allograft vasculopathy.
  512. Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression
  513. The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (Rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs …
  514. Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte: evidence for inhibition of CREB/ATF …
  515. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts.
  516. Reversal of ongoing heart, kidney, and pancreas allograft rejection and suppression of accelerated heart allograft rejection in the rat by Rapamycin.
  517. Glucocorticoid-induced insulin resistance of protein synthesis is independent of the Rapamycin-sensitive pathways in rat skeletal muscle
  518. Long-term in vivo effects of Rapamycin on humoral and cellular immune responses in the rat
  519. … signals that control cell proliferation in mammalian balance epithelia: key roles for phosphatidylinositol-3 kinase, mammalian target of Rapamycin, and S6 kinases in …
  520. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow [published erratum appears in …
  521. Immunosuppressant Rapamycin inhibits protein kinase C α and p38 mitogen-activated protein kinase leading to the inhibition of chondrogenesis
  522. FK506 and Rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA.
  523. THE IMMUNOSUPPRESSIVE EFFECT OF Rapamycin ON MOUSE SMALL BOWEL TRANSPLANTATION1
  524. Studies on selective reductions of Rapamycin
  525. Rapamycin: biological and therapeutic effects, binding by immunophilins and molecular targets of action
  526. PHARMACOKINETICS AND TOLERABILITY OF 40–0-[2-HYDROXYETHYL] Rapamycin IN DE NOVO LIVER TRANSPLANT RECIPIENTS1
  527. The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or Rapamycin alone and in triple combination.
  528. The future role of target of Rapamycin inhibitors in renal transplantation
  529. Rapamycin-induced long-term allograft survival depends on persistence of alloantigen.
  530. Effects of Rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin …
  531. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (Rapamycin) by electrospray-MS/MS after …
  532. Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant Rapamycin.
  533. Comparison of the effect of Rapamycin and FK506 on release of prostacyclin and endothelin in vitro
  534. A nonimmunosuppressive triene-modified Rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans-isomerase
  535. Cleavage of the cyclohexyl-subunit of Rapamycin results in loss of immunosuppressive activity
  536. A high performance liquid chromatographic method for the determination of Rapamycin (sirolimus) in rat serum, plasma, and blood and in monkey serum
  537. Cyclosporin A, FK506, Rapamycin: the use of a quantitative analytic tool to discriminate immunosuppressive drug interactions.
  538. Quantitative comparison of Rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction.
  539. Methionine Interference in Rapamycin Production Involves Repression of DemethylRapamycin Methyltransferase andS-Adenosylmethionine Synthetase
  540. A highly convergent strategy towards Rapamycin. Stereoselective construction of the C 8–C 18 fragment
  541. FK506 and Rapamycin binding to FKBP: Common elements in immunophilin-ligand complexation
  542. Cloning and sequence analysis of a Rapamycin-binding protein-encoding gene (RBP1) from Candida albicans
  543. Functional and histopathologic effects of Rapamycin on mouse kidney
  544. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent Rapamycin
  545. Structural basis for peptidomimicry by the effector element of Rapamycin
  546. Involvement of the Rapamycin-sensitive pathway in the insulin regulation of muscle protein synthesis in streptozotocin-diabetic rats
  547. COADMINISTRATION OF NEORAL AND THE NOVEL Rapamycin ANALOG, SDZ RAD, TO RAT LUNG ALLOGRAFT RECIPIENTS: Potentiation of …
  548. Efficacies of sirolimus (Rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of …
  549. ADJUNCTIVE Rapamycin AND CsA TREATMENT INHIBITS MONOCYTE/MACROPHAGE ASSOCIATED CYTOKINES/CHEMOKINES IN SENSITIZED CARDIAC …
  550. Rapamycin (sirolimus) inhibits heart cell growth in vitro
  551. Rapamycin‐resistant phosphorylation of the initiation factor‐4E‐binding protein (4E‐BP1) in v‐SRC‐transformed hamster fibroblasts
  552. Acid catalyzed functionalization of Rapamycin
  553. Discordant effects of Rapamycin on proliferation and p70S6 kinase phosphorylation in normal and neoplastic rat chromaffin cells
  554. Missense mutations at the FKBP12-Rapamycin-binding site of TOR1
  555. Nutritional and intestinal effects of the novel immunosuppressive agents: deoxyspergualin, Rapamycin, and mycophenolate mofetil
  556. Rapamycin inhibits protein kinase C activity and stimulates Na+ transport in A6 cells
  557. inhibition by Rapamycin of leukocyte migration and bronchial hyperreactivity induced by injection of Sephadex beads to guinea‐pigs
  558. The RB/p107/p130 phosphorylation pathway is not inhibited in Rapamycin-induced G1-prolongation of NIH3T3 cells.
  559. The mechanism of unresponsiveness to allografts induced by Rapamycin and Rapamycin/cyclosporine treatment in rats.
  560. Calorimetric measurements of the complexation of cyclosporin A, ascomycin, fujimycin, and Rapamycin with lithium chloride and with an immunophilin
  561. ANALYSIS OF FUNCTIONAL RENAL ALLOGRAFT TOLERANCE WITH SINGLE-DOSE Rapamycin BASED INDUCTION IMMUNOSUPPRESSION1
  562. Genetic relationships among actinomycetes that produce the immunosuppressant macrolides FK506, FK520/FK523 and Rapamycin
  563. Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma
  564. Rapamycin inhibits airway leukocyte infiltration and hyperreactivity in guinea pigs
  565. Synthetic approaches to Rapamycin
  566. Synthesis of the Tricarbonyl Subunit (C8−C19) of Rapamycin via Tandem Chan Rearrangement−Oxidation
  567. Rapamycin synthetic studies. 2. Elaboration of the C (10)-C (26) perimeter
  568. Use of Rapamycin in a transplant patient who developed cyclosporin neurotoxicity
  569. Prolactin and insulin synergize to regulate the translation modulator PHAS-I via mitogen-activated protein kinase-independent but wortmannin-and Rapamycin …
  570. Manipulation of the C (22)-C (27) region of Rapamycin: stability issues and biological implications
  571. Opposing effects of Rapamycin and cyclosporin A on activation-induced Ca2+ release
  572. Detection of noncovalent FKBP-FK506 and FKBP-Rapamycin complexes by capillary electrophoresis-mass spectrometry and capillary electrophoresis-tandem mass …
  573. Comparative effects of Rapamycin FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat
  574. Rapamycin insensitivity in Schistosoma mansoni is not due to FKBP12 functionality
  575. Lipase mediated hydrolysis of Rapamycin 42-hemisuccinate benzyl and methyl esters
  576. The effect of the immunophilin ligands Rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines.
  577. Rapamycin: A new and highly active immunosuppressive macrolide with an efficacy superior to cyclosporine
  578. Effect of a short course of Rapamycin, cyclosporin A, and donor-specific transfusion on rat cardiac allograft survival.
  579. Cyclosporin A, FK506 and Rapamycin produce multiple, temporally distinct, effects on memory following single-trial, passive avoidance training in the chick
  580. Effect of Rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine.
  581. Synthesis of I‐125 labeled photoaffinity Rapamycin analogs
  582. Interleukin 4-inducible phosphorylation of HMG-I (Y) is inhibited by Rapamycin
  583. inhibition of CTL induction by Rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity.
  584. Effects of cyclosporin A, Rapamycin, and FK520 on peripheral T-cell deletion and anergy
  585. The effect of cyclosporin A, FK506 and Rapamycin on the murine contact sensitivity reaction
  586. Structure of FKBP12. 6 in complex with Rapamycin
  587. SUPERIORITY OF SIROLIMUS (Rapamycin) OVER CYCLOSPORINE IN AUGMENTING ALLOGRAFT AND XENOGRAFT SURVIVAL IN MICE TREATED WITH …
  588. Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors
  589. inhibition of host-versus-graft and graft-versus-host responses after small bowel transplantation in rats by Rapamycin.
  590. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists.
  591. DETERMINATION OF AN IMPROVED SIROLIMUS (Rapamycin)-BASED REGIMEN FOR INDUCTION OF ALLOGRAFT TOLERANCE IN MICE TREATED WITH …
  592. Structure of the human 25 kDa FK506 binding protein complexed with Rapamycin
  593. The effects of Rapamycin on humoral immunity in vivo. Suppression of primary responses but not of ongoing alloantibody synthesis or memory responses.
  594. Hypersensitivity to Rapamycin of BJAB B lymphoblastoid cells.
  595. … IMMUNOMODULATION LEADS TO ENHANCED ALLOGRAFT SURVIVAL IN COMBINATION WITH CYCLOSPORINE A AND Rapamycin, BUT NOT FK5061
  596. The effect of Rapamycin on c-jun expression in human lymphocytes
  597. Tritium labelling of RAD001—a new Rapamycin derivative
  598. Relationship between multiple biologic effects of Rapamycin and the inhibition of pp70S6 protein kinase activity. Analysis in mutant clones of a T cell lymphoma.
  599. In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by Rapamycin leads to a clinical-pathological syndrome discrete from that …
  600. Rapamycin Prolongs Survival of Murine Recipients of Fully Allogeneic Donor Grafts When Administered during the Graft‐versus‐Host Disease Process a
  601. Isolation and identification of new Rapamycin dihydrodiol metabolites from dexamethasoneinduced rat liver microsomes
  602. Rapamycin and FK506 induce long-term potentiation by pairing stimulation via an intracellular Ca2+ signaling mechanism in rat hippocampal CA1 neurons
  603. … triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, Rapamycin and their analogues …
  604. … C/EBP homologous protein (CHOP) by amino acid deprivation requires insulin-like growth factor I, phosphatidylinositol 3-kinase, and mammalian target of Rapamycin …
  605. Insulin regulation of insulin-like growth factor-binding protein-1 gene expression is dependent on the mammalian target of Rapamycin, but independent of …
  606. Conformational changes of Rapamycin and analogs upon complexing with FKBP associated with activity: an application of second derivative CD spectroscopy
  607. inhibition of S6 Kinase by Rapamycin Blocks Maturation ofRana dybowskiiOocytes
  608. Reversible isomerization of Rapamycin demonstrated by liquid chromatography
  609. The human gene encoding FKBP-Rapamycin associated protein (FRAP) maps to chromosomal band 1p36. 2
  610. Studies towards the total synthesis of Rapamycin: Preparation of the cyclohexyl C33 C42 fragment and further coupling to afford the C22 C42 carbon unit
  611. The effect of anti‐IL‐4 monoclonal antibody, Rapamycin and interferon‐γ on airway hyperreactivity to acetylcholine in mice
  612. IL-2 induces beta2-integrin adhesion via a wortmannin/LY294002-sensitive, Rapamycin-resistant pathway. Phosphorylation of a 125-kilodalton protein correlates with …
  613. Biochemical and structural studies of the FK506-and Rapamycin-binding proteins (FKBPs).
  614. Rapamycin-sensitive phosphorylation of ribosomal protein S17 by p70 S6 kinase
  615. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and Rapamycin
  616. Cyclosporine and Rapamycin affect protein kinase C induction of the intracellular activation signal, activator of DNA replication.
  617. The effect of cyclosporin A, FK506, and Rapamycin on the murine chronic graft‐versus‐host response—an in vivo model of Th2‐like activity
  618. Efficacy of Rapamycin, RS-61443 and cyclophosphamide in the prolongation of survival of discordant pig to rabbit cardiac xenografts.
  619. Rapamycin graft pretreatment in small bowel and kidney transplantation in the rat.
  620. Left main Rapamycin-coated stent: Invasive versus noninvasive angiographic follow-up
  621. Investigation of Rapamycin transport and uptake across absorptive human intestinal cell monolayers
  622. Effects of wortmannin and Rapamycin on CSF-1-mediated responses in macrophages
  623. Cyclosporin A, Rapamycin and FK506 decrease prolactin release from rat pituitary cells in primary culture
  624. Sirolimus: mammalian target of Rapamycin inhibitor to prevent kidney rejection
  625. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and Rapamycin
  626. Up-regulation of cell surface sodium channels by cyclosporin A, FK506, and Rapamycin in adrenal chromaffin cells
  627. Synergistic effect of Rapamycin and cyclosporine in prevention of acute kidney allograft rejection in the mouse
  628. Isolation of a human cDNA encoding a 25 kDa FK-506 and Rapamycin binding protein
  629. Suppression of allograft responses by combining alloantigen-specific iv pre-sensitization with suboptimal doses of Rapamycin
  630. Rapamycin
  631. Comparison of binding characteristics of four Rapamycin metabolites to the 14 and 52 kDa immunophilins with their pharmacologic activity measured by the mixed …
  632. Hemolytic uremic syndrome after renal transplantation: immunosuppressive therapy with Rapamycin
  633. Immunosuppressants FK506 and Rapamycin have different effects on the biosynthesis of cytoplasmic actin during the early period of T cell activation
  634. Inducible membrane recruitment of small GTP-binding proteins by Rapamycin-based system in living cells
  635. Intragraft cytokine expressionf in tolerant rat renal allografts with Rapamycin and cyclosporin immunosuppression
  636. Evidence that Rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats.
  637. Ethanol potentiates the stimulatory effects of insulin and phosphocholine on mitogenesis by a zinc-dependent and Rapamycin-sensitive mechanism in fibroblasts and …
  638. … CD8+ T cells tolerized in vivo: employing a model of Ld-specific TCR transgenic mice transplanted with allogenic hearts under the cover of a short-term Rapamycin …
  639. Insulin regulation of hepatic insulin-like growth factor-binding protein-1 (IGFBP-1) gene expression and mammalian target of Rapamycin (mTOR) signalling is impaired …
  640. Saccharomyces cerevisiae contains a homolog of human fkbp‐13, a membrane‐associated fk506/Rapamycin binding protein
  641. An unexpected inhibitory effect of Rapamycin against germination of spores of Bacillus brevis strain Nagano
  642. Identification of a 14 kDa FK-506/Rapamycin binding immunophilin from calf thymus
  643. … –electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl) Rapamycin
  644. Rapamycin inhibits activation of ryanodine receptors from skeletal muscle by the fatty acyl CoA–acyl CoA binding protein complex
  645. Exclusion of the 13-kDa Rapamycin binding protein gene (FKBP2) as a candidate gene for multiple endocrine neoplasia type 1
  646. Towards the synthesis of the C37-C42 fragment of Rapamycin: intramolecular reactions of allyl silanes with oxonium ions generated from α-alkoxy sulfones.
  647. Quantitative and temporal analysis of the cellular interaction of FK-506 and Rapamycin in T-lymphocytes.
  648. … ARE NOT REQUIRED FOR INDUCTION OF ALLOGRAFT TOLERANCE IN MICE TREATED WITH ANTILYMPHOCYTE SERUM, Rapamycin, AND DONOR BONE …
  649. A comparison of the effects of Rapamycin and cyclosporine on kidney and heart morphology in a rabbit heterotopic heart transplant model
  650. Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by Rapamycin, cyclosporin A, and inhibitors of …
  651. Cyclosporine, FK-506, Rapamycin, and other immunomodulators
  652. Rapamycin INDUCES TGF-β PRODUCTION IN LYMPOCYTES
  653. Marked prolongation of rat skin xenografts induced by intrathymic injection of xenogeneic splenocytes and a short course of Rapamycin in antilymphocyte serum …
  654. inhibition of cellular transfer of experimental autoimmune uveoretinitis by Rapamycin
  655. Rapamycin: a future in cancer treatment?
  656. Reduction of Sephadex-induced lung inflammation and bronchial hyperreactivity by Rapamycin.
  657. K+ currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and Rapamycin
  658. 14-3-3τ associates with a translational control factor FKBP12-Rapamycin-associated protein in T-cells after stimulation by pervanadate
  659. IL-2-dependent induction of G1 cyclins in primary T cells is not blocked by Rapamycin or cyclosporin A
  660. Evidence that FK506 and Rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and …
  661. Partial characterization of a 52 kDa CsA/FK506/Rapamycin binding protein
  662. Rapamycin: Therapeutic range investigations
  663. Brief treatment with Rapamycin in vivo increases responsiveness to alloantigens measured by the mixed lymphocyte response
  664. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or Rapamycin to induce tolerance.
  665. Up-regulation of insulin-like growth factor binding protein-5 is independent of muscle cell differentiation, sensitive to Rapamycin, but insensitive to wortmannin and …
  666. The effect of cyclosporine, Rapamycin and FK 506 the survival following allogeneic bone marrow transplantation
  667. Treatment of normal skeletal muscle with FK506 or Rapamycin results in halothane-induced muscle contracture
  668. EFFECT OF IN VIVO Rapamycin TREATMENT ON DE NOVO T-CELL DEVELOPMENT IN RELATION TO INDUCTION OF AUTOIMMUNE-LIKE …
  669. Swinging the vote for Rapamycin
  670. Activation of 70‐kDa S6 kinase, induced by the cytokines interleukin‐3 and erythropoietin and inhibited by Rapamycin, is not an absolute requirement for cell …
  671. Rapamycin increases transforming growth factor-β mRNA expression in immortalized rat proximal renal tubular cells
  672. Divergent effects of Rapamycin on mouse and rat cells following mitogenic stimulation
  673. Differential effects of the immunosuppressive macrolides FK-506 and Rapamycin on activation-induced T-cell apoptosis
  674. Induction of tolerance to skin allografts by intrathymic injection of donor splenocytes. Effect of donor-recipient strain combination and supplemental Rapamycin.
  675. Isolation and identification of a C39 demethylated metabolite of Rapamycin from pig liver microsomes and evaluation of its immunosuppressive activity
  676. … from pig liver microsomes, identification by electrospray tandem mass spectrometry and in vitro immunosuppressive activity of a Rapamycin tris‐epoxide metabolite
  677. Ionization of the c7 methoxy group in Rapamycin by 5 M lithium perchlorate-diethyl ether
  678. Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and Rapamycin
  679. Mammalian target of Rapamycin: Immunosuppressive drugs offer new insights into cell growth regulation
  680. Rapamycin-induced apoptosis is p53-independent in human prostate carcinoma PC-3 cells
  681. Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and Rapamycin
  682. Stereoselective construction of the C 21–C 42 fragment of Rapamycin
  683. Rapamycin FOR REFRACTORY RENAL ALLOGRAFT REJECTION.
  684. C‐14 labelling of NVP RAD001—a new Rapamycin derivative
  685. The immunosuppressive macrolides FK-506 and Rapamycin
  686. Inhibitors of mammalian target of Rapamycin
  687. inhibition of the Mr 70,000 S6 kinase pathway by Rapamycin results in chromosome malsegregation in yeast and mammalian cells
  688. Possible involvement of Rapamycin-sensitive pathway in Bcl-2 expression in human neuroblastoma SH-SY5Y cells
  689. Ionizing radiation enhances double-strand-break repair in Rapamycin-treated ataxia telangiectasia lymphoblasts
  690. Effect of Rapamycin on prolactin-stimulated S6 kinase activity and milk product formation in mouse mammary explants
  691. Differential effect of Rapamycin and cyclosporin A in proliferation in a murine T cell line expressing either intermediate or high affinity receptor for IL-2
  692. A short-term combination therapy with cyclosporine and Rapamycin or leflunomide induces long-term heart allograft survival in a strongly immunogenic strain …
  693. FK-506 and Rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells
  694. FK506 and Rapamycin: Differential sensitivity of human, baboon, cynomolgus monkey, dog and pig lymphocytes
  695. Late adjunctive therapy with single doses of Rapamycin in skin-allografted mice treated with antilymphocyte serum and donor bone marrow cells
  696. Rapamycin inhibits substance P-induced protein synthesis and phosphorylation of PHAS-I (4E-BP1) and p70 S6 kinase (p70 (S6K)) in human astrocytoma cells
  697. … peptide corresponding to residues 65–79 of an HLA class II sequence: functional similarities but mechanistic differences with the immunosuppressive drug Rapamycin
  698. Synthesis and bioactivity of photolabile sirolimus (Rapamycin) analogs
  699. Rapamycin for GVHD prophylaxis-potential for severe myelotoxicity
  700. Provocative effects of the immunosuppressants Rapamycin, tacrolimus, and dexamethasone on Pneumocystis carinii pneumonitis in contrast to the anti-Pneumocystis …
  701. Comparative effects of FK-506, Rapamycin and cyclosporin A, on the in vitro differentiation of dorsal root ganglia explants and septal cholinergic neurons
  702. Anti‐CD28 antibody‐and IL‐4‐induced human T cell proliferation is sensitive to Rapamycin
  703. Rapamycin inhibits aldolase A expression during human lymphocyte activation
  704. The effects of FK 506, cyclosporine, and Rapamycin on liver growth in vitro and in vivo
  705. Analogous conformations of both binding and effector regions in cyclosporin A, FK506 and Rapamycin
  706. X-ray Crystal Structure of 28-O-MethylRapamycin complexed with FKBP12:  Is the Cyclohexyl Moiety Part of the Effector Domain of Rapamycin?
  707. Rapamycin, cyclosporine, and perioperative donor-specific transfusions induce prolongation of cardiac allograft survival in the rat.
  708. Structure-activity relationships involving modifications to the macrolides FK-506 and Rapamycin
  709. Comparative study of CSA and FK506 versus newer immunosuppressive drugs MMF and Rapamycin on coronary endothelial function in vitro
  710. PHAS-I phosphorylation in response to foetal bovine serum (FBS) is regulated by an ERK1/ERK2-independent and Rapamycin-sensitive pathway in 3T3-L1 …
  711. Structural analysis of Rapamycin and related compounds using [M + Li]+ ions generated by liquid secondary ion mass spectrometry
  712. The gene structure and promoter analysis of mouse lymphocyte signal transduction molecule α4 that is related to the yeast TAP42 involved in a Rapamycin-sensitive …
  713. The transcriptional profile of Saccharomyces cerevisiae exposed to Rapamycin mimics the profile induced by amino acid starvation
  714. … with chiral homoallylic ethers: An application to the asymmetric synthesis od (11R, 14S)-anti-and (31R, 34S)-syn-segements of immunosuppressant Rapamycin
  715. SAFETY AND PHARMACOKINETIC PROFILE OF ASCENDING SINGLE DOSES OF ORAL LIQUID SIROLIMUS (Rapamycin) IN PEDIATRIC PATIENTS WITH STABLE …
  716. … suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a Rapamycin derivative, SDZ-RAD
  717. … factor β1 inhibits interleukin‐1‐induced but enhances ionomycin‐induced interferon‐γ production in at cell lymphoma: Comparison with the effects of Rapamycin
  718. Long-term viability of articular cartilage after microsurgical whole-joint transplantation and immunosuppression with Rapamycin, mycophenolate mofetil, and tacrolimus
  719. Effect of cyclosporin A, Rapamycin, and FK-506 on corneal epithelial cells and lymphocyte proliferation
  720. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and Rapamycin
  721. Responsiveness of preactivated B cells to IL-2 and IL-6. Effect of cyclosporine and Rapamycin.
  722. Differential effects of cyclosporin-A and Rapamycin on in vivo thymocyte maturation
  723. Immunopharmacology of Rapamycin (A review)
  724. Synergism between corticosteroids and Rapamycin for the treatment of intraocular inflammation
  725. Rapamycin induces binding activity to the terminal oligopyrimidine tract of ribosomal protein mRNA in rats
  726. Intrasplenic liver parenchymal cells in conjunction with low-dose Rapamycin and cyclosporine induce a unique and specific prolongation of rat cardiac and small bowel …
  727. Target of Rapamycin (TOR) signaling coordinates tRNA and 5S rRNA gene transcription with growth rate in yeast
  728. HPLC Analysis of Rapamycin
  729. TGF-beta Provides the Rationale for the Synergistic Immunpsuppression with Rapamycin (RAPA), Cyclosporine (CsA) and Tacrolimus (TAC)
  730. Pharmacokinetic and pharmacodynamic correlations of cyclosporine (CsA) and Rapamycin (RAPA) in 120 patients treated for at least 2 years at a single center.
  731. Effects of mycophenolic acid, Rapamycin, and carvedilol on the PDGF-induced fibronectin secretion by rat vascular smooth muscle cells: Implication of MAP kinase
  732. The Effect of Immunosuppressive Agents (FK‐506, Rapamycin) on Renal P450 Systems in Rat Models
  733. A comparison of in vivo responses to cyclosporine, FK506, and Rapamycin following allogeneic immune challenge
  734. Rapamycin inhibits the in vitro release of soluble CD23 by SAC/IL-2/IL-4-activated human peripheral blood B lymphocytes
  735. Comparison of FK‐506, Rapamycin, Ascomycin, and Cyclosporine in Mouse Models of Host‐versus‐Graft Disease and Heterotopic Heart Transplantation
  736. Generation and evaluation of putative neuroregenerative drugs: Part 2: Screening virtual libraries of novel polyketides which possess the binding domain of Rapamycin
  737. Steroids, Rapamycin, and breast cancer cells.
  738. ADDITION OF Rapamycin TO CYCLOSPORINE-PREDNISONE BASED IMMUNOSUPPRESSION REDUCES THE CLINICAL RISK OF PRETRANSPLANT ANTI …
  739. Rapamycin treatment depresses
  740. Osmotic pump delivery of Rapamycin
  741. An open-label multi-center clinical study of the efficacy and safety of Rapamycin in combination with CsA and steroid to prevent the acute rejection of kidney …
  742. inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with Rapamycin or A77 1726 (leflunomide)
  743. Prevention of cardiac allograft rejection by FK506 and Rapamycin: assessment by histology and nuclear magnetic resonance
  744. Induction of IL-5 expression by IL-2 is resistant to the immunosuppressive agents cyclosporin A and Rapamycin.
  745. Rapamycin inhibits the in vitro release of soluble interleukin-2 receptor by activated peripheral blood mononuclear cells (PBMC) independently of the mode of …
  746. Rapamycin (Sirolimus) reduces luminal narrowing after balloon angioplasty in porcine coronary arteries
  747. The Rapamycin sensitivity of human T-cell leukaemia virus type I-induced T-cell proliferation is mediated independently of the polypyrimidine motifs in the 5′ long …
  748. Signaling Pathways for Translation: Stress, Calcium, and Rapamycin
  749. Rapamycin and reduced dose cyclosporin produce effective immunosuppression for de novo renal transplant recipients
  750. Differentiation by Rapamycin
  751. Generation and evaluation of putative neuroregenerative drugs: Part 1: virtual point mutations to the polyketide Rapamycin
  752. Triglyceride (TG) elevations in renal transplant recipients treated with sirolimus (Rapamycin, RAPA) added to a cyclosporine (CsA)/prednisone (pred) regimen
  753. Rapamycin: a new immunosuppressive agent capable of inhibiting chronic rejection?
  754. Effects of Rapamycin and FK 506 on Rat Sertoli Cells In Vitro
  755. The Immunosuppressant Rapamycin Induces Inactivation
  756. Effect of immunosuppressants FK506 and Rapamycin on the function of progesterone receptor: protein” p59-HBI”, intersection between immunology and endocrinology …
  757. Effects of Rapamycin on the proliferation and the prodution of IL-2, IFN-γ, TNF-α of spleniclymphocytes in mice [J]
  758. Rapamycin-inducible Secretion of a Therapeutic Protein in the Eye After Transduction With Viral Vectors
  759. High performance liquid chromatographic isolation and spectroscopic characterization of metabolites from the bile of rats receiving Rapamycin (sirolimus) …
  760. In vitro IgE production by interleukin 4-stimulated human peripheral blood mononuclear cells is suppressed by Rapamycin
  761. Conformational sensitivity analysis of FKBP–FK506/Rapamycin complexes
  762. Rapamycin (sirolimus, RapamuneTM): A novel immunosuppressive agent
  763. Cytokine expression in a stringent, single-dose Rapamycin, renal allograft model
  764. Induction of Rapamycin sensitivity by the Gli oncogene.
  765. Conversion from cyclosporine to Rapamycin in renal transplant recipients-Report of an initial experience.
  766. IL-2 DEPENDENT Rapamycin RESISTENT SIGNALS ARE REQUIRED FOR TOLERANCE INDUCTION AND T CELL APOPTOSIS
  767. Supercritical fluid chromatography for therapeutic drug monitoring of immunosuppressants: selectivity for cyclosporine A, FK 506 (tacrolimus), and Rapamycin
  768. Total syntheses of Rapamycin and 32-(S)-dihydroRapamycin.
  769. Rapamycin does not improve renal function or reduce profibrotic gene expression in chronic allograft nephropathy
  770. THE Rapamycin ANALOGUE SDZ RAD INHIBITS LPS AND ANTI-CD3mAb INDUCED IL-10 SYNTHESIS IN VITRO AND IN HUMAN RENAL ALLOGRAFT …
  771. Studies directed towards the synthesis of Rapamycin
  772. Choosing rational combinations of therapeutic agents: Contrasting effects of costimulation blockade plus Rapamycin or cyclosporin on intragraft expression of …
  773. Effects of FK506 and Rapamycin on formation of the neural tube in chick embryos
  774. Increased LFA-1-mediated homotypic cell adhesion is associated with the G1 growth arrest induced by Rapamycin in a T cell lymphoma
  775. The biosynthesis of Rapamycin
  776. Studies towards the total synthesis of Rapamycin
  777. FOUR-YEAR CONTROL OF A CLINICAL Rapamycin ASSAY
  778. Control of translation by a novel, Rapamycin-sensitive signaling pathway.
  779. The total synthesis of (-)-Rapamycin
  780. Total synthesis of Rapamycin.
  781. Rapamycin inhibits HMGB1 expression and releases in RAW264. 7 cells induced by lipopolysaccharides in vitro
  782. Effects of Rapamycin and insulin on the cell cycle and apoptosis of hybridoma cell cultures
  783. Rapamycin inhibits proliferating cell nuclear antigen expression and arrests keratinocytes in the G 1 phase of the cell cycle in vitro.
  784. The Immunophilin Ligand Rapamycin: A Probe for the Analysis of the Relationship of Apoptosis to the Cell Cycle
  785. Comparison between effects of mycophenolate mofetil and Rapamycin on proliferation and apoptosis of cyst-lining epithelial cells of ADPKD patients
  786. Synthetic methods directed towards the synthesis of Rapamycin.
  787. … ALLOGRAFT NEPHROPATHY: A PROSPECTIVE RANDOMISED TRIAL OF CYCLOSPORIN REDUCTION WITH OR WITHOUT Rapamycin.: Abstract# 432 Poster …
  788. Methionine Interference in Rapamycin
  789. Evaluation of the Influence of FK 506, Rapamycin, and Cyclosporine on Processing and Presentation of Particulate Antigen by Macrophages: Assessment of a …
  790. Sirolimus (Rapamycin) monotherapy prevents graft vascular disease in non-human primates
  791. Use of anti-CD25 monoclonal antibody in combination with Rapamycin to reduce or eliminate cyclosporine treatment during the induction phase of …
  792. Efficacy of 40-O-(2-hydroxyethyl)-Rapamycin in preventing chronic renal allograft rejection in rats
  793. Effect of cyclosporin A, FK506 and Rapamycin on proliferation and soluble IL-2 receptor release from mitogenically stimulated rat spleen cells
  794. Coadministered neoral and the new Rapamycin derivative, SDZ RAD, for nonhuman primate lung transplantation: systematic pharmcokinetic-based trials to maximize …
  795. Effects of Rapamycin on number and activity of endothelial progenitor cells
  796. Total Synthesis of Rapamycin
  797. Rapamycin has no effect on established allograft vasculopathy
  798. Total Synthesis of Rapamycin
  799. Therapeutic monitoring of cyclosporine, FK-506, and Rapamycin
  800. Insensitivity towards inhibition by cyclosporin A, Rapamycin and tacrolimus in human intestinal lamina propria T lymphocytes
  801. Cyclosporine but not Rapamycin stimulates endothelin-1 secretion by endothelial cells: Potential significance in transplant vasculopathy
  802. Rapamycin RESCUE IN PEDIATRIC LIVER RECIPIENTS WITH TACROLIMUS TOXICITY. A PRELIMINARY EFFECT: CONCENTRATION ANALYSIS.: Abstract# 210 …
  803. Studies towards the total synthesis of Rapamycin
  804. Inhibitory Effects of Rapamycin on the Experimental Allograft Rejection
  805. Innovative technique for immunosuppresion involving administration of Rapamycin loaded formed blood elements
  806. Regulation and identification of Rapamycin sensitive phosphorylation sites of p70s6k
  807. Studies directed toward the synthesis of the southern fragment of Rapamycin
  808. Inhibitors of Mammalian Target of Rapamycin
  809. Effect of Rapamycin on allograft rejection and immune response in mice
  810. In vitro and in vivo assessment of Rapamycin as an immunosuppressive agent in the rabbit
  811. Synthetic studies on the C10-C17 fragment of Rapamycin
  812. Effects of Rapamycin on the proliferation and the prodution of IL-2, IFN-?, TNF-? of spleniclymphocytes in mice
  813. Synergism between corticosteroids and Rapamycin for the treatment of intraocular inflammation
  814. Rapamycin and C (27)-demethoxyRapamycin: An efficient stereocontrolled synthesis of the C (1)-C (20) and C (22)-C (26) fragments.
  815. The effect of Rapamycin in prologation of adrenal allograft survival in the rat
  816. inhibition of cellular transfer of experimental autoimmune uveoretinitis by Rapamycin
  817. Rapamycin and other natural products affect regulation of the growth and differentiation of Saccharomyces cerevisiae.
  818. Biosynthesis of Rapamycin by streptomyces hygroscopicus
  819. Rapamycin, FRAP and the Control of 5’TOP mRNA Translation
  820. Synergistic effects of mycophenolate mofetil (MMF) and sirolimus (Rapamycin, RAPA) in prevention of acute heart, pancreas and kidney allograft rejection and in …
  821. Therapeutic window of whole blood Rapamycin concentration in recipients of renal transplantation
  822. Syntheses and biological activities of natural products: Rapamycin, balanol and the maduropeptin chromophore.
  823. The immunosuppressive effect of Rapamycin on lymphocytic proliferation and DTH, GVHR
  824. Risk factors for Rapamycin-induced thrombocytopenia and leukopenia in renal transplant recipients
  825. Immunosuppressive effect of Rapamycin on heart allotransplantation in the rat [J]
  826. The effect of soy protein on serum lipids in kidney transplant patients receiving Rapamycin.
  827. Aberrant expression of mammalian target of Rapamycin in stage ⅢB colon cancer and its significance
  828. Rapamycin Inhibits 3T3-L1 Adipocyte Differentiation Independent of Clonal Expansion
  829. Effect of Rapamycin on the cyclosporin A-resistant CD28-mediated
  830. Synthetic approaches to the tricarbonyl subunit of Rapamycin
  831. Molecular mechanisms of action of the immunosuppressive drugs cyclosporin A, FK506 and Rapamycin.
  832. Effects of Rapamycin on chronic nephrotoxicity induced by cyclosporine A in rats
  833. Rapamycin antagonizes interleukin-6 mediated growth arrest and differentiation of myeloblastic M1 cells
  834. Cyclin D3, a key cyclin in human lymphocyte proliferation and Rapamycin-mediated immunosuppression.
  835. EXTREME HYPERLIPIDEMIA RESULTING FROM Rapamycin-DERIVED DRUG ADMINISTRATION.: Abstract# 827 Poster Board#-Session: P84-III
  836. Siloxanes as templates in asymmetric synthesis: Studies directed towards the synthesis of Rapamycin.
  837. FK 506 versus cyclosponne a for steroid-free synergistic combination therapy with Rapamycin in a discordant large animal donor xenoislet transplant model
  838. Studies of the Rapamycin-sensitive signaling network using genomics, chemical genetics, and small molecule microarrays.
  839. Rapamycin increases the expression of genes responsible for extracellular matrix remodelling compared to neoral in rat allografts
  840. Inhibitory effects of Rapamycin on intimal hyperplasia after PTCA in the porcine coronary model: a 3-month follow-up
  841. Regulation of the cell integrity pathway by Rapamycin-sensitive TOR function in budding yeast
  842. Rapamycin Inhibits Estrogen-Mediated Transcription in Breast Cancer Cell Lines
  843. Tissue Distribution of Rapamycin and Cyclosporine in the Rat: Comparison of Single vs. Dual Drug Therapy
  844. inhibition by Rapamycin of PDGF-and bFGF-induced human tenon fibroblast proliferation in vitro
  845. Effects of Rapamycin and wortmannin on the insulin stimulation of protein synthesis in rat skeletal muscle and L6 myoblasts
  846. The expression of mammalian target of Rapamycin in autogenous vein graft in rats
  847. The Effects of Immunosuppressants Rapamycin and Cyclosporin A on the Proliferation, Cell Cycle, and Cyclin Expression of Cultured Human Keratinocyte Cell Line …
  848. The effects of Rapamycin and cyclosporin a on tolerance induction through bone marrow transplantation with costimulation blockade
  849. Cyclosporin and FK506, but not Rapamycin, increase DNFB induced TNF-alpha expression in human epidermal sheets.
  850. Mass spectrometric analysis of the Rapamycin-dependent phosphorylation sites of the yeast protein kinase NPR1
  851. Effects of stent-based delivery of Rapamycin and methotrexate on neointimal formation in a porcine coronary model
  852. Effects of cyclosporin and Rapamycin on the in vitro activation of human CD8+ lymphocytes in comparison with peripheral blood mononuclear cells.
  853. Evaluation of Rapamycin coated stents by multi row detector computed angiography: comparison to quantitative angiographic results
  854. Cyclosporin A and FK506, but not Rapamycin, increase DNFB induced TNF-alpha expression in human epidermal sheets.
  855. Using natural products to elucidate molecular events within cells: Molecular mechanisms of action of cyclosporine, FK506, and Rapamycin.
  856. SDZ-RAD PREVENTS CYCLOSPORINE-INDUCED inhibition OF BRAIN ENERGY METABOLISM: COMPARISON WITH Rapamycin.: Abstract# 314 Poster Board …
  857. Rapamycin POTENTIATES NF-κB AND AP-1 ACTIVATION IN TNF-α TREATED PRIMARY RAT HEPATOCYTES.: Abstract# 308 Poster Board#-Session: P155-I
  858. The Mechanism of Insulin-Induced Clonal Expansion in Adipocyte Differentiation–the Importance of PI3 Kinae-Rapamycin-Sensitive Pathway
  859. Inhibitory effects of Rapamycin and ascomycin on hair growth induced by cyclosporin A and FK506 in mice.
  860. Effects of Rapamycin-treated HSP60-pulsed dendritic cells on the progression of the atherosclerotic plaque in mice
  861. inhibition of S6 Kinase by Rapamycin Blocks Maturation of Rana dybowskii Oocytes
  862. Relationship between multiple biological effects of Rapamycin and the inhibition of pp70 S6 protein kinase activity: Analysis in mutant clones of a T cell lymphoma.
  863. The study of Rapamycin-eluting polymer-coated stents to prevent restenosis in the porcine coronary injury model
  864. Differential effects of cyclosporine and Rapamycin on costimulation blockade induced allograft tolerance: Intragraft CTL gene expression analysis
  865. BRIEF COMMUNICATIONS: EFFECT OF Rapamycin ON RENAL ALLOGRAFT SURVIVAL IN CANINE RECIPIENTS TREATED WITH ANTILYMPHOCYTE SERUM …
  866. Rapamycin RESCUE IN PEDIATRIC LIVER RECIPIENTS WITH TACROLIMUS TOXICITY.: Abstract# 211 Poster Board#-Session: P58-I
  867. Rapamycin (RAPA) lowers dose requirements of cyclosporin (CsA) in renal transplant patients (RTx)
  868. … Lewis acid-mediated Mukaiyama aldol reaction of α-alkoxythiolketene acetals with α, β-disubstituted enals: synthesis of the C26–C33 segment of Rapamycin
  869. Rapamycin selectively inhibits translation of mRNAs encoding elongation factor and ribosomal protein
  870. FK506 versus CSA for steroid-free synergistic combination therapy with Rapamycin (Rapa) in a discordant xenoislet model
  871. SHORT TERM ANTILYMPHOCYTE SERUM, Rapamycin AND DONOR BONE MARROW SIGNIFICANTLY SUPPRESS ANTIDONOR ANTIBODY AND PROLONG …
  872. … studies n bioactive natural products. Part I, An approach towards the nootrophic agent huperzine A. Part II, Synthesis of the tricarbonyl subunit of Rapamycin
  873. EFFECT OF TACROLIMUS (FK506) AND SIROLIMUS (Rapamycin) MONO-AND COMBINATION THERAPY IN PROLONGATION OF RENAL ALLOGRAFT …
  874. Coadministration of neoral and the novel Rapamycin analog, sdzrad, to. lung allograft recipients: potentiation of immunosuppressive efficacy and reduction of toxicity …
  875. Rapamycin (Rapa) And Cyclosporin A (Csa) Enhance Transforming Growth Factor Beta (TGF-β1) Expression in Immortalized Rat Proximal Tubules (IRPTC)† 1840
  876. Rapamycin (RAPA) ENHANCES TRANSFORMING GROWTH FACTOR BETA (TGF-β1) EXPRESSION IN IMMORTALIZED RAT PROXIMAL TUBULES CELLS …
  877. Prevention of Arterial Restenosis by Rapamycin and Mycophenolate Mofetil: A New Role for Novel Immunosuppressants in the Prevention of Post-Balloon Angioplasty …
  878. Rapamycin synergizes with dst plus anti-CD154 to block auto and allo-immune response and induce islet allograft engraftment in spontaneous autoimmune diabetic …
  879. Mating stimulate protein phosphorylation and synthesis via Rapamycin-and wortmannin-sensitive manner in male accessory glands of D. melanogaster
  880. Combined use of mycophenolate mofetil (MMF) and Rapamycin (RAPA) in prevention of acute heart allograft rejection and reversal of ongoing cardiac allograft …
  881. Chronic Rejection in Non-human Primates: Sirolimus (Rapamycin), but not Cyclosporin, Prevents Graft Vascular Disease (GVD) in Aortic Allografts after Acute …
  882. Provocative effects of the immunosuppressants Rapamycin, tacrolimus, and dexamethasone on Pneumocystis carinii pneumonitis in contrast to the anti-Pneumocystis …
  883. Synthesis of the C-21-C-42 fragment of Rapamycin and total synthesis of Rapamycin.
  884. PMA Induced Ser/Thr Phosphorylation of IRS-1 Mediated by Rapamycin-Sensitive Pathway
  885. Desensitization of Insulin Action through Ser/Thr Phosphorylation and Degradation of IRS-1 by Activation of Rapamycin-Sensitive Pathway
  886. 24 HPLC (ESI)-MS IDENTIFICATION OF SIROLIMUS (Rapamycin) METABOLITES GENERATED IN A RABBIT MICROSOMAL SYSTEM AND CONFIRMATION WITH …
  887. Interleukin-2 and Rapamycin regulation of cyclin E-Cdk2 kinase, the Cdk inhibitor, P27KIP1, and the T lymphocyte cell cycle.
  888. 192 SENSITIVE AND SPECIFIC QUANTIFICATION OF SIROLIMUS (Rapamycin) AND ITS METABOLITES IN BLOOD AND URINE OF KIDNEY GRAFT RECIPIENTS …
  889. OP-4. Studies towards the Total Synthesis of Rapamycin
  890. 74 DETERMINATION OF Rapamycin IN WHOLE BLOOD BY HPLC
  891. # 680 In vitro evaluation of Rapamycin sensitivity and synergy with cisplatin and camptothecin in medulloblastoma
  892. Purification and characterization of a 50 kiloDalton lymphocyte-derived binding protein for cyclosporin, FK-506 and Rapamycin.
  893. … from carbohydrates: Application of the (2, 3)-Wittig rearrangement of carbohydrate-derived alpha-alkoxy tertiary allylic ethers to the syntheses of Adda and Rapamycin.
  894. Efficacy of FK-506 and Rapamycin in Prolongation of Allograft Rat Limb Survival
  895. # 764 Rapamycin effects phosphorylation of p70S6 kinase and other intermediaries in medulloblastoma
  896. I. The formal synthesis of FK-506. II. A simple synthesis of vicinal tricarbonyls. III. Studies toward the synthesis of Rapamycin.
  897. Glucose-induced polypyrimidine-tract-binding protein (PTB) to the 3´-untranslated region of the insulin mRNA is inhibited by Rapamycin
  898. METABOLISM AND PHARMACOKINETICS OF THE NEW IMMUNOSUPPRESSANT 40-O-(2-HYDROXY)-ETHYL-Rapamycin
  899. 138 Rapamycin AND CYCLOSPORINE DRUG STUDIES IN THE RAT MODEL
  900. Rapamycin: an anti-cancer immunosuppressant?
  901. Determinants of Rapamycin sensitivity in breast cancer cells
  902. Antileukemic activity of Rapamycin in acute myeloid leukemia
  903. Molecular organization of target of Rapamycin complex 2
  904. Rapamycin-induced oligospermia
  905. mTOR-targeted therapy of cancer with Rapamycin derivatives
  906. Rapamycin pre-treatment protects against apoptosis
  907. Activation of Akt and eIF4E survival pathways by Rapamycin-mediated mammalian target of Rapamycin inhibition
  908. Signaling by target of Rapamycin proteins in cell growth control
  909. Differential effects of Rapamycin on mammalian target of Rapamycin signaling functions in mammalian cells
  910. Rapamycin alleviates toxicity of different aggregate-prone proteins
  911. Prolonged Rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
  912. Rapamycin attenuates load-induced cardiac hypertrophy in mice
  913. Use of Rapamycin slows progression of cardiac transplantation vasculopathy
  914. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease
  915. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
  916. Rapamycin is an effective inhibitor of human renal cancer metastasis
  917. Maintenance immunosuppression with target-of-Rapamycin inhibitors is associated with a reduced incidence of de novo malignancies
  918. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
  919. Campath‐1H induction plus Rapamycin monotherapy for renal transplantation: results of a pilot study
  920. Phosphorylation of Mammalian Target of Rapamycin (mTOR) at Ser-2448 IsMediated by p70S6 Kinase
  921. Target of Rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression
  922. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by Rapamycin
  923. Characterization of the FKBP⊙ Rapamycin⊙ FRB Ternary Complex
  924. inhibition of target of Rapamycin signaling by Rapamycin in the unicellular green alga Chlamydomonas reinhardtii
  925. Insulin/IGF and target of Rapamycin signaling: a TOR de force in growth control
  926. Targeting the molecular target of Rapamycin (mTOR)
  927. inhibition of mTOR signaling with Rapamycin regresses established cardiac hypertrophy induced by pressure overload
  928. The molecular target of Rapamycin (mTOR) as a therapeutic target against cancer
  929. Regulation of adipocyte differentiation and insulin action with Rapamycin
  930. Effects of Rapamycin in the Eker rat model of tuberous sclerosis complex
  931. Targeting the mammalian target of Rapamycin (mTOR): a new approach to treating cancer
  932. Target of Rapamycin-mediated amino acid signaling in mosquito anautogeny
  933. Multiple roles of Tap42 in mediating Rapamycin-induced transcriptional changes in yeast
  934. Rapamycin impairs antigen uptake of human dendritic cells1
  935. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy
  936. Mammalian target of Rapamycin inhibition as therapy for hematologic malignancies
  937. Dissociation of raptor from mTOR is a mechanism of Rapamycin‐induced inhibition of mTOR function
  938. GβL, a positive regulator of the Rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR
  939. Mammalian target of Rapamycin: a new molecular target for breast cancer
  940. Combination of Rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
  941. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of Rapamycin and its targets
  942. Immunosuppressants and skin cancer in transplant patients: focus on Rapamycin
  943. Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients
  944. Specific binding to intracellular proteins determines arterial transport properties for Rapamycin and paclitaxel
  945. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells
  946. Targeting mammalian target of Rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells
  947. Upstream of the mammalian target of Rapamycin: do all roads pass through mTOR?
  948. Rictor, a novel binding partner of mTOR, defines a Rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
  949. Phospholipase D confers Rapamycin resistance in human breast cancer cells
  950. Thr2446 is a novel mammalian target of Rapamycin (mTOR) phosphorylation site regulated by nutrient status
  951. Nephrotoxicity of Rapamycin: an emerging problem in clinical medicine
  952. Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity
  953. The mammalian target of Rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity
  954. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis
  955. Rapamycin reduces disease activity and normalizes T cell activation–induced calcium fluxing in patients with systemic lupus erythematosus
  956. Rapamycin suppresses experimental aortic aneurysm growth
  957. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling
  958. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets
  959. Antiangiogenic potential of the mammalian target of Rapamycin inhibitor temsirolimus
  960. Mammalian TOR complex 2 controls the actin cytoskeleton and is Rapamycin insensitive
  961. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice
  962. The Pim kinases control Rapamycin-resistant T cell survival and activation
  963. Akt activates the mammalian target of Rapamycin by regulating cellular ATP level and AMPK activity
  964. Mammalian target of Rapamycin, a molecular target in squamous cell carcinomas of the head and neck
  965. Finding new components of the target of Rapamycin (TOR) signaling network through chemical genetics and proteome chips
  966. Stent implantation activates RhoA in human arteries: inhibitory effect of Rapamycin
  967. Regulation of targets of mTOR (mammalian target of Rapamycin) signalling by intracellular amino acid availability.
  968. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients
  969. Sustained activation of the JNK cascade and Rapamycin-induced apoptosis are suppressed by p53/p21Cip1
  970. Combination of the mTOR inhibitor Rapamycin and CC-5013 has synergistic activity in multiple myeloma
  971. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance
  972. Gene expression-based chemical genomics identifies Rapamycin as a modulator of MCL1 and glucocorticoid resistance
  973. Rapamycin activates Tap42‐associated phosphatases by abrogating their association with Tor complex 1
  974. Preliminary observations regarding angiographic pattern of restenosis after Rapamycin-eluting stent implantation
  975. Mutasynthesis of Rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis
  976. Curcumin inhibits the mammalian target of Rapamycin‐mediated signaling pathways in cancer cells
  977. Mammalian target of Rapamycin pathway blockade slows progression of diabetic kidney disease in rats
  978. The solution structure of the FATC domain of the protein kinase target of Rapamycin suggests a role for redox-dependent structural and cellular stability
  979. Mammalian target of Rapamycin regulates IRS-1 serine 307 phosphorylation
  980. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of Rapamycin pathway
  981. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells
  982. Insights into TOR function and Rapamycin response: chemical genomic profiling by using a high-density cell array method
  983. Survival signaling by Notch1: mammalian target of Rapamycin (mTOR)–dependent inhibition of p53
  984. Antitumoral activity of Rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex
  985. Rapamycin successfully treats post‐transplant autoimmune hepatitis
  986. Increased activation of the mammalian target of Rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance
  987. Rapamycin: signaling in vascular smooth muscle
  988. Therapeutic potential of target of Rapamycin inhibitors
  989. Synergistic augmentation of Rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors
  990. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro
  991. Rheb binding to mammalian target of Rapamycin (mTOR) is regulated by amino acid sufficiency
  992. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells
  993. Inhibitory effect of Rapamycin on corneal neovascularization in vitro and in vivo
  994. Regulation of peroxisome proliferator–activated receptor-γ activity by mammalian target of Rapamycin and amino acids in adipogenesis
  995. inhibition of mTOR signaling with Rapamycin attenuates renal hypertrophy in the early diabetic mice
  996. Identification of S6 kinase 1 as a novel mammalian target of Rapamycin (mTOR)-phosphorylating kinase
  997. Rapamycin inhibits IL-4—induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo
  998. Mammalian target of Rapamycin inhibition
  999. Phase I/II study of the mammalian target of Rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
  1000. Mechanical stimuli regulate Rapamycin-sensitive signalling by a phosphoinositide 3-kinase-, protein kinase B-and growth factor-independent mechanism
  1001. Dosing of Rapamycin is critical to achieve an optimal antiangiogenic effect against cancer
  1002. A possible linkage between AMP‐activated protein kinase (AMPK) and mammalian target of Rapamycin (mTOR) signalling pathway
  1003. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF
  1004. Acute Rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies
  1005. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone
  1006. AKT activity determines sensitivity to mammalian target of Rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression
  1007. Inhibitors of the mammalian target of Rapamycin
  1008. Homodirectional changes in transcriptome composition and mRNA translation induced by Rapamycin and heat shock
  1009. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design
  1010. Oral Rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study
  1011. Rapamycin-mediated inhibition of mammalian target of Rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation
  1012. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma
  1013. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer
  1014. Effect of Rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer
  1015. Efficacy of a Rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse models
  1016. Rapamycin confers preconditioning-like protection against ischemia–reperfusion injury in isolated mouse heart and cardiomyocytes
  1017. Drosophila target of Rapamycin kinase functions as a multimer
  1018. Targeting the Akt/mammalian target of Rapamycin pathway for radiosensitization of breast cancer
  1019. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with Rapamycin
  1020. Arabidopsis TARGET OF Rapamycin interacts with RAPTOR, which regulates the activity of S6 kinase in response to osmotic stress signals
  1021. Rapamycin in cardiovascular medicine
  1022. Mechanical stimuli and nutrients regulate Rapamycin‐sensitive signaling through distinct mechanisms in skeletal muscle
  1023. FKBP12-Rapamycin-associated protein or mammalian target of Rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus
  1024. S6K1−/−/S6K2−/− mice exhibit perinatal lethality and Rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein …
  1025. Determinants of sensitivity and resistance to Rapamycin-chemotherapy drug combinations in vivo
  1026. Brain-derived neurotrophic factor induces mammalian target of Rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal …
  1027. In vitro study of release mechanisms of paclitaxel and Rapamycin from drug-incorporated biodegradable stent matrices
  1028. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of Rapamycin by amino acids and certain cellular stresses
  1029. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways
  1030. Rapamycin‐sensitive signalling in long‐term consolidation of auditory cortex‐dependent memory
  1031. Systemic Rapamycin inhibits retinal and choroidal neovascularization in mice
  1032. inhibition of the mammalian target of Rapamycin (mTOR) by Rapamycin increases chemosensitivity of CaSki cells to paclitaxel
  1033. Target of Rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of …
  1034. Rapamycin‐treated, alloantigen‐pulsed host dendritic cells induce ag‐specific T cell regulation and prolong graft survival
  1035. Activation of mammalian target of Rapamycin in cytomegalic neurons of human cortical dysplasia
  1036. Mutation in TSC2 and activation of mammalian target of Rapamycin signalling pathway in renal angiomyolipoma
  1037. inhibition of mammalian target of Rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells
  1038. Role of mammalian target of Rapamycin signaling in compensatory renal hypertrophy
  1039. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors
  1040. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy
  1041. Activation of the Akt/mammalian target of Rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers
  1042. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of Rapamycin signaling
  1043. BDNF regulates the translation of a select group of mRNAs by a mammalian target of Rapamycin-phosphatidylinositol 3-kinase-dependent pathway during neuronal …
  1044. Antitumor efficacy of intermittent treatment schedules with the Rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in …
  1045. The mammalian target of Rapamycin signaling network and gene regulation
  1046. Combination mammalian target of Rapamycin inhibitor Rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple …
  1047. Role of glycogen synthase kinase 3β in Rapamycin-mediated cell cycle regulation and chemosensitivity
  1048. Immediate response of mammalian target of Rapamycin (mTOR)‐mediated signalling following acute resistance exercise in rat skeletal muscle
  1049. Proteomic analysis reveals hyperactivation of the mammalian target of Rapamycin pathway in neurofibromatosis 1–associated human and mouse brain tumors
  1050. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
  1051. Mutual antagonism of target of Rapamycin and calcineurin signaling
  1052. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas
  1053. inhibition of corneal neovascularization by Rapamycin
  1054. Calcineurin inhibitors, but not Rapamycin, reduce percentages of CD4+ CD25+ FOXP3+ regulatory T cells in renal transplant recipients
  1055. Androgens induce prostate cancer cell proliferation through mammalian target of Rapamycin activation and post-transcriptional increases in cyclin D proteins
  1056. Dexamethasone represses signaling through the mammalian target of Rapamycin in muscle cells by enhancing expression of REDD1
  1057. In vitro release of the mTOR inhibitor Rapamycin from poly (ethylene glycol)-b-poly (ε-caprolactone) micelles
  1058. Low-dose oral Rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis
  1059. Antitumor activity of Rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer
  1060. Translational control via the mammalian target of Rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons
  1061. Rapamycin induces Smad activity in prostate cancer cell lines
  1062. Resistance exercise increases muscle protein synthesis and translation of eukaryotic initiation factor 2Bϵ mRNA in a mammalian target of Rapamycin …
  1063. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and Rapamycin on the induction of FOXP3 in human T cells
  1064. The mammalian target of Rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif
  1065. Effects of the mammalian target of Rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
  1066. Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells
  1067. Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex–mammalian target of Rapamycin pathway
  1068. Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: implications in the antiproliferative response to Rapamycin
  1069. New targets for therapy in breast cancer: mammalian target of Rapamycin (mTOR) antagonists
  1070. Modulation of the mammalian target of Rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid
  1071. Human cytomegalovirus infection induces Rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase
  1072. Mammalian target of Rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor …
  1073. … predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At …
  1074. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of Rapamycin
  1075. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by Rapamycin
  1076. Rpd3p relocation mediates a transcriptional response to Rapamycin in yeast
  1077. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of Rapamycin pathway in breast cancer cells
  1078. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of Rapamycin kinase inhibitor, in patients with advanced refractory renal cell …
  1079. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy
  1080. Activation of the mammalian target of Rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes
  1081. Akt1 Activation Can Augment Hypoxia-Inducible Factor-1α Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin–Independent …
  1082. Rapamycin inhibits GM-CSF-induced neutrophil migration
  1083. The mammalian target of the Rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy
  1084. Delayed graft function and cast nephropathy associated with tacrolimus plus Rapamycin use
  1085. Biosynthesis of pipecolic acid by RapL, a lysine cyclodeaminase encoded in the Rapamycin gene cluster
  1086. Recent developments in targeting the mammalian target of Rapamycin (mTOR) kinase pathway
  1087. Domains of Gln3p interacting with karyopherins, Ure2p, and the target of Rapamycin protein
  1088. Rapamycin-eluting stents for the treatment of unprotected left main coronary disease
  1089. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation
  1090. Activation of mammalian target of Rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase–positive anaplastic large cell …
  1091. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer
  1092. Activation of mammalian target of Rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1
  1093. Mammalian target of Rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma …
  1094. inhibition of mammalian target of Rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras
  1095. Raptor, a binding partner of target of Rapamycin
  1096. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring …
  1097. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
  1098. Molecular mechanisms through which amino acids mediate signaling through the mammalian target of Rapamycin
  1099. … outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent …
  1100. Rapamycin biosynthesis: elucidation of gene product function
  1101. Effect of Rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Eμ-TCL1 transgenic mice
  1102. Roles of glutamate receptors and the mammalian target of Rapamycin (mTOR) signaling pathway in activity-dependent dendritic protein synthesis in …
  1103. New Rapamycin derivatives by precursor‐directed biosynthesis
  1104. Thyroid Hormone Induces Rapid Activation of Akt/Protein Kinase B-Mammalian Target of Rapamycin-p70S6K Cascade through Phosphatidylinositol 3-Kinase in …
  1105. Target of Rapamycin-dependent activation of S6 kinase is a central step in the transduction of nutritional signals during egg development in a mosquito
  1106. inhibition of mammalian target of Rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity
  1107. … growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin (PI3K/Akt/mTOR) …
  1108. Novel role of the small GTPase Rheb: its implication in endocytic pathway independent of the activation of mammalian target of Rapamycin
  1109. Chronic inhibition of mammalian target of Rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and …
  1110. Rapamycin-induced translational derepression of GCN4 mRNA involves a novel mechanism for activation of the eIF2α kinase GCN2
  1111. Control of dendritic arborization by the phosphoinositide-3′-kinase–Akt–mammalian target of Rapamycin pathway
  1112. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing’s sarcoma cell proliferation
  1113. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin
  1114. Mammalian target of Rapamycin as a therapeutic target in leukemia
  1115. Activation of mammalian target of Rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma
  1116. Nutrient-dependent multimerization of the mammalian target of Rapamycin through the N-terminal HEAT repeat region
  1117. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of Rapamycin
  1118. Mammalian target of Rapamycin (mTOR) inhibitors as anti-cancer agents
  1119. Long-term treatment of bile duct-ligated rats with Rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms
  1120. Mechanism by which mammalian target of Rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis
  1121. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of Rapamycin
  1122. Mammalian target of Rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab
  1123. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to Rapamycin in an Akt-dependent manner via p38 MAPK signaling
  1124. The Rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation
  1125. Pilot trial of oral Rapamycin for recalcitrant restenosis
  1126. Effect of Rapamycin on renal ischemia‐reperfusion injury in mice
  1127. Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance
  1128. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of Rapamycin/p70S6K leading to increased angiogenesis and …
  1129. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression
  1130. Successful conversion to Rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation
  1131. Synergistic effect of targeting mTOR by Rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells
  1132. Cyclosporin A and tacrolimus, but not Rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells
  1133. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells
  1134. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of Rapamycin (mTOR) signalling
  1135. Target of Rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding …
  1136. … sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of Rapamycin …
  1137. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway
  1138. Mammalian target of Rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway
  1139. Human cytomegalovirus infection alters the substrate specificities and Rapamycin sensitivities of raptor-and rictor-containing complexes
  1140. Regulation of Leucine Uptake by tor1+ in Schizosaccharomyces pombe Is Sensitive to Rapamycin
  1141. TCR engagement increases hypoxia-inducible factor-1α protein synthesis via Rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells
  1142. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam …
  1143. Mammalian target of Rapamycin (mTOR) signaling is required for a late-stage fusion process during skeletal myotube maturation
  1144. Local application of Rapamycin inhibits neointimal hyperplasia in experimental vein grafts
  1145. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by Rapamycin through a p38 MAPK …
  1146. GATA factor translation is the final downstream step in the amino acid/target-of-Rapamycin-mediated vitellogenin gene expression in the anautogenous …
  1147. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis
  1148. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty
  1149. Akt1/Akt2 and mammalian target of Rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell …
  1150. Fibronectin stimulates non–small cell lung carcinoma cell growth through activation of Akt/mammalian target of Rapamycin/S6 kinase and inactivation of LKB1/AMP …
  1151. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of Rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long …
  1152. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines: an approach to suppress R5 strains of HIV-1
  1153. … in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson’s disease by a mechanism involving mammalian target of Rapamycin …
  1154. Glucagon represses signaling through the mammalian target of Rapamycin in rat liver by activating AMP-activated protein kinase
  1155. Isolation and Characterization of Pre‐Rapamycin, the First Macrocyclic Intermediate in the Biosynthesis of the Immunosuppressant Rapamycin by S. hygroscopicus
  1156. Type D personality predicts death or myocardial infarction after bare metal stent or sirolimus-eluting stent implantation: a Rapamycin-Eluting Stent Evaluated at …
  1157. A high-throughput method for screening of Rapamycin-producing strains of Streptomyces hygroscopicus by cultivation in 96-well microtiter plates
  1158. Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of Rapamycin-p70 S6 kinase 1 pathway
  1159. Comparative effects of paclitaxel and Rapamycin on smooth muscle migration and survival: role of AKT-dependent signaling
  1160. Production of novel Rapamycin analogs by precursor-directed biosynthesis
  1161. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells1
  1162. Effects of Rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood
  1163. Predictive and prognostic role of activated mammalian target of Rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy
  1164. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of Rapamycin (mTOR)-induced negative feedback down-regulates …
  1165. A Rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and …
  1166. Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of Rapamycin and for recognition by raptor
  1167. A nuclear transport signal in mammalian target of Rapamycin is critical for its cytoplasmic signaling to S6 kinase 1
  1168. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of Rapamycin (mTOR)-independent
  1169. … undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated …
  1170. Antiangiogenic and immunomodulatory effects of Rapamycin on islet endothelium: relevance for islet transplantation
  1171. Rapamycin mimics the incompatibility reaction in the fungus Podospora anserina
  1172. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties
  1173. An open prospective pilot study on the use of Rapamycin after penetrating high-risk keratoplasty
  1174. Ex vivo Rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant Rapamycin therapy
  1175. Post-transcriptional regulation of the androgen receptor by Mammalian target of Rapamycin
  1176. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its …
  1177. Efficacy of Rapamycin in patient with juvenile rheumatoid arthritis
  1178. Mammalian target of Rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation
  1179. Effects of Rapamycin on accumulation of α‐, β‐ and γ‐globin mRNAs in erythroid precursor cells from β‐thalassaemia patients
  1180. Rapamycin and chronic kidney disease: beyond the inhibition of inflammation
  1181. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of Rapamycin pathway
  1182. inhibition of the mammalian target of Rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells
  1183. LY294002 and Rapamycin co‐operate to inhibit T‐cell proliferation
  1184. The mTOR inhibitor Rapamycin down-regulates the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
  1185. The immunosuppressant Rapamycin exacerbates neurotoxicity of Aβ peptide
  1186. … transcriptionally and posttranslationally through phosphatidylinositol 3′-kinase/Akt, heat shock protein 90, and mammalian target of Rapamycin in transformed NK …
  1187. From Rapa Nui to Rapamycin: targeting PI3K/Akt/mTOR for cancer therapy
  1188. Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of Rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways …
  1189. Statins induce mammalian target of Rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs
  1190. Target of Rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
  1191. Phophatidylinositol-3 Kinase/Mammalian Target of Rapamycin/p70S6K Regulates Contractile Protein Accumulation in Airway Myocyte Differentiation
  1192. Amino acid signaling through the mammalian target of Rapamycin (mTOR) pathway: role of glutamine and of cell shrinkage
  1193. Rapamycin: friend, foe, or misunderstood?
  1194. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ
  1195. The product of the UTH1 gene, required for Bax‐induced cell death in yeast, is involved in the response to Rapamycin
  1196. Effects of FK506 and Rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes
  1197. Sustained intraocular Rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits
  1198. Effects of Rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells
  1199. Mammalian target of Rapamycin
  1200. Rapamycin analogs for stent-based local drug delivery
  1201. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of Rapamycin pathway
  1202. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by Rapamycin
  1203. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of Rapamycin activity and increased translation under hypoxic conditions
  1204. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses Rapamycin action by stabilizing these …
  1205. Mechanisms of action of Rapamycin in gliomas
  1206. Enhancement of translation elongation in neurons by brain‐derived neurotrophic factor: Implications for mammalian target of Rapamycin signaling
  1207. Oral Rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study
  1208. Effects of combined treatment with Rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts
  1209. Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of Rapamycin (mTOR) and extracellular signal-regulated kinase (ERK …
  1210. Rapamycin and tumor growth: mechanisms behind its anticancer activity
  1211. inhibition of mammalian target of Rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-κB …
  1212. Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of Rapamycin signaling pathway
  1213. Modulation of insulin action by dietary proteins and amino acids: role of the mammalian target of Rapamycin nutrient sensing pathway
  1214. Rituximab in association with Rapamycin for post-transplant lymphoproliferative disease treatment
  1215. … macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a Rapamycin-sensitive, mTOR-related …
  1216. Rapamycin‐mediated induction of γ‐globin mRNA accumulation in human erythroid cells
  1217. Differing responses of Gat1 and Gln3 phosphorylation and localization to Rapamycin and methionine sulfoximine treatment in Saccharomyces cerevisiae
  1218. Mammalian target of Rapamycin inhibitors in combination with letrozole in breast cancer
  1219. … 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of Rapamycin signaling pathway and …
  1220. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells
  1221. Combination therapy of mycophenolate mofetil and Rapamycin in prevention of chronic renal allograft rejection in the rat1
  1222. Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy
  1223. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and Rapamycin
  1224. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability
  1225. … identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and Rapamycin
  1226. Gln3 phosphorylation and intracellular localization in nutrient limitation and starvation differ from those generated by Rapamycin inhibition of Tor1/2 in …
  1227. Rapamycin preserves renal function compared with cyclosporine A after ischemia/reperfusion injury
  1228. … -inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of Rapamycin (mTOR) pathway is …
  1229. Superior T-cell suppression by Rapamycin and FK506 over Rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory …
  1230. Estrogen-induced activation of mammalian target of Rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain
  1231. … progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin pathway: progesterone receptor as …
  1232. Acceleration of apoptosis in CD4+ CD8+ thymocytes by Rapamycin accompanied by increased CD4+ CD25+ T cells in the periphery1
  1233. Intracellular network of phosphatidylinositol 3‐kinase, mammalian target of the Rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen‐activated protein kinases …
  1234. Interleukin-12-induced interferon-γ production by human peripheral blood T cells is regulated by mammalian target of Rapamycin (mTOR)
  1235. Pilot study of oral Rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial)
  1236. … artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of Rapamycin/p70 ribosomal S6 kinase …
  1237. Interferon α-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of Rapamycin signaling pathway
  1238. ROS fusion tyrosine kinase activates a SH2 domain–containing phosphatase-2/phosphatidylinositol 3-Kinase/mammalian target of Rapamycin signaling axis to form …
  1239. Hyperactivation of mammalian target of Rapamycin (mTOR) signaling by a gain-of-function mutant of the Rheb GTPase
  1240. Oral Rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice
  1241. Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs
  1242. inhibition of insulin signaling and adipogenesis by Rapamycin: effect on phosphorylation of p70 S6 kinase vs eIF4E-BP1
  1243. Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or Rapamycin
  1244. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of Rapamycin
  1245. Insulin-like growth factor I-mediated protection from Rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling …
  1246. Efficacy of polyphenon E, red ginseng, and Rapamycin on benzo (a) pyrene-induced lung tumorigenesis in A/J mice
  1247. … of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of Rapamycin in leukemic cells
  1248. Sustained activation of the mammalian target of Rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in …
  1249. Rapamycin antagonizes NF-κB nuclear translocation activated by TNF-α in primary vascular smooth muscle cells and enhances apoptosis
  1250. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of Rapamycin
  1251. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis
  1252. Mammalian target of Rapamycin (mTOR) inhibitors
  1253. Glucose-stimulated DNA synthesis through mammalian target of Rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent …
  1254. Targeting the AIB1 oncogene through mammalian target of Rapamycin inhibition in the mammary gland
  1255. Activation of mammalian target of Rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular …
  1256. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology …
  1257. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a Rapamycin-and farnesylation-dependent manner
  1258. Rapamycin analogs with reduced systemic exposure
  1259. Mammalian target of Rapamycin and protein kinase A signaling mediate the cardiac transcriptional response to glutamine
  1260. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis
  1261. Exercise‐induced alterations in extracellular signal‐regulated kinase 1/2 and mammalian target of Rapamycin (mTOR) signalling to regulatory mechanisms of mRNA …
  1262. Mechanistic insights into impaired dendritic cell function by Rapamycin: inhibition of Jak2/Stat4 signaling pathway
  1263. Cyclin D3 is down-regulated by Rapamycin in HER-2-overexpressing breast cancer cells
  1264. Rapamycin in children after liver transplantation
  1265. inhibition of the phosphatidylinositol 3-kinase/mammalian target of Rapamycin pathway in hematologic malignancies
  1266. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal …
  1267. Activation of mammalian target of Rapamycin in postmenopausal ovarian endometriosis
  1268. Fatal infection after Rapamycin eluting coronary stent implantation
  1269. Effect of Rapamycin on the healing of the bile duct
  1270. Rapamycin in lung transplantation
  1271. Evidence for cyclin D3 as a novel target of Rapamycin in human T lymphocytes
  1272. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation
  1273. Lipase-catalyzed regioselective esterification of Rapamycin: synthesis of temsirolimus (CCI-779)
  1274. Role of oral Rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial)
  1275. Structure-based design of AP23573, a phosphorus-containing analog of Rapamycin for anti-tumor therapy.
  1276. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN
  1277. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest
  1278. … of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of Rapamycin (RAD001) offers improved …
  1279. Ex vivo Rapamycin generates donor Th2 cells that potently inhibit graft-versus-host disease and graft-versus-tumor effects via an IL-4-dependent mechanism
  1280. Studies investigating pretransplant donor-specific blood transfusion, Rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin …
  1281. Early renal benefit of Rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients
  1282. inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung …
  1283. … Receptor Substrate-1 on Ser307 and Ser612 and Impairs the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Insulin Biosynthetic Pathway in …
  1284. Insulin facilitation of muscle protein synthesis following resistance exercise in hindlimb-suspended rats is independent of a Rapamycin-sensitive pathway
  1285. The role of heme oxygenase 1 in Rapamycin-induced renal dysfunction after ischemia and reperfusion injury
  1286. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53
  1287. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma
  1288. Perturbed IFN-γ-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of Rapamycin-IFN-γ treatment
  1289. Roles of phosphatidylinositol 3′-kinase and mammalian target of Rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial …
  1290. EFFECT OF Rapamycin ON THE FATE OF P23H OPSIN ASSOCIATED WITH RETINITS PIGMENTOSA (AN AMERICAN OPHTHALMOLOGICAL SOCIETY …
  1291. Synergistic immunosuppressive effects of rosmarinic acid and Rapamycin in vitro and in vivo1
  1292. Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, Rapamycin, and anti-interleukin-2 antibody1
  1293. Signaling interactions of Rapamycin combined with erlotinib in cervical carcinoma xenografts
  1294. Rapamycin inhibits release of tumor necrosis factor-[alpha] from human vascular smooth muscle cells
  1295. CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of Rapamycin pathway
  1296. Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of Rapamycin/p70 S6K pathway
  1297. Mammalian target of Rapamycin is required for thrombopoietin‐induced proliferation of megakaryocyte progenitors
  1298. The fission yeast TOR proteins and the Rapamycin response: an unexpected tale
  1299. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune®, Rapamycin) in pediatric patients with stable chronic renal failure undergoing …
  1300. Use of Rapamycin-impregnated stents in coronary arteries
  1301. In Vivo and In Vitro Effects of SAR 943, a Rapamycin Analogue, on Airway Inflammation and Remodeling
  1302. Farnesylthiosalicylic Acid Inhibits Mammalian Target of Rapamycin (mTOR) Activity Both in Cells and in Vitro by Promoting Dissociation of the mTOR-Raptor Complex
  1303. Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of Rapamycin pathway
  1304. Pharmacokinetics of sirolimus (Rapamycin) in subjects with mild to moderate hepatic impairment
  1305. Low-dose radiation plus Rapamycin promotes long-term bone marrow chimerism
  1306. Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model
  1307. Anti–third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with Rapamycin and BM cell dose
  1308. Combination of imatinib with Rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib
  1309. Outcomes of using Firebird Rapamycin eluting stents in routine coronary intervention practice: one-year results from the pilot study of Firebird in China registry
  1310. Prolactin activates mammalian target-of-Rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 …
  1311. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug Rapamycin: A direct role as an antifibrotic agent?
  1312. Pmr1, a Golgi Ca2+/Mn2+-ATPase, is a regulator of the target of Rapamycin (TOR) signaling pathway in yeast
  1313. Rapamycin ameliorates experimental autoimmune myocarditis
  1314. First experience with Rapamycin-based immunosuppression to improve kidney function after heart transplantation
  1315. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital …
  1316. The mammalian target of Rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9 …
  1317. Differential effects of Rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling
  1318. Rapamycin causes activation of protein phosphatase-2A1 and nuclear translocation of PCNA in CD4+ T cells
  1319. Rapamycin: a new string to the antiproteinuric bow?
  1320. … the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated …
  1321. Mammalian target of Rapamycin inhibitors in sarcomas
  1322. Liposomal formulations of tacrolimus and Rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts
  1323. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts
  1324. 5‐HT stimulates eEF2 dephosphorylation in a Rapamycin‐sensitive manner in Aplysia neurites
  1325. Blockage of 2-deoxy-D-ribose-induced angiogenesis with Rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer …
  1326. Rapamycin in lung transplantation: preliminary results
  1327. Tsc1 haploinsufficiency without mammalian target of Rapamycin activation is sufficient for renal cyst formation in Tsc1+/− mice
  1328. Novel sulfur-containing Rapamycin analogs prepared by precursor-directed biosynthesis
  1329. Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth
  1330. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
  1331. Akt and mammalian target of Rapamycin regulate separate systems of proteolysis in renal tubular cells
  1332. … with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of Rapamycin in breast cancer
  1333. Mammalian target of Rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional …
  1334. The effect of Rapamycin on the healing of the ureteric anastomosis and wound healing
  1335. Effect of SU11248 on gastrointestinal stromal tumor‐T1 cells: Enhancement of growth inhibition via inhibition of 3‐kinase/Akt/mammalian target of Rapamycin signaling
  1336. Combination of a Rapamycin analog (CCI‐779) and interferon‐γ is more effective than single agents in treating a mouse model of tuberous sclerosis complex
  1337. Overcoming T cell–mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and Rapamycin
  1338. Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the Rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital …
  1339. Rapamycin inhibits liver growth during refeeding in rats via control of ribosomal protein translation but not cap-dependent translation initiation
  1340. … is regulated by phosphorylation and turnover of protein kinase C βII mediated by phosphatidylinositol 3-kinase-and mammalian target of Rapamycin …
  1341. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience
  1342. Heme oxygenase-1 mediates the protective effects of Rapamycin in monocrotaline-induced pulmonary hypertension
  1343. Successful treatment of a severe case of idiopathic pulmonary fibrosis with Rapamycin
  1344. Evaluation of Rapamycin chemical stability in volatile-organic solvents by HPLC
  1345. Characterization of the cloned full-length and a truncated human target of Rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay
  1346. Rapamycin reduces neointima formation during vascular injury.
  1347. Effects of aerobic exercise training on the protein kinase B (PKB)/mammalian target of Rapamycin (mTOR) signaling pathway in aged skeletal muscle
  1348. Effects of Rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice
  1349. Effects of cyclosporin A and a Rapamycin derivative (SAR943) on chronic allergic inflammation in sensitized rats
  1350. Rapamycin induces a caspase‐independent cell death in human monocytes
  1351. Acute renal failure following kidney transplantation associated with myoglobinuria in patients treated with Rapamycin
  1352. Rapamycin inhibits cdk4 activation, p 21WAF1/CIP1 expression and G1‐phase progression in transformed mouse fibroblasts
  1353. Oral Rapamycin to prevent human coronary stent restenosis: a pilot study
  1354. A downstream kinase of the mammalian target of Rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability
  1355. Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of …
  1356. In rat hepatocytes glucagon increases mammalian target of Rapamycin phosphorylation on serine 2448 but antagonizes the phosphorylation of its downstream …
  1357. Podospora anserina target of Rapamycin
  1358. Mammalian target of Rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-β1 in prostate cancer …
  1359. Actin cytoskeleton is required for nuclear accumulation of Gln3 in response to nitrogen limitation but not Rapamycin treatment in Saccharomyces cerevisiae
  1360. Post-Rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center
  1361. Farnesylthiosalicylic acid blocks mammalian target of Rapamycin signaling in breast cancer cells
  1362. Prevention of lethal acute GVHD with an agonistic CD28 antibody and Rapamycin
  1363. Effects of simian virus 40 large and small tumor antigens on mammalian target of Rapamycin signaling: small tumor antigen mediates hypophosphorylation of eIF4E …
  1364. Rapamycin‐sensitive induction of eukaryotic initiation factor 4F in regenerating mouse liver
  1365. Nutrient restriction differentially modulates the mammalian target of Rapamycin signaling and the ubiquitin-proteasome system in skeletal muscle of cows and their …
  1366. The Saccharomyces cerevisiae phosphatase activator RRD1 is required to modulate gene expression in response to Rapamycin exposure
  1367. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of Rapamycin and simvastatin
  1368. Mammalian target of Rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option
  1369. … and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-γ is regulated by mammalian target of Rapamycin
  1370. The influence of the Rapamycin-derivate SDZ RAD on the healing of airway anastomoses
  1371. Cilomilast, tacrolimus and Rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis
  1372. The impact of cyclosporine dose reduction with or without the addition of Rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy
  1373. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of Rapamycin and cyclosporine
  1374. Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of Rapamycin-dependent …
  1375. Mammalian target of Rapamycin is a promising target for novel therapeutic strategy against cancer.
  1376. Effects of cyclosporin A, FK506 and Rapamycin on calcineurin phosphatase activity in mouse brain
  1377. Both mitogen activated protein kinase and the mammalian target of Rapamycin modulate the development of functional renal proximal tubules in matrigel
  1378. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of Rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast …
  1379. Effects of Rapamycin on cardiac and skeletal muscle contraction and crossbridge cycling
  1380. Frap, FKBP12 Rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene
  1381. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both Rapamycin-sensitive and-insensitive …
  1382. Modulation of translation‐initiation in CHO‐K1 cells by Rapamycin‐induced heterodimerization of engineered eIF4G fusion proteins
  1383. Rapamycin antagonizes cyclosporin A‐and tacrolimus (FK506)‐mediated augmentation of linker for activation of T cell expression in T cells
  1384. Activation of mammalian target of Rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL–expressing cells
  1385. Proteomic analysis of anti‐angiogenic effects by a combined treatment with vinblastine and Rapamycin in an endothelial cell line
  1386. The PCPH oncoprotein antagonizes the proapoptotic role of the mammalian target of Rapamycin in the response of normal fibroblasts to ionizing radiation
  1387. Sirolimus (Rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts
  1388. Mammalian target of Rapamycin inhibitors in renal cell carcinoma: current status and future applications
  1389. Investigating mammalian target of Rapamycin inhibitors for their anticancer properties
  1390. Rapamycin treatment results in GATA factor-independent hyperphosphorylation of the proline utilization pathway activator in Saccharomyces cerevisiae
  1391. The Rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27 Kip1
  1392. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of Rapamycin inhibitor, temsirolimus
  1393. Generating Rapamycin analogues by directed biosynthesis: starter acid substrate specificity of mono-substituted cyclohexane carboxylic acids
  1394. Electron microscopic and biochemical study of the effects of Rapamycin on glycogen autophagy in the newborn rat liver
  1395. … 4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of Rapamycin (mTOR)-and non …
  1396. Rapamycin in patients with chronic renal allograft dysfunction
  1397. Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of Rapamycin, and ribosomal S6 kinase 1 signaling pathways …
  1398. … of metallothionein rescues chronic alcohol intake-induced cardiomyocyte dysfunction: role of Akt, mammalian target of Rapamycin and ribosomal p70s6 kinase
  1399. Rapamycin inhibits E2F-dependent expression of minichromosome maintenance proteins in vascular smooth muscle cells
  1400. Targeting metastatic leiomyosarcoma by Rapamycin plus gemcitabine: an intriguing clinical observation
  1401. Vanadate and Rapamycin synergistically enhance insulin-stimulated glucose uptake
  1402. Rapamycin control of transgene expression from a single AAV vector in mouse salivary glands
  1403. Cutaneous leukocytoclastic vasculitis in a patient with myelodysplatic syndrome after therapy with the Rapamycin analogue everlimus: Case report and review of the …
  1404. Determining sensitivity to Rapamycin and its analogues in breast cancer patients
  1405. Rapamycin pre‐treatment preserves viability, ATP level and catabolic capacity during carbon starvation of Saccharomyces cerevisiae
  1406. Rapamycin and FK506 reduce skeletal muscle voltage sensor expression and function
  1407. Extracellular ATP-induced proliferation of adventitial fibroblasts requires phosphoinositide 3-kinase, Akt, mammalian target of Rapamycin, and p70 S6 kinase …
  1408. The mTOR pathway in estrogen response: A potential for combining the Rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara®) in breast …
  1409. inhibition of mammalian target of Rapamycin modulates expression of adhesion molecules in endothelial cells
  1410. SUMO modification through Rapamycin-mediated heterodimerization reveals a dual role for Ubc9 in targeting RanGAP1 to nuclear pore complexes
  1411. Cyclosporine and Rapamycin act in a synergistic and dose-dependent manner in a model of immunosuppressant-induced kidney damage
  1412. Current Data with Mammalian Target of Rapamycin Inhibitors in Advanced Renal Cell Carcinoma
  1413. Novel site‐specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model
  1414. The phosphatase subunit tap42 functions independently of target of Rapamycin to regulate cell division and survival in Drosophila
  1415. Rapamycin control of exocrine protein levels in saliva after adenoviral vector-mediated gene transfer
  1416. Farnesyltransferase inhibitors and Rapamycin in the treatment of multiple myeloma
  1417. RACK1 mRNA translation is regulated via a Rapamycin-sensitive pathway and coordinated with ribosomal protein synthesis
  1418. Mammalian target of Rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate
  1419. Bone morphogenetic protein-2–induced transformation involves the activation of mammalian target of Rapamycin
  1420. Rapamycin prolongs susceptibility of responding T cells to tolerance induction by CD8+ veto cells
  1421. Current status of mammalian target of Rapamycin inhibitors in lung cancer
  1422. Rapamycin inhibits vascular remodeling in an experimental model of allograft vasculopathy and attenuates associated changes in fibrosis-associated gene …
  1423. Rapamycin and dendritic cells: keep on movin’
  1424. Involvement of c-Jun NH2 terminal kinase and p38MAPK in Rapamycin-mediated inhibition of neointimal formation in rat carotid arteries
  1425. Involvement of the VDE homing endonuclease and Rapamycin in regulation of the Saccharomyces cerevisiae GSH11 gene encoding the high affinity …
  1426. Immunomodulatory effects of combination of pooled human gammaglobulin and Rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction
  1427. Six-month intravascular ultrasound follow-up of coronary bifurcation lesions treated with Rapamycin-eluting stents: technical considerations
  1428. Trace analysis of Rapamycin in human blood by micellar electrokinetic chromatography
  1429. Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of Rapamycin, additively inhibit rhabdomyosarcoma growth
  1430. Differential translation of TOP mRNAs in Rapamycin-treated human B lymphocytes
  1431. Rapamycin for androgen-independent prostrate cancer (AIPC)
  1432. Rapamycin for cardiac transplant rejection and vasculopathy: one stone, two birds?
  1433. Sirolimus and everolimus: inhibitors of mammalian target of Rapamycin in liver transplantation
  1434. Rapamycin inhibits choroidal neovascularization
  1435. Deletion of HOG1 leads to Osmosensitivity in starvation-induced, but not Rapamycin-dependent Atg8 degradation and proteolysis: Further evidence for different …
  1436. Structure and function of mammalian target of Rapamycin [J]
  1437. Comparison of Rapamycin and paclitaxel eluting stent in patients with multi-vessel coronary disease
  1438. Retracted: Rapamycin Attenuates Liver Graft Injury in Cirrhotic Recipient—The Significance of Down‐Regulation of Rho‐ROCK‐VEGF Pathway
  1439. Pharmacokinetics of Rapamycin-eluting stents in miniswine coronary model.
  1440. Combination therapy with sirolimus (Rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report
  1441. Combination of the mammalian target of Rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A …
  1442. Rapamycin and chronic lung rejection
  1443. Synergistic suppression of rat neointimal hyperplasia by Rapamycin and imatinib mesylate: implications for the prevention of accelerated arteriosclerosis
  1444. An intramolecular ionic hydrogen bond stabilizes a cis amide bond rotamer of a ring‐opened Rapamycin‐degradation product
  1445. The effect of combined Rapamycin/cyclosporine on the changes in pro-fibrotic gene expression that occur during the development of allograft vasculopathy in rats …
  1446. Modulation of tissue factor expression by Rapamycin and FK-506 in lipopolysaccharide-stimulated human mononuclear cells and serum-stimulated aortic smooth …
  1447. Effect of Rapamycin on hepatic osteodystrophy in rats with portasystemic shunting
  1448. Preclinical rationale for therapeutic targeting of mTOR by CC-I779 and Rapamycin in Hodgkin lymphoma
  1449. Potential role of mammalian target of Rapamycin inhibitors in breast cancer therapy
  1450. Altered centrosomes in ataxia‐telangiectasia cells and Rapamycin‐treated Chinese hamster cells
  1451. Determination of Rapamycin: quantification of the sodiated species by an ion trap mass spectrometer as an alternative to the ammoniated complex analysis by triple …
  1452. Nutritional studies on the growth of the Rapamycin-producing Streptomyces hygroscopicus
  1453. A novel technique for on‐capillary preconcentration of anionic compounds applied to the trace analysis of Rapamycin in human blood by capillary electrophoresis
  1454. … of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of Rapamycin (mTOR) inhibitor everolimus …
  1455. Glucose-induced binding of the polypyrimidine tract-binding protein (PTB) to the 3′-untranslated region of the insulin mRNA (ins-PRS) is inhibited by Rapamycin
  1456. A phase I trial of gefitinib (ZD1839) plus Rapamycin for patients with recurrent malignant glioma
  1457. Clinical use of Rapamycin in renal allograft recipients identifies its relevant toxicity profile and raises unsolved questions: a single-center experience
  1458. Lung toxicity induced by Rapamycin
  1459. Countervailing effects of Rapamycin (sirolimus) on nuclear factor-κB activities in neointimal and medial smooth muscle cells
  1460. Dose-dependent inhibition of myointimal hyperplasia by orally administered Rapamycin
  1461. Association of Rapamycin and co-stimulation blockade using anti-B7 antibodies in renal allotransplantation in baboons
  1462. inhibition of growth and metastasis of hepatocellular carcinoma by Rapamycin: experiment with mice
  1463. Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl] Rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro
  1464. Rapamycin inhibits platelet-derived growth factor-induced collagen, but not fibronectin, synthesis in rat mesangial cells
  1465. A combination of anergic cells’ adoptive transfer and Rapamycin therapy prolongs cardiac allograft survival in mice
  1466. Local application of Rapamycin inhibiting restenosis in experimental vein graft
  1467. Negative regulation of interleukin-12 production by a Rapamycin-sensitive signaling pathway: a brief communication
  1468. Rapamycin-based rescue therapy after chronic rejection in a pediatric liver transplant patient
  1469. Altered trafficking of CD8+ memory T cells after implantation of Rapamycin-eluting stents in patients with coronary artery disease
  1470. Rapamycin at six years can exhibit normal renal function without proteinuria or neoplasia after renal transplantation. A single-center experience
  1471. Expression of placental mammalian target of Rapamycin (mTOR) is altered in relation to fetal growth and mTOR regulates leucine transport
  1472. Regulation of hepatic insulin-like growth factor-binding protein-1 gene expression by insulin: central role for mammalian target of Rapamycin independent of forkhead …
  1473. Rapamycin–a Potential Mechanistically Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.
  1474. In vivo and in vitro effect of CCI-779 a Rapamycin analogue on HNSCC.
  1475. Pathologic assessment of cardiomyocytes in heart transplant recipients treated with Rapamycin or cyclosporine
  1476. Pharmacodynamic-guided, modified continuous reassessment method (mCRM)-based, dose finding study of Rapamycin in adult patients with solid tumors
  1477. Pharmacokinetics and safety of ABT-578, a sirolimus (Rapamycin) analogue, after single intravenous bolus injection in healthy male volunteers
  1478. Rapamycin Inhibits Retinal and Choroidal Neovascularization in Mice
  1479. In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.
  1480. Dual effects of Rapamycin on immuno-suppression and tumor inhibition
  1481. Rapamycin inhibits the pathogenesis of posterior capsule opacification: experimental study on rabbit [J]
  1482. Sphingosine-1-phosphate–induced smooth muscle cell migration involves the mammalian target of Rapamycin
  1483. Phase I study of gefitinib and Rapamycin in patients with recurrent or progressive glioblastoma (Gbm)
  1484. Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early …
  1485. Effect of Rapamycin on cytokine profile in kidney transplant recipients treated with triple drug therapy
  1486. Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection
  1487. Effect of Rapamycin on Phenotype of Vascular Smooth Muscle Cell and Arterial Intimal Hyperplasia Post Balloon Injury in Rat [J]
  1488. Rapamycin plays a new role as differentiator of vascular smooth muscle phenotype. Focus on “The mTOR/p70 S6K1 pathway regulates vascular smooth muscle …
  1489. … -up of the unrestricted use of the sirolimus-eluting stent compared to the use of a standard bare metal stent as part of the Rapamycin-Eluting-Stent Evaluated at …
  1490. Observations on quadruple immunosuppression maintenance therapy using Rapamycin, low-dose cyclosporine, mycophenolate mofetil, and prednisone following …
  1491. Mode of action of FK506 and Rapamycin
  1492. Phase I study of Rapamycin (R) in combination with CYP3A4 modifier, ketoconazole (K), in patients with advanced malignancies
  1493. Renal calcium handling after Rapamycin conversion in chronic allograft dysfunction
  1494. Studies towards the synthesis of Rapamycin: Regiocontrol in the addition of carbanions to enantiomerically pure epoxides and the formation of a highly substituted …
  1495. Rapamycin.
  1496. Thrombosis caused by active Rapamycin stents
  1497. Effect of Rapamycin and dexamethasone on differentiation and maturation of murine bone marrow-derived dendritic cells
  1498. Comparison of Rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy
  1499. Why inhibitors of mammalian target of Rapamycin will be important in organ transplantation
  1500. Stent release of a Rapamycin analogue: tissue pharmacokinetics of rapid versus delayed release
  1501. Rapamycin: from the laboratory to the treatment of patients’ arteries
  1502. Experimental study on the effects of Rapamycin in prevention of rat corneal allograft rejection
  1503. Rapamycin overcomes multidrug resistance (MDR) mediated by P-glycoprotein (Pgp), Multidrug Resistance Protein-1 (MRP-1), Breast Cancer Resistance Protein …
  1504. Complete assignments of the 1H and 13C resonances of 40‐epi‐(N1‐tetrazolyl)‐Rapamycin and revised 13C assignments for Rapamycin
  1505. The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma.
  1506. Oral Rapamycin for the prevention of in-stent restenosis
  1507. Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.
  1508. Surviving Rapamycin
  1509. Lack of effect of Rapamycin in anti-CCP antibody production in a rheumatoid arthritis kidney allograft recipient
  1510. Mammalian target of Rapamycin inhibitors in transplantation: novel immunosuppressive strategies with sirolimus
  1511. Efficacy of Early Use of Rapamycin for Patients after Renal Transplantation and the Complications
  1512. 1139-52 Biolimus A9: a new generation Rapamycin analogue inhibits intimal hyperplasia in a porcine model
  1513. Rapamycin eluting stents
  1514. Mammalian target of Rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole
  1515. Rapamycin: sc-3504
  1516. Investigation of Rapamycin and Rapamycin metabolites.
  1517. Inhibitors of mammalian target of Rapamycin: mechanism of action explains efficacy and toxicity
  1518. Rapamycin even when combined with cyclosporine attenuates tumor growth but does not induce regression of established walker sarcomas
  1519. Sirolimus (Rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: An initial experience in Taiwan
  1520. Clinic application of Rapamycin-eluting stent for coronary heart disease [J]
  1521. Intravitreal toxicity of Rapamycin
  1522. Two-year experience with Rapamycin in kidney transplantation
  1523. Safety and efficacy of sirolimus-eluting stent (cypher) in acute myocardial infarction: A substudy of the Rapamycin-Eluting Stent Evaluation at Rotterdam Cardiology …
  1524. Sirolimus-eluting stents for treatment of in-stent restenosis in the real world: Preliminary results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology …
  1525. Rapamycin Combined with Cyclosporine in the Prevention of Acute Renal Allograft Rejection: Randomized Prospective Control Study
  1526. Adverse effects of local or systemic application of Rapamycin for the prevention of neointimal hyperplasia
  1527. Effect of combined regimen of Rapamycin and Cyclosporine on renal transplant recipients [J]
  1528. Short-term Rapamycin for inhibition of neointima formation after balloon-mediated aortic injury in rats: is there a window of opportunity for systemic prophylaxis of …
  1529. Pilot study with oral Rapamycin in patients undergoing stenting in coronary arteries: Buenos Aires experience (ORAR trial)
  1530. CONTRASTING EFFECTS OF CYCLOSPORIN AND Rapamycin IN DE NOVO GENERATION OF ALLOANTIGEN-STIMULATED REGULATORY T CELLS.
  1531. Combination of the mTOR inhibitor Rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) inhibits proliferation and induces apoptosis …
  1532. Effects of Rapamycin-treated HSP60-pulsed dendritic cells on the progression of the atherosclerotic plaque in mice [J]
  1533. Curcumin disrupts the complexes of the mammalian target of Rapamycin
  1534. Review on Rapamycin as a potential therapeutic agent against neurodegenerative disease
  1535. TOR (target of Rapamycin)-mediated regulation of translation
  1536. Comparison of Different Therapies Of CYPHERTM Stent For Patients with Bifurcated Lesion Using Rapamycin
  1537. Experimental study of effect of Rapamycin on proliferation of rat aortic smooth muscle cells
  1538. Influence of CTLA4Ig combined with Rapamycin on the survival of renal allografts in rats [J]
  1539. Local applied slow-releasing Rapamycin inhibits neointima hyperplasia in vein graft
  1540. Rapamycin PREVENTS INTERSTITIAL FIBROSIS IN RENAL ALLOGRAFTS THROUGH DECREASING ANGIOGENESIS AND INFLAMMATION.
  1541. … Regulatory (CD4+ CD25+ CD127LowFOXP3+) Cells to High Purity by Inhibiting Expansion of CD4+ CD25+ CD127HighFOXP3-Conventional T Cells with Rapamycin …
  1542. Rapamycin impairs the healing of the ureteric anastomosis
  1543. Effects of Rapamycin on the early development of zebrafish (Danio rerio)
  1544. The combination of arsenic trioxide and Rapamycin has potent inhibitory effects on acute myeloid leukemia (AML) cells
  1545. avb3-integrin-targeted paramagnetic nanoparticles deliver Rapamycin into the vascular wall and inhibit stenosis following balloon injury
  1546. Treatment of lesions with a high risk of stenosis. comparative study in 300 patients of Rapamycin-and paclitaxel-eluting polymer-based stents, and bare metal stents
  1547. Rapamycin Has Biological Activity in a Subset of Patients with Myelodysplastic Syndrome-Results of a Phase I/II Trial.
  1548. Effect of Mycophenolic Acid and Rapamycin on the Proliferation of Glomerular Mesangial Cell of Rat
  1549. Regulation of the mammalian target of Rapamycin complex 2 (mTORC2)
  1550. Rapamycin NOT CYCLOSPORINE INDUCES REGULATORY CD8+ FOXP3+ CELLS.
  1551. Comparison of the effects of Rapamycin-eluting stent implantation and coronary artery bypass grafting in treatment of patients with multi-vessel coronary disease
  1552. Glucose-stimulated DNA Synthesis through Mammalian Target of Rapamycin (mTOR) Is Regulated by KATP Channels
  1553. Subretinal sustained delivery of Rapamycin in the rabbit eye
  1554. Constitutive Activation of Akt and mTOR by Flt3 Internal Tandem Duplications Mediates Myeloid Leukemogenesis and Can Be Inhibited by Rapamycin.
  1555. Long-term clinical efficiency of endovascular treatment using Cypher Rapamycin-eluting stents in patients with coronary heart disease
  1556. DOES Rapamycin EFFECT WOUND HEALING?
  1557. Successful retransplantation using Rapamycin in a patient with previous calcineurin inhibitor-induced posterior leukoencephalopathy syndrome.
  1558. Rapamycin inhibits the development of gallbladder adenocarcinoma in BK5. erbB2 transgenic mice
  1559. Rapamycin disruption of mTOR-mLST8-raptor complex inhibits cell motility
  1560. In vitro Rapamycin and costimulation generates Th1/Tc1 or Th2/Tc2 central memory effectors: Differential regulation by in vivo Rapamycin after allogeneic BMT
  1561. Effect of combination of curcumin and Rapamycin on proliferation of rat glomerular mesangial cells
  1562. Signaling by Target of Rapamycin Proteins
  1563. Distinct mechanisms by which low and high Rapamycin doses raise plasma triglycerides in guinea pigs
  1564. Everolimus: a classical mammalian target of Rapamycin inhibitor?
  1565. Murine Ultrasonography Confirms That Rapamycin Is Effective Against Autoimmune Lymphoproliferative Syndrome (ALPS).
  1566. STABILIZATION OF LONG-TERM PEDIATRIC RENAL ALLOGRAFTS WITH Rapamycin.
  1567. A tissue selective Rapamycin analog inhibits MDA-MB-231 breast cancer cell-induced osteolytic bone metastases in nude mice
  1568. Rapamycin throws a master switch.
  1569. Rapamycin-CUSTOMIZED DENDRITIC CELLS ARE RESISTANT TO MATURATION INDUCED BY CD40 LIGATION—A CONDITION PIVOTAL TO THEIR …
  1570. USE OF Rapamycin IN CHILDREN POST LIVER TRANSPLANTATION
  1571. Mammalian Target of Rapamycin inhibition Synergistically Increases Cytotoxicity of Vinorelbine in Breast Cancer Cells.
  1572. The role of caspase-3 in Rapamycin-induced apoptosis of hepatocellular carcinoma BEL-7402 cells
  1573. Enhanced Killing of Chronic Myelogenous Leukemia Cells by Rapamycin and Imatinib Is Associated with Differential inhibition of 4E-BP1 and eIF4E Phosphorylation …
  1574. Rapamycin Induces Balb/C Murine CD4+CD25+Foxp3+ T Cells Proliferations.
  1575. Effect of locally administered Rapamycin and cyclosporin A on penetrating keratoplasty rejection rat model
  1576. Curcumin inhibits the mammalian target of Rapamycin-mediated signaling pathways
  1577. Bone-targeted Rapamycin analogs inhibit osteolysis and tumor growth in a PC-3-GFP intratibial bone cancer model in nude mice
  1578. The expression of mammalian target of Rapamycin and its substrates in autogenous vein graft in rats
  1579. Effects of Rapamycin on Notch1/Jagged1 signal pathway and the expression of fibronectin in TGF-β, induced rat renal intertitial fibroblasts [J]
  1580. The mTOR Inhibitor Rapamycin Inhibits Drug Transport in Multidrug Resistant Cell Lines and in Acute Myeloid Leukemia (AML) Cells.
  1581. Effect of Rapamycin on Corneal Neovascularization
  1582. THE EFFECT OF Rapamycin ON BILE DUCT HEALING
  1583. Safety and efficacy comparison between Rapamycin-eluting stent with biodegradable polymer or permanent polymer in patients with coronary artery disease
  1584. Rapamycin added to human CD25+ cell cultures activated through CD3/CD28 enriches for CD4+ CD25+ CD27+ Foxp3+ regulatory T cells
  1585. Effect of Mycophenolic Acid and Rapamycin on the Proliferation and Collagen Synthesis of the Vascular Smooth Muscle Cell of Rat
  1586. Two-year experience with Rapamycin in kidney transplantation
  1587. Effects of Rapamycin on the function of human dendritic cells
  1588. Effects of Rapamycin on Rho-kinase and p27 mRNA expressions in a porcine coronary intimal proliferation model induced by interleukin-1beta
  1589. IN CONTRAST TO CYCLOSPORIN, Rapamycin SPARES FOXP3+ CD4+ T-CELLS IN VIVO.
  1590. Rapamycin THERAPY IN PANCREAS ALLOGRAFT RECIPIENTS
  1591. Sustained Rapamycin drug delivery system in prevention of high risk corneal allograft rejection and neovascularization in rabbits
  1592. The role of GSK3β in Rapamycin-mediated cell cycle regulation
  1593. Rapamycin Treatment Results in GATA
  1594. Possible molecular target therapy with Rapamycin in MDS
  1595. Blocking mTOR by Rapamycin reduces HIF-1α function in human gastric cancer cells in vitro and inhibits angiogenesis and tumor growth in vivo
  1596. Influence of CTLA4Ig combined with Rapamycin on the survival of renal allografts in rats
  1597. Combination therapy of bevacizumab with Rapamycin in antitumor activity.
  1598. EVALUATION OF APOPTOSIS IN PERIPHERAL HUMAN LYMPHOCYTES EXPOSED TO Rapamycin.
  1599. … IN CHRONIC ALLOGRAFT NEPHROPATHY (CAN) FOLLOWING CALCINEURIN INHIBITORS (CNI) WITHDRAWAL AND CONVERSION TO Rapamycin.
  1600. Application of Rapamycin in the patients with liver injury following renal transplantation: a report of 7 cases
  1601. Establishment of a Rapamycin-resistant cell line that retains sensitivity to PI3 kinase inhibitors.
  1602. mTOR (mammalian target of Rapamycin) inhibition with RAD001 induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitizes DLBCL cells to …
  1603. A Novel Serum-Stable Micelle System for Controlled Release of Rapamycin
  1604. The effects of Rapamycin for the chole-sterol rabbits after balloon injury
  1605. Effect of New Immunosuppressant-Rapamycin on One-Way Mixed Lymphocyte Culture
  1606. inhibition of repopulation is not a determining factor for the radiosensitizing effects of Rapamycin
  1607. Antitumor efficacy of Rapamycin derivertive RAD001 in human ovarian cancer
  1608. Dendritic cells, Rapamycin and transplant tolerance
  1609. Troglitazone Exerts a Cell-Dependent Effect on the Extracellular Secretion of VEGF165 Independently from the Rapamycin Sensitivity or the Level of eIF4E …
  1610. Rapamycin inhibited the growth of hepatocellular carcinoma in nude mice
  1611. Rapamycin-Eluting Stents for the Treatment of In-Stent Restenosis
  1612. Effect of Rapamycin on Renal Ischemia Reperfusion Injury
  1613. Mutant type glutathione S-transferase theta 1 gene homologue to mTOR in myelodysplastic syndrome: possible clinical application of Rapamycin
  1614. A RARE CASE OF Rapamycin INDUCED SECRETORY DIARRHEA IN A LIVER TRANSPLANT PATIENT: 544
  1615. Clinical application of domestic Rapamycin-eluting stents in coronary heart disease patients
  1616. The Studies of Antitumor Effect of Rapamycin on Human Hepatocellular Carcinoma BEL-7402 Cells in vitro
  1617. Investigation of the Function and Regulatory Mechanisms of the Mammalian Target of Rapamycin
  1618. New progress of Rapamycin in prevention and treatment of chronic allograft nephropathy
  1619. Mammalian Target of Rapamycin (mTOR)
  1620. Rapamycin treatment during fractionated radiotherapy causes cell death in 3D culture
  1621. 18F-Labeled analog of Rapamycin for PET imaging
  1622. Rapamycin-SENSITTVE SIGNAL TRANSDUCTION PATHWAYS AND THE CONTROL OF ADIPOGENESIS
  1623. Therapeutic effect of Rapamycin in the treatment of malignancies in recipients after kidney transplantation
  1624. Sirolimus (Rapamycin) impairs renal function
  1625. Rapamycin INHIBITS NK CELL FUNCTION
  1626. … WITH THYMOGLOBULIN/ZENAPAX INDUCTION, TACROLIMUS AND STEROID MAINTENANCE, COMPARING Rapamycin WITH MYCOPHENOLATE MOFETIL …
  1627. Rapamycin modifies the vascular tone of rat isolated aortas
  1628. Rapamycin-INDUCED PROTEINURIA: INCIDENCE, OUTCOME AND THERAPEUTIC HANDLING.
  1629. Prolonged survival of renal allografts with domestic Rapamycin in rats [J]
  1630. … FUNCTIONS OF REGULATORY T CELLS, LEADING, IN CONJUNCTION WITH A BRIEF SUB-THERAPEUTIC COURSE OF Rapamycin, TO ROBUST, DONOR …
  1631. Clinical Benefits of Rapamycin-Eluting Stent Implantation in Patients With Acute Coronary Syndromes
  1632. The role of phosphorylation in the regulation of the mammalian target of Rapamycin.
  1633. The clinical effect of homemade Rapamycin-eluting stent on acute myocardial infarction
  1634. Regulation of skeletal muscle differentiation by a Rapamycin-sensitive signaling pathway
  1635. THE MAMMALIAN TARGET OF Rapamycin (mTOR) AS A TARGET FOR CANCER CHEMOTHERAPY
  1636. Combination therapy targeting hypoxia inducible factor-α (HIF-1 α) and Tissue Factor (TF) by the mTOR inhibitor Rapamycin and the histone deacetylase inhibitor …
  1637. Rapamycin is efficacious against gliomas and acts as an anti-VEGF and anti-invasion agent
  1638. DIFFERENT FUNCTIONAL, HISTOLOGICAL AND INMUNOHISTOCHEMICAL PATTERNS INDUCED BY THE ASSOCIATION OF Rapamycin WITH FK506 OR …
  1639. Orally Administered Rapamycin Can Inhibit Myointimal Hyperplasia: Should It Be Used?
  1640. Effects of Rapamycin-eluted stent on platelet function in patients with coronary heart disease
  1641. Regulation of the GATA-type transcription factor Gln3p by the target of Rapamycin protein (TOR).
  1642. Combination of Rapamycin and somatostatin analogues for the treatment of nonfunctioning pituitary tumors
  1643. The experimental study on the effects of Rapamycin and statin on chronic transplant vasculopathy
  1644. Rapamycin targets Cyclin/Cdk/p21/PCNA complexes and Cyclin D1 reverses Rapamycin action by stabilizing these complexes
  1645. Rapamycin conversion for immunosuppressive therapy in the setting of renal insufficiency in patients with heart transplantation: pilot observations
  1646. Inhibitory Effect of Rapamycin on Corneal Neovascularization induced by Angiogenin in Rabbits
  1647. NURSING IMPLICATIONS REGARDING THE MANAGEMENT OF SIDE EFFECTS IN A PHASE I STUDY USING GEFITINIB WITH Rapamycin.
  1648. Clinical Contrast Investigation of Rapamycin Eluting Stent between Chinese Making and Imported
  1649. The role of mammalian target of Rapamycin (mTOR) in a rat model of autoimmune myocarditis
  1650. Effect of Rapamycin on Mouse Chronic Lymphocytic Leukemia and the Development of Nonhematopoietic Malignancies in Em-TCL1 Transgenic Mice
  1651. Overview of Therapeutic Potential of Rapamycin for Coronary Artery Diseases in the Era of the Drug-Eluting Stent
  1652. Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis
  1653. Rapamycin for Cardiac Transplant Rejection and Vasculopathy
  1654. Rapamycin synergistically enhances the cytotoxicity of paclitaxel in breast cancer cells
  1655. Oral Rapamycin attenuates progression of atherosclerotic plaque in ApoE knockout mice
  1656. Clinical Research of Rapamycin-Eluting Stent in Treatment of Multi-Vessel Coronary Disease
  1657. Rapamycin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells
  1658. Biocompatibility of Rapamycin-Batroxobin Eluting Stent in Porcine Coronary Artery
  1659. Effect of Rapamycin on anti-HLA donor antibody formation in patients with transplant coronary artery disease
  1660. Combination of the mTOR Inhibitor Rapamycin and Revlimid™(CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).
  1661. Characterization of the FKBP·Rapamycin·FRB Ternary Complex  [J. Am. Chem. Soc. 2005, 127, 4715−4721].
  1662. Is there a role for oral Rapamycin in restenosis prevention after bare-metal stent implantation?
  1663. Isolation and Genetic Analysis of Rapamycin-sensitive mutants in Aspergillus nidulans.
  1664. Overexpression of the Bad mutant (S112A) partially disrupts the ability of IGF-I to protect cells from Rapamycin-induced apoptosis
  1665. One year effect of Rapamycin eluting stent in patients with coronary heart disease
  1666. The role of mammalian target of Rapamycin (mTOR) in insulin resistance
  1667. Rapamycin AND SANGLIFEHRIN A CAN INHIBIT INTERLEUKIN-18 PRODUCTION FROM DENDRITIC CELLS IN VITRO AND IN VIVO.
  1668. MRI detection of Rapamycin and AP-Cav therapeutic rescue from endothelial over expression of Akt in transgenic mice
  1669. SENSITIVITY OF HUMAN METASTATIC MELANOMA CELLS TO THE ESTER ANALOG OF Rapamycin, CCI-779
  1670. Synergistic growth inhibition by Iressa and Rapamycin in Renal Cell Carcinoma (RCC) with wild-type VHL
  1671. Six-month results of a biodegradable polymer and Rapamycin-coating stent for coronary artery disease
  1672. The mTOR inhibitor, Rapamycin, inhibits growth of Ewing’s sarcoma in vitro and in vivo
  1673. EEEICACY AND SAFETY OF Rapamycin-BASED IMMUNOSUPPRESSION REGIMEN WITH OR WITHOUT CSA IN RENAL TRANSPLANTATION: A SYSTEMATIC …
  1674. Rapamycin Inhibits Rabbit Corneal Neovascularization Induced by Angiogenin
  1675. Preclinical analysis of Rapamycin plus EGFR or MEK1/2 inhibitors in renal cell carcinoma (RCC)
  1676. Effect of Rapamycin (RPM) on interleukin-10 gene expression in rats with postburn Staphylococcus aureus sepsis
  1677. Effect of Rapamycin on mouse CLL and development of non-hematopoietic malignancies in Eμ-TCL1 transgenic mice
  1678. Effect of isoflavones alone and in combination with Rapamycin on mTOR pathway in human glioblastoma cells (U87).
  1679. Rapamycin INHIBITS THE SPONTANEOUS FORMATION OF DE NOVO CANCER IN P53 KNOCKOUT MICE.
  1680. Urokinase-induced smooth muscle cell migration involves the mammalian target of Rapamycin
  1681. Importance of mammalian target of Rapamycin inhibitors in the prevention of cardiac allograft vasculopathy
  1682. Rapamycin enhances the number and function of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro
  1683. Clinical contrast investigation of Rapamycin eluting stent between Chinese making and imported in the treatment of coronary artery disease
  1684. Rapamycin inhibits activation of STAT3 in renal tissue of IgA nephropathy rats
  1685. The mTOR inhibitor Rapamycin inhibits proadhesive activity of arterial intimal smooth muscle cells
  1686. Identification of a highly effective Rapamycin schedule that markedly reduces the size, multiplicity and phenotypic progression of tobacco carcinogen-induced murine …
  1687. Mammals Target Protein of Rapamycin (mTOR) Expression in Adult Acute Myeloid Leukemia Patients
  1688. A Randomized Comparison Between Paclitaxel-Eluting Stents and Rapamycin-Eluting Stents for Patients With Coronary Artery Diseases
  1689. Silencing mTOR signal by small interfering RNA enhances Rapamycin-induced autophagy in malignant glioma cells.
  1690. CYCLOSPORINE AND Rapamycin ACT IN A SYNERGISTIC AND DOSE-DEPENDENT MANNER IN A MODEL OF IMMUNOSUPPRESSANT-INDUCED KIDNEY …
  1691. The role of the mammalian target of Rapamycin (mTOR) in long term potentiation
  1692. Nursing intervention of chronic renal diseases patients orally taking Rapamycin after underwent kidney transplantation [J]
  1693. The effect of Rapamycin after cyclosporin dose reduction on chronic allograft nephropathy
  1694. The Saccharomyces Cerevisiae Phosphatase Activator YPTPA1/RRD1 is Required to Modulate Gene Expression in Response to Rapamycin Exposure
  1695. COMBINATION OF Rapamycin PLUS MUTANT TGF-b/Fc TO INDUCE IMMUNE TOLERANCE.
  1696. Effect of Akt (PKB) on the activity of mammalian target of Rapamycin (mTOR)
  1697. Effect of Rapamycin Eluting Stent on Level of C-reactive Protein in Patients with Acute Coronary Syndrome After Angioplasty [J]
  1698. PI3K and mTOR signalling pathways: perspectives for Rapamycin and its derivatives as antineoplastic targeted therapies
  1699. Effectiveness and safety of Rapamycin-based immunosuppression regimens on preserving or withdrawing CsA in renal transplantation: a systematic review
  1700. The modulation of neointimal proliferation and p27 kip expression after implanting Rapamycin-eluting stents in the porcine coronary model
  1701. Different released Rapamycin eluting stents to reduce in-stent neointimal hyperplasia in a porcine coronary model
  1702. CHIMERISM PLAYS AN ACTIVE ROLE IN TRANSPLANTATION TOLERANCE INDUCED BY ALS, Rapamycin AND DONOR BONE MARROW INFUSION
  1703. Effect of Biodegradable Rapamycin-Eluting Stent on Neointimal Proliferation in Porcine Coronary Artery Model
  1704. Rapamycin INHIBITS IL-10 INDUCTION BY LATENT MEMBRANE PROTEIN 1 OF EPSTEIN BARR VIRUS.
  1705. Editorial [Hot Topic: Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia (Executive Editors: Francis J. Giles/Maher Albitar)]
  1706. A Gene Expression Connectivity Map Identifies Rapamycin as a Glucocorticoid Resistance Reversal Agent in Lymphoblastic Leukemia.
  1707. Rapamycin-sensitive TOR signaling regulates intestinal growth and morphogenesis in zebrafish
  1708. TARGET OF Rapamycin (TOR) MEDIATES THE ENDODERM-INTESTINE TRANSITION IN ZEBRAFISH: 68
  1709. Lactic-co-glycolic acid polymer with Rapamycin coated stent reduces neo-intimal formation in a porcine coronary model
  1710. The mammalian target of Rapamycin controls cell motility through its effectors S6K1 and 4E-BP1
  1711. SAFETY AND EFFICACY OF A STEROID-FREE REDUCED-DOSE NEORAL/Rapamycin MAINTENANCE IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION …
  1712. inhibition of mTOR signaling with Rapamycin attenuates renal hypertrophy in the early diabetic mice
  1713. Combinations of Cytotoxic Drugs, Ionizing Radiation, and Mammalian Target of Rapamycin (mTOR) Inhibitors
  1714. Effects of stent-based delivery of Rapamycin and methotrexate on neointimal formation in a porcine coronary model
  1715. Rapamycin MANIPULATION OF HOST-DERIVED, ALLOANTIGEN-PULSED DENDRITIC CELLS PLUS POSTOPERATIVE Rapamycin, BUT NOT FK506 …
  1716. Ex Vivo Rapamycin Generates Th2 Cells with Enhanced Mitochondrial Function and Reduced Apoptosis Via Intrinsic and Extrinsic Pathways.
  1717. combination with the immunosuppressive drug Rapamycin, seems to forestall rejection in mice. Transferring this protocol to the human clinic should be fairly straight …
  1718. Rapamycin-generated CD4+, Th2 cells modulate graft-versus-host reaction via an IL-4 dependent mechanism
  1719. The assessment of human islets for transplantation and the effect of the immunosuppressant Rapamycin on MIN-6 cells, rat and human islets
  1720. 549: The Effect of Rapamycin Immunosuppression on Native Polycystic Kidney Volumes in Renal Transplant Patients
  1721. Calcineurin inhibitors but not Rapamycin abrogate activation of the immunomodulatory enzyme indoleamine 2, 3-dioxygenase.
  1722. Translational control of gene expression in rat liver in relation to mammalian target of Rapamycin signaling
  1723. Rapamycin Protects Allografts From Rejection While Simultaneously Attacking Tumors in Immunosuppressed Mice
  1724. Rapamycin and IL-10 induce Ag-specific T regulatory type 1 cells (Tr1) and b-islet allograft tolerance in diabetic mice
  1725. In Vitro and in Vivo Cyclosporine-Induced Tumor Angiogenesis and Tumor Growth Are Blocked By Simultaneous Application of Rapamycin
  1726. Rapamycin INHIBITS EPSTEIN BARR VIRUS+ B CELL LYMPHOMA THROUGH MODULATION OF CELL CYCLE PROTEIN EXPRESSION.
  1727. Newly identified kit ITD in childhood AML induces ligand independent growth and is responsive to a synergistic effect of imatinib and Rapamycin
  1728. Effects of the immunomodulatory drugs tacrolimus, Rapamycin and cilomilast on dendritic cell function in a model of allergic contact dermatitis
  1729. Rapamycin exerts an anti-inflammatory action in vitro and in vivo by inducing monocyte apoptosis and modulating cytokine/chemokines secretion
  1730. Site specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model
  1731. Rapamycin sensitizes tumor cells to chemotherapy-induced apoptosis and induces cell cycle arrest in ALK+ anaplastic large cell lymphoma.
  1732. Sustained Rapamycin Drug Delivery System for Prevention of High Risk Corneal Allograft Rejection and Neovascularization in Rabbits
  1733. Everolimus Is Comparably Effective to Rapamycin Acting Synergistically with Imatinib in the Treatment of Constitutively Active Mutations of the Juxtamembrane …
  1734. Unrestricted Utilization of Sirolimus-Eluting Stents in the “Real World”: The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital …
  1735. Serotonin-mediated activation of Rapamycin-sensitive S6 kinase-S6 ribosomal protein signal transduction pathway in synaptosomes.
  1736. Rapamycin INHIBITS EPSTEIN BARR VIRUS+ B CELL LYMPHOMA PROLIFERATION THROUGH MODULATION OF CELL CYCLE PROTEIN EXPRESSION.
  1737. Effects of Rapamycin Eluting Stents on Blood Tissue Factor and Tissue Factor Pathway Inhibitor in Patients With Acute Coronary Syndromes
  1738. DONOR SPECIFIC TRANSFUSION COMBINED WITH Rapamycin PROLONGED THE CARDIAC GRAFT SURVIVAL IN MICE.
  1739. Activity of panitumumab plus Rapamycin against wild type (WT) and mutant epidermal growth factor receptor (EGFr)-expressing NSCLC xenografts
  1740. TACROLIMUS DECREASES, CYCLOSPORINE INCREASES, AND Rapamycin HAS NO EFFECT ON PROFIBROTIC GENE MRNA EXPRESSION IN RENAL …
  1741. Rapamycin Generated Murine Th2/Tc2 Cells Potently Abrogate Fully MHC-Mismatched Hematopoietic Stem Cell (HSC) Graft Rejection.
  1742. 548: inhibition of the mTOR Pathway by Rapamycin Reverses Renal Cystogenesis in Polycystic Kidney Disease Models
  1743. The mTOR inhibitor Rapamycin inhibits p27 protein degradation by downregulating the expression of its ubiquitin ligase Skp2 in breast cancer
  1744. Induction of apoptosis in Ewing’s Sarcoma cells by simultaneous treatment with antisense oligodeoxynucleotides (AS-ODNs) to the EWS/FLI-1 gene and Rapamycin
  1745. Construction of eukaryotic expression vector of mammalian target of Rapamycin antisense RNA and its expression in vascular smooth muscle cell
  1746. INFLUENCE OF IMMUNOPHILLINS INHIBITORS–CYCLOSPORINE-A, TACROLIMUS AND Rapamycin–ON INSULIN SECRETION IN HEART TRANSPLANT …
  1747. Targeting the ICOS-B7h Costimulatory Pathway Synergizes with Rapamycin to Regulate Alloresponses in Islet Transplantation: 0102
  1748. Short and long-term therapeutic effects of Rapamycin-eluting stent and paclitaxel-eluting stent in treatment of coronary disease with complicated lesions
  1749. The Immunomodulatory Agent Rapamycin Potentiates the Antiviral Activity of the Fusion Inhibitor T20 Against R5 Strains of HIV-1
  1750. Binding of mTOR (Mammalian Target of Rapamycin) to the Raptor-eIF4E-4EBP1 complex changes during myogenic differentiation.
  1751. COMBINATION OF Rapamycin AND ANTI-LFA-1 PREVENTS REJECTION OF RAT ISLET XENOGRAFTS.: 042
  1752. Hypoxia and Rapamycin induced changes to the cell cycle of multicellular spheroids and human tumour xenografts leading to potential therapeutic advantage
  1753. 1853: A Propsective Study With Thymoglobulin/Daclizumab Induction, Tacrolimus and Steroid Maintenance, Comparing Rapamycin With Mycophenolate Mofetil as …
  1754. Anti-angiogenic and immunomodulatory effects of Rapamycin on pancreatic islet endothelial cells: relevance for islets engraftment after transplantation
  1755. A comparison study on FTY720, 40-O-(2-hydroxyethyl)-Rapamycin and cyclosporine to prolong the survival of mouse heart allograft
  1756. Role of p53 in TRAIL-induced apoptosis in glioblastoma multiforme and modulation by taxol, Rapamycin or temozolomide
  1757. DIFFERENTIAL EFFECT OF CALCINEURIN INHIBITORS, ANTI-CD25 ANTIBODIES AND Rapamycin ON THE INDUCTION OF FOXP3 IN HUMAN T-CELLS IN VIVO …
  1758. … mechanisms regulating proliferation, antigen responsiveness, and differentiation of CD4⁺ T lymphocytes: a central role for the mammalian target of Rapamycin (mTOR …
  1759. Overexpression of a critical target of Rapamycin, translation regulatory protein 4E-BP1, is largely restricted to locally advanced breast and prostate cancers and is lost …
  1760. Receptor activator of NF-kB (RANK) and its ligand RANK-L coincide with expression of Rapamycin receptor FKBP12 in neointimal dendritic cells
  1761. The PI3K inhibitor LY294002 and the mTOR inhibitor Rapamycin sensitize melanoma cells to cisplatin and temozolomide
  1762. Rapamycin and Anti-LFA-1 Monoclonal Antibody Prevent the Rejection of Rat Islet Xenografts and Induce Tolerance in BALB/c Mice
  1763. Glucagon Represses Insulin Signaling through Mammalian Target of Rapamycin (mTOR) in Perfused Rat Liver
  1764. MYCOPHENOLATE MOFETIL (MMF)/Rapamycin (RAPA) COMPARED TO OTHER COMMON IMMUNOSUPPRESSIVE REGIMENS IN KIDNEY …
  1765. Ras Homologue Enrich in Brain (Rheb) Enhances Hypertrophic Response via the Mammalian Target of Rapamycin (mTOR)/p70S6K Pathway
  1766. … OF HUMAN BONE MARROW DERIVED MESENCHYMAL PROGENITORS—A SIGNAL TRANSDUCTION BASE FOR PLEIOTROPY OF Rapamycin DERIVATES.
  1767. grammed autophagy in the fat body during the final larval stage. TOR (target of Rapamycin) kinases, the central components of a conserved nutri-ent-sensing …
  1768. ANTI-CD25 MAB, ANTI-IL2 MAB AND IL2 BLOCK TOLERANCE INDUCTION THROUGH ANTI-CD154 MAB AND Rapamycin IN XENOGENEIC ISLET …
  1769. Schedule-dependent activity of combined epidermal growth factor receptor (EGFR) and mammalian target of Rapamycin (mTOR) targeting in PTEN negative breast …
  1770. Differential effects of the immunosuppressive agents cyclosporine A, Rapamycin and FK-506 on drug transport by the ATP-binding cassette (ABC) proteins P …
  1771. Amino acid transporter ASCT2 expression regulates mammalian Target‐of‐Rapamycin (mTOR) growth and survival signaling in human hepatoma cells
  1772. … WITHDRAWAL (PW) TRIAL IN KIDNEY TRANSPLANT PATIENTS TREATED WITH MYCOPHENOLATE SODIUM (MS) COMPARING Rapamycin® VS. C2 DOSED …
  1773. Rapamycin AND ANTI-LFA-1 THERAPY MEDIATE ISLET GRAFT SPECIFIC TOLERANCE IN CONCORDANT XENOGENEIC ISLET TRANSPLANTATION.
  1774. PHARMACOKINETICS OF ONCE A DAY DOSE OF CYCLOSPORINE IN COMBINATION WITH Rapamycin AND PREDNISONE IN RENAL TRANSPLANTATION IN …
  1775. ROLE OF THE MAMMALIAN TARGET OF Rapamycin IN THE REGULATION OF SKELETAL MUSCLE PROTEIN SYNTHESIS AND eIF2B EPSILON mRNA …
  1776. IGF-1 rescues Rapamycin-induced cell growth inhibition
  1777. CONCOMITANT USE OF CYCLOSPORINE-A (CyA) AND Rapamycin (RAPA) WITH A CONSECUTIVE CONVERSION TO RAPA AND MYCOPHENOLATE MOFETIL …
  1778. UP-02.50: A study of the role of insulin like growth factor 1 (IGF1) and Rapamycin sensitive signaling in an androgen independent prostate cancer cell line
  1779. … GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR GEFITINIB AND THE MAMMALIAN TARGET OF Rapamycin (mTOR) INHIBITOR EVEROLIMUS
  1780. QUADRUPLE IMMUNOSUPPERSSIVE MAINTENANCE THERAPY USING Rapamycin, LOW-DOSE CYCLOSPORINE, MYCOPHENOLATE MOFETIL, AND …
  1781. PJ-138 New Sesquiterpene Lactone Compared with Rapamycin Inhibits Migration Rather than Proliferation in Rat Vascular Smooth Muscle Cells
  1782. Combination therapy targeting the EWS/FLI-1 oncogene with antisense oligonucleotides and Rapamycin induces apoptosis of Ewing’s sarcoma cells in vitro and …
  1783. … 3-kinase; RTK, receptor tyrosine kinase; S6K, ribosomal S6 kinase; TNF-α, tumor necrosis factor α; TOR, target of Rapamycin; TSC, tuberous sclerosis complex …
  1784. LONG-TERM LIMB ALLOGRAFT SURVIVAL USING A SHORT COURSE OF ANTI-CD45RB MONOCLONAL ANTIBODY, LF15-0195 AND Rapamycin IN A MOUSE …
  1785. A role for HO-1 in the renal function impairment in Rapamycin-treated animals submitted to ischemic and reperfusion injury (IRI).
  1786. Bone Morphogenetic Protein 2 (BMP-2) promotes foci formation through the activation of mammalian target of Rapamycin
  1787. GSK-3/Rb12 Pathway as a Novel Target of Rapamycin in Prostate Cancer
  1788. PII‐9: Improved platelet function in renal transplant patients after conversion from azathioprin to Rapamycin
  1789. Drug-eluting stents, 5-sirolimus stents and oral Rapamycin
  1790. Autophagic Cell Death in Leukemia Cells Regulated by Ceramide and Sphingosine-1-Phosphate through Mammalian Target of Rapamycin.
  1791. 4-(N-Methyl-N-nitrosamino)-1 (3-pyridyl)-1-butanone (NNK) Restored the Cap-dependent Protein Translation Blocked by Rapamycin
  1792. The Saccharomyces cerevisiae GATA-factor activators’ response to the 14-3-3 proteins, nutrient limitation, Rapamycin and MSX treatment, and cis-acting …
  1793. 1871: Rapamycin and Ischemia on Experimental Transplant Arteriosclerosis
  1794. 1158-52 Proteomic profiling of restenotic lesions unveils increased expression of structural proteins that are inhibited by intramural delivery of Rapamycin
  1795. … and Activator of Transcription-1 (STAT1)-dependent Gene Transcription by Lipopolysaccharide and InterferonγIs Regulated by Mammalian Target of Rapamycin
  1796. P-205 STUDIES ON FUNGAL SECONDARY METABOLISM USING Rapamycin AS A MOLECULAR PROBE
  1797. Sphingosine-1-phosphate–induced smooth muscle cell migration involves the mammalian target of Rapamycin
  1798. Rapamycin: something old, something new, sometimes borrowed and now renewed
  1799. Rapamycin and mTOR kinase inhibitors
  1800. Rapamycin is a neuroprotective treatment for traumatic brain injury
  1801. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex
  1802. Rapamycin prevents early steps of the development of diabetic nephropathy in rats
  1803. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
  1804. Targeting mammalian target of Rapamycin (mTOR) for health and diseases
  1805. A role for mammalian target of Rapamycin in regulating T cell activation versus anergy
  1806. A rational mechanism for combination treatment of Huntington’s disease using lithium and Rapamycin
  1807. Antitumor activity of Rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma
  1808. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
  1809. The Rapamycin-binding domain of the protein kinase mammalian target of Rapamycin is a destabilizing domain
  1810. The mammalian target of Rapamycin signaling pathway: twists and turns in the road to cancer therapy
  1811. The mammalian target of Rapamycin complex 2 controls folding and stability of Akt and protein kinase C
  1812. Rapamycin, a specific inhibitor of the mammalian target of Rapamycin, suppresses lymphangiogenesis and lymphatic metastasis
  1813. Neuroprotection of Rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement
  1814. inhibition of the mammalian target of Rapamycin impedes lymphangiogenesis
  1815. Contrasting Effects of Cyclosporine and Rapamycin in De Novo Generation of Alloantigen‐Specific Regulatory T Cells
  1816. Metformin inhibits mammalian target of Rapamycin–dependent translation initiation in breast cancer cells
  1817. Roles of rapH and rapG in positive regulation of Rapamycin biosynthesis in Streptomyces hygroscopicus
  1818. Temsirolimus, an inhibitor of mammalian target of Rapamycin
  1819. The Mammalian target of Rapamycin pathway regulates nutrient-sensitive glucose uptake in man
  1820. Silencing mammalian target of Rapamycin signaling by small interfering RNA enhances Rapamycin-induced autophagy in malignant glioma cells
  1821. Selective survival of naturally occurring human CD4+ CD25+ Foxp3+ regulatory T cells cultured with Rapamycin
  1822. Mammalian target of Rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model
  1823. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells
  1824. mTOR inhibition by Rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes
  1825. The mammalian target of Rapamycin-signaling pathway in regulating metabolism and growth,
  1826. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
  1827. Hypoxia-inducible factor 1α is regulated by the mammalian target of Rapamycin (mTOR) via an mTOR signaling motif
  1828. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol
  1829. Rapamycin treatment for a child with germline PTEN mutation
  1830. Effect of Rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
  1831. PRAS40 is a target for mammalian target of Rapamycin complex 1 and is required for signaling downstream of this complex
  1832. Use of sirolimus (Rapamycin) to treat refractory Crohn’s disease
  1833. Rapamycin affects early fracture healing in mice
  1834. Mammalian target of Rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
  1835. The role of hypothalamic mammalian target of Rapamycin complex 1 signaling in diet-induced obesity
  1836. Re-evaluating the roles of proposed modulators of mammalian target of Rapamycin complex 1 (mTORC1) signaling
  1837. Mammalian target of Rapamycin inhibitor dyslipidemia in kidney transplant recipients
  1838. Dose-and schedule-dependent inhibition of the mammalian target of Rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with …
  1839. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins
  1840. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy
  1841. Mammalian target of Rapamycin (mTOR) orchestrates the defense program of innate immune cells
  1842. Rapamycin modulates the eNOS vs. shear stress relationship
  1843. Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation
  1844. The mammalian target of Rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes
  1845. Gonadal impact of target of Rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview
  1846. Phase I trial of the novel mammalian target of Rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to …
  1847. Randomized trial of three Rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis
  1848. Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the Rapamycin-sensitive PI (3) K-mTOR-p70S6K pathway
  1849. The role of mammalian target of Rapamycin inhibitors in the treatment of advanced renal cancer
  1850. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and Rapamycin
  1851. Mammalian target of Rapamycin as a therapeutic target in oncology
  1852. Pilot study of Rapamycin in patients with hormone-refractory prostate cancer
  1853. Regulation of androgen receptor transcriptional activity by Rapamycin in prostate cancer cell proliferation and survival
  1854. Changes in tumor metabolism as readout for Mammalian target of Rapamycin kinase inhibition by Rapamycin in glioblastoma
  1855. Response of a neuronal model of tuberous sclerosis to mammalian target of Rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved …
  1856. inhibition of Mammalian target of Rapamycin by Rapamycin causes the regression of carcinogen-induced skin tumor lesions
  1857. Chemoprevention and treatment of experimental Cowden’s disease by mTOR inhibition with Rapamycin
  1858. Antitumor activity of Rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
  1859. In human endothelial cells Rapamycin causes mTORC2 inhibition and impairs cell viability and function
  1860. Mammalian target of Rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells
  1861. Mammalian target of Rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation
  1862. Differential impact of mammalian target of Rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells
  1863. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling
  1864. Dissecting the Akt/mammalian target of Rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative
  1865. Rapamycin impairs in vivo proliferation of islet beta-cells
  1866. Total synthesis of Rapamycin
  1867. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by Rapamycin
  1868. Systemic inhibition of mammalian target of Rapamycin inhibits fear memory reconsolidation
  1869. The Target of Rapamycin pathway antagonizes pha-4/FoxA to control development and aging
  1870. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+ CD25+ FOXP3+ regulatory T-cells
  1871. Mammalian target of Rapamycin in the human placenta regulates leucine transport and is down‐regulated in restricted fetal growth
  1872. The mTOR inhibitor Rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis
  1873. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3‐E1 cells and primary mouse bone marrow stromal cells
  1874. Antidepressive-like effects of Rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders
  1875. Alterations in mammalian target of Rapamycin signaling pathways after traumatic brain injury
  1876. Regulatory effects of mammalian target of Rapamycin-activated pathways in type I and II interferon signaling
  1877. Preparation of Rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation
  1878. Bnip3 mediates the hypoxia-induced inhibition on mammalian target of Rapamycin by interacting with Rheb
  1879. Sirolimus (Rapamycin): from the soil of Easter Island to a bright future
  1880. Susceptibility of human mesenchymal stem cells to tacrolimus, mycophenolic acid, and Rapamycin
  1881. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of Rapamycin/p70S6K1 pathway
  1882. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ …
  1883. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells
  1884. Dietary energy balance modulates signaling through the Akt/mammalian target of Rapamycin pathways in multiple epithelial tissues
  1885. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/WF1 mice
  1886. Isolation of hyperactive mutants of mammalian target of Rapamycin
  1887. P-Rex1 links mammalian target of Rapamycin signaling to Rac activation and cell migration
  1888. Rapamycin inhibits polyglutamine aggregation independently of autophagy by reducing protein synthesis
  1889. Bevacizumab and Rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
  1890. Phosphoprotein pathway mapping: Akt/mammalian target of Rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival
  1891. Delivery of Rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells
  1892. Rapamycin regulates the phosphorylation of rictor
  1893. Inhibitors of mammalian target of Rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo
  1894. Distinct signaling mechanisms activate the target of Rapamycin in response to different B‐cell stimuli
  1895. Therapeutic effect of Rapamycin on gallbladder cancer in a transgenic mouse model
  1896. Rapamycin sensitivity of the Schizosaccharomyces pombe tor2 mutant and organization of two highly phosphorylated TOR complexes by specific and common …
  1897. Activated mammalian target of Rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma
  1898. Expression of an activated mammalian target of Rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy
  1899. The effect of immunosuppressive drug Rapamycin on regulatory CD4+ CD25+ Foxp3+ T cells in mice
  1900. Impact of Rapamycin on liver regeneration
  1901. Curcumin inhibits Akt/mammalian target of Rapamycin signaling through protein phosphatase-dependent mechanism
  1902. Combination of Rapamycin and IL-2 increases de novo induction of human CD4+ CD25+ FOXP3+ T cells
  1903. Translational control of c-MYC by Rapamycin promotes terminal myeloid differentiation
  1904. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells
  1905. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by Rapamycin and siRNA against …
  1906. Mammalian target of Rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids
  1907. Evaluation of antileukaemic effects of Rapamycin in patients with imatinib‐resistant chronic myeloid leukaemia
  1908. Antiproliferative effects of Rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines
  1909. Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling
  1910. Mammalian target of Rapamycin: master regulator of cell growth in the nervous system
  1911. Binding of Rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities
  1912. Epstein Barr virus, Rapamycin, and host immune responses
  1913. Regression of subependymal giant cell astrocytoma with Rapamycin in tuberous sclerosis complex
  1914. Effect of Rapamycin on wound healing: an experimental study
  1915. Saccharomyces cerevisiae FKBP12 binds Arabidopsis thaliana TOR and its expression in plants leads to Rapamycin susceptibility
  1916. ASCT2 silencing regulates mammalian target-of-Rapamycin growth and survival signaling in human hepatoma cells
  1917. Small molecule enhancers of Rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of …
  1918. Mammalian target of Rapamycin (mTOR) is involved in the neuronal differentiation of neural progenitors induced by insulin
  1919. Defects in skin γδ T cell function contribute to delayed wound repair in Rapamycin-treated mice
  1920. Effective in vivo targeting of the mammalian target of Rapamycin pathway in malignant peripheral nerve sheath tumors
  1921. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function
  1922. IL-1β-driven ST2L expression promotes maturation resistance in Rapamycin-conditioned dendritic cells
  1923. Mitogen-activated protein kinase upregulates the dendritic translation machinery in long-term potentiation by controlling the mammalian target of Rapamycin pathway
  1924. CXCR6 induces prostate cancer progression by the AKT/mammalian target of Rapamycin signaling pathway
  1925. Combination strategy targeting the hypoxia inducible factor-1α with mammalian target of Rapamycin and histone deacetylase inhibitors
  1926. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly (ε-caprolactone) micelles of Rapamycin
  1927. Calcineurin inhibitors and Rapamycin: cancer protection or promotion?
  1928. A central role for neuronal AMP-activated protein kinase (AMPK) and mammalian target of Rapamycin (mTOR) in high-protein diet–induced weight loss
  1929. … exercise overcomes the age-related insulin resistance of muscle protein metabolism by improving endothelial function and Akt/mammalian target of Rapamycin …
  1930. Endoplasmic reticulum and Golgi localization sequences for mammalian target of Rapamycin
  1931. Mammalian target of Rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute …
  1932. Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro
  1933. Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen–Induced …
  1934. Rapamycin prevents the development of nephritis in lupus-prone NZB/WF1 mice
  1935. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by Rapamycin
  1936. Rapamycin as an inhibitor of osteogenic differentiation in bone marrow-derived mesenchymal stem cells
  1937. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice
  1938. Intramural Delivery of Rapamycin With αvβ3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury
  1939. FK506 binding protein mediates glioma cell growth and sensitivity to Rapamycin treatment by regulating NF-κB signaling pathway
  1940. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: Rapamycin triggers dephosphorylation and delocalization of the mTORC2 …
  1941. Oncogenic tyrosine kinase NPM/ALK induces activation of the Rapamycin-sensitive mTOR signaling pathway
  1942. Target of Rapamycin (TOR) signaling controls epithelial morphogenesis in the vertebrate intestine
  1943. Antiangiogenic therapy with mammalian target of Rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer
  1944. Mammalian target of Rapamycin and S6 kinase 1 positively regulate 6-thioguanine-induced autophagy
  1945. Preparation and characterization of Rapamycin-loaded PLGA coating stent
  1946. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and Rapamycin induces growth arrest of adult T-cell leukemia cells
  1947. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of Rapamycin signaling
  1948. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor with potent in …
  1949. Rapamycin retards growth and causes marked alterations in the growth plate of young rats
  1950. … fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of Rapamycin (mTOR) signaling cascade
  1951. Autophagy activation by Rapamycin eliminates mouse Mallory‐Denk bodies and blocks their proteasome inhibitor‐mediated formation
  1952. Mammalian target of Rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer
  1953. Defective TGF-β signaling sensitizes human cancer cells to Rapamycin
  1954. A retroinhibition approach reveals a tumor cell–autonomous response to Rapamycin in head and neck cancer
  1955. Effects of Rapamycin on gene expression, morphology, and electrophysiological properties of rat hippocampal neurons
  1956. inhibition of mammalian target of Rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E …
  1957. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of Rapamycin in mammary carcinomas, mammary gland …
  1958. Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression
  1959. Activation of mammalian target of Rapamycin complex 1 and insulin resistance induced by palmitate in hepatocytes
  1960. … concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of Rapamycin/eIF4E …
  1961. Enhancing mammalian target of Rapamycin (mTOR)–targeted cancer therapy by preventing mTOR/Raptor inhibition-initiated, mTOR/Rictor-independent Akt activation
  1962. Leucine stimulates mammalian target of Rapamycin signaling in C2C12 myoblasts in part through inhibition of adenosine monophosphate-activated protein kinase
  1963. Rapamycin Inhibits Proliferation of Epstein-Barr Virus–Positive B-cell Lymphomas Through Modulation of Cell-Cycle Protein Expression
  1964. Solution structure of the Legionella pneumophila Mip-Rapamycin complex
  1965. Combined therapeutic effects of vinblastine and Rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis
  1966. Azoospermia in a renal transplant recipient during sirolimus (Rapamycin) treatment
  1967. Differential involvement of IκB kinases α and β in cytokine-and insulin-induced mammalian target of Rapamycin activation determined by Akt
  1968. The role of targeting mammalian target of Rapamycin in lung cancer
  1969. Amelioration of protein misfolding disease by Rapamycin: translation or autophagy?
  1970. Monitoring biological action of Rapamycin in renal transplantation
  1971. Efficacy of Rapamycin in scleroderma: a case study
  1972. Statin therapy, alone or with Rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study
  1973. Target of Rapamycin and LST8 proteins associate with membranes from the endoplasmic reticulum in the unicellular green alga Chlamydomonas reinhardtii
  1974. Regulation of mammalian target of Rapamycin activity in PTEN-inactive prostate cancer cells by IκB kinase α
  1975. … regulates hippocampal neurons by elevation of intracellular calcium and activation of calcium/calmodulin protein kinase II and mammalian target of Rapamycin
  1976. The Akt/mammalian target of Rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation
  1977. The mammalian target of Rapamycin pathway as a potential target for cancer chemoprevention
  1978. Rapamycin: brain excitability studied in vitro
  1979. Rapamycin‐mediated G1 arrest involves regulation of the Cdk inhibitor Sic1 in Saccharomyces cerevisiae
  1980. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion
  1981. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of Rapamycin pathway
  1982. Acidosis-sensing glutamine pump SNAT2 determines amino acid levels and mammalian target of Rapamycin signalling to protein synthesis in L6 muscle cells
  1983. Phosphorylation of ribosomal p70 S6 kinase and Rapamycin sensitivity in human colorectal cancer
  1984. Mammalian Target of Rapamycin Repression by 3, 3′-Diindolylmethane Inhibits Invasion and Angiogenesis in Platelet-Derived Growth Factor-D–Overexpressing …
  1985. Endothelial Akt signaling is rate-limiting for Rapamycin inhibition of mouse mammary tumor progression
  1986. Aging, stem cells, and mammalian target of Rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells
  1987. The mammalian target of Rapamycin kinase and tumor growth inhibition
  1988. Nonimmunosuppressive effects of mammalian target of Rapamycin inhibitors
  1989. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro
  1990. Interplay of PI3K and cAMP/PKA signaling, and Rapamycin-hypersensitivity in TGFβ1 enhancement of FSH-stimulated steroidogenesis in rat ovarian …
  1991. … human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase–dependent mammalian target of Rapamycin raptor complex 1 …
  1992. mTOR is the Rapamycin-sensitive kinase that confers mechanically-induced phosphorylation of the hydrophobic motif site Thr (389) in p70S6k
  1993. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells
  1994. Juvenile hormone connects larval nutrition with target of Rapamycin signaling in the mosquito Aedes aegypti
  1995. Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-κB activation
  1996. Protein phosphatase 2A and Rapamycin regulate the nuclear localization and activity of the transcription factor GLI3
  1997. Effect of Rapamycin therapy on coronary artery physiology early after cardiac transplantation
  1998. Low-dose mTOR inhibition by Rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat
  1999. Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of Rapamycin
  2000. Bevacizumab and Rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer
  2001. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging
  2002. IL-2– and IL-15–induced activation of the Rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes
  2003. Mammalian Target of Rapamycin (mTOR) is Activated in Cutaneous Vascular Malformations in Vivo
  2004. Reduction of CCR5 with low-dose Rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
  2005. Evaluation of the mammalian target of Rapamycin pathway and the effect of Rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs
  2006. Differential effects of Rapamycin in anti-GBM glomerulonephritis
  2007. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy
  2008. Coupling of mammalian target of Rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2a-and glycogen synthase …
  2009. Mammalian target of Rapamycin and caspase inhibitors in polycystic kidney disease
  2010. Pharmacodynamic-guided modified continuous reassessment method–based, dose-finding study of Rapamycin in adult patients with solid tumors
  2011. Statin-dependent suppression of the Akt/mammalian target of Rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma
  2012. Impact of mammalian target of Rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic …
  2013. Antiproliferative and proapoptotic effects of Rapamycin and celecoxib in malignant melanoma cell lines
  2014. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the Rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat …
  2015. Exploiting the mammalian target of Rapamycin pathway in hematologic malignancies
  2016. Simultaneous hybrid coronary revascularization using totally endoscopic left internal mammary artery bypass grafting and placement of Rapamycin eluting stents in the …
  2017. Degradation of Rapamycin and its ring-opened isomer: role of base catalysis
  2018. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with Rapamycin
  2019. Superoxide anions regulate TORC1 and its ability to bind Fpr1: Rapamycin complex
  2020. The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of Rapamycin complex 1
  2021. Topical Rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
  2022. Cardiac restricted overexpression of kinase-dead mammalian target of Rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function
  2023. Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production
  2024. Mammalian target of Rapamycin (mTOR) pathway signalling in lymphomas
  2025. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and Rapamycin combination therapy
  2026. Nucleophosmin mediates mammalian target of Rapamycin–Dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes
  2027. Effects of Rapamycin on cell proliferation and phosphorylation of mTOR and p70S6K in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB
  2028. Mammalian target of Rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass
  2029. Fatty acid synthase inhibitors modulate energy balance via mammalian target of Rapamycin complex 1 signaling in the central nervous system
  2030. Rapamycin does not improve insulin sensitivity despite elevated mammalian target of Rapamycin complex 1 activity in muscles of ob/ob mice
  2031. inhibition of apoptosis through localized delivery of Rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery
  2032. Epithelial-to-mesenchymal transition of human proximal tubular epithelial cells: effects of Rapamycin, mycophenolate, cyclosporin, azathioprine, and …
  2033. Regulatory effects of mammalian target of Rapamycin-mediated signals in the generation of arsenic trioxide responses
  2034. Leptin induces macrophage lipid body formation by a phosphatidylinositol 3-kinase-and mammalian target of Rapamycin-dependent mechanism
  2035. Non‐human primate fetal kidney transcriptome analysis indicates mammalian target of Rapamycin (mTOR) is a central nutrient‐responsive pathway
  2036. Compared effect of immunosuppressive drugs cyclosporine A and Rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG‐CoA reductase
  2037. On the action of cyclosporine A, Rapamycin and tacrolimus on M. avium including subspecies paratuberculosis
  2038. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of Rapamycin complex 1 (mTORC1)-mediated phosphorylation
  2039. Improved blood compatibility of Rapamycin-eluting stent by incorporating curcumin
  2040. Follicle-stimulating hormone increases tuberin phosphorylation and mammalian target of Rapamycin signaling through an extracellular signal-regulated kinase …
  2041. Monitoring antitumor efficacy of Rapamycin in Kaposi sarcoma
  2042. Phosphatidylinositol 3-kinase-AKT-mammalian target of Rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer
  2043. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 …
  2044. Initial testing (stage 1) of the mTOR inhibitor Rapamycin by the pediatric preclinical testing program
  2045. Insulin‐like growth factor‐1 (IGF‐1) and leucine activate pig myogenic satellite cells through mammalian target of Rapamycin (mTOR) pathway
  2046. Rapamycin impairs β-cell proliferation in vivo
  2047. … acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of Rapamycin …
  2048. Upstream signaling inhibition enhances Rapamycin effect on growth of kidney cancer cells
  2049. Hsf1 activation inhibits Rapamycin resistance and TOR signaling in yeast revealed by combined proteomic and genetic analysis
  2050. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in Rapamycin
  2051. The YCR079w gene confers a Rapamycin-resistant function and encodes the sixth type 2C protein phosphatase in Saccharomyces cerevisiae
  2052. Combination of Rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells
  2053. … Signaling Pathway Induces Resistance to the Apoptotic Activities of SCH66336 (Lonafarnib) through Akt/Mammalian Target of Rapamycin–Mediated Increases in …
  2054. Antiproliferative effect of Rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition
  2055. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of Rapamycin inhibitor, in patients with relapsed or refractory hematologic …
  2056. Ocular toxicity and distribution of subconjunctival and intravitreal Rapamycin in horses
  2057. Response of U87 glioma xenografts treated with concurrent Rapamycin and fractionated radiotherapy: possible role for thrombosis
  2058. Mammalian target of Rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth
  2059. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post–lung transplantation with Rapamycin treatment
  2060. Regulation of neurogenesis and epidermal growth factor receptor signaling by the insulin receptor/target of Rapamycin pathway in Drosophila
  2061. inhibition of mammalian target of Rapamycin signaling by 2-(morpholin-1-yl) pyrimido [2, 1-α] isoquinolin-4-one
  2062. Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and Rapamycin
  2063. Intracellular mechanisms of metabolism regulation: the role of signaling via the mammalian target of Rapamycin pathway and other routes
  2064. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of Rapamycin signaling in endometrial carcinoma
  2065. The mammalian target of Rapamycin pathway and its role in molecular nutrition regulation
  2066. Cotylenin A, a new differentiation inducer, and Rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2
  2067. Effects of Rapamycin in liver transplantation.
  2068. Rapamycin inhibits multiple stages of c-Neu/ErbB2–induced tumor progression in a transgenic mouse model of HER2-positive breast cancer
  2069. Rapamycin enriches for CD4+ CD25+ CD27+ Foxp3+ regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with …
  2070. Rapamycin down-regulates LDL-receptor expression independently of SREBP-2
  2071. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of Rapamycin inhibitors in cell lines derived from childhood solid tumors
  2072. Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of Rapamycin pathway components
  2073. Effects of Rapamycin on active Heymann nephritis
  2074. Rationale for a phase I trial of erlotinib and the mammalian target of Rapamycin inhibitor everolimus (RAD001) for patients with relapsed non–small cell lung cancer
  2075. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of Rapamycin through the STAT3-SOCS3 pathway
  2076. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin module for acute myelogenous leukemia therapy: from bench to bedside
  2077. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment
  2078. … and inducible nitric-oxide synthase expression through the integrin/integrin-linked kinase/Akt/mammalian target of Rapamycin pathway in osteoblasts
  2079. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G 1 cell cycle …
  2080. Rapamycin enhances the number of alloantigen-induced human CD103+ CD8+ regulatory T cells in vitro
  2081. GADD34 inhibits mammalian target of Rapamycin signaling via tuberous sclerosis complex and controls cell survival under bioenergetic stress
  2082. Delivery of Rapamycin‐loaded nanoparticle down regulates ICAM‐1 expression and maintains an immunosuppressive profile in human CD34+ progenitor‐derived …
  2083. Four-year clinical follow-up of the Rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry
  2084. Human melanoma cytolysis by combined inhibition of mammalian target of Rapamycin and vascular endothelial growth factor/vascular endothelial growth factor …
  2085. Surgical wound‐healing complications in heart transplant recipients treated with Rapamycin
  2086. Mammalian target of Rapamycin as a target in hematological malignancies
  2087. Does addition of estradiol improve the efficacy of a Rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial
  2088. The effects of Rapamycin in the progression of renal fibrosis
  2089. Mechanism of apoptosis induced by IFN-α in human myeloma cells: role of Jak1 and Bim and potentiation by Rapamycin
  2090. p21-activated kinase 1 is activated through the mammalian target of Rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in …
  2091. Effect of supplemental dietary zinc on the mammalian target of Rapamycin (mTOR) signaling pathway in skeletal muscle and liver from post-absorptive mice
  2092. Combined treatment with triptolide and Rapamycin prolongs graft survival in a mouse model of cardiac transplantation
  2093. Synergistic effect of mTOR inhibitor Rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells
  2094. Rapamycin stimulates arginine influx through CAT2 transporters in human endothelial cells
  2095. Mammalian target of Rapamycin is the key effector of phosphatidylinositol-3-OH–initiated proliferative signals in the thyroid follicular epithelium
  2096. Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of Rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer
  2097. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of Rapamycin (RAD001) decreases glioma proliferation and invasion
  2098. EMAP-II downregulation contributes to the beneficial effects of Rapamycin after vascular injury
  2099. Rescue of Degradation‐Prone Mutants of the FK506‐Rapamycin Binding (FRB) Protein with Chemical Ligands
  2100. Antiproliferative and overadditive effects of Rapamycin and FTY720 in pancreatic cancer cells in vitro
  2101. Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy
  2102. Randomized trial of Rapamycin-and paclitaxel-eluting stents with identical biodegradable polymeric coating and design
  2103. Nutrient content of diet affects the signaling activity of the insulin/target of Rapamycin/p70 S6 kinase pathway in the African malaria mosquito Anopheles gambiae
  2104. Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity
  2105. Rapamycin together with herceptin significantly increased anti‐tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells
  2106. Short-and long-term effects of cytochalasin D, paclitaxel and Rapamycin on wall thickening in experimental porcine vein grafts
  2107. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of Rapamycin pathway in Barrett’s-associated esophageal adenocarcinoma
  2108. A phase II study of oral mammalian target of Rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)
  2109. Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination
  2110. External application of Rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model
  2111. Rapamycin blunts nutrient stimulation of eIF4G, but not PKCε phosphorylation, in skeletal muscle
  2112. ABT-263 and Rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
  2113. mTOR inhibitors (Rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours
  2114. DCO2 on-line measurement used in Rapamycin fed-batch fermentation process
  2115. Identification of the Rapamycin‐sensitive phosphorylation sites within the Ser/Thr‐rich domain of the yeast Npr1 protein kinase
  2116. Golgi Manganese Transport Is Required for Rapamycin Signaling in Saccharomyces cerevisiae
  2117. How to control lymphangiogenesis: A novel role for Rapamycin
  2118. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of Rapamycin
  2119. Components of the Vid30c are needed for the Rapamycin-induced degradation of the high-affinity hexose transporter Hxt7p in Saccharomyces cerevisiae
  2120. An approach to analyse the specific impact of Rapamycin on mRNA-ribosome association
  2121. Ex vivo Rapamycin generates apoptosis-resistant donor Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection
  2122. Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer
  2123. Rapamycin prevents mesenteric neo‐angiogenesis and reduces splanchnic blood flow in portal hypertensive mice
  2124. Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, Rapamycin and paclitaxel
  2125. Chylous ascites in a renal transplant recipient under sirolimus (Rapamycin) treatment
  2126. Combination antifungal therapy involving amphotericin B, Rapamycin and 5-fluorocytosine using PEG-phospholipid micelles
  2127. Serotonin Induces Memory-Like, Rapamycin-Sensitive Hyperexcitability in Sensory Axons of Aplysia That Contributes to Injury Responses
  2128. Activation of the mammalian target of Rapamycin complex 1 is both necessary and sufficient to stimulate eukaryotic initiation factor 2Bɛ mRNA translation and protein …
  2129. Human herpesvirus‐8 (HHV‐8)‐associated primary effusion lymphoma in two renal transplant recipients receiving Rapamycin
  2130. An RNA Interference Screen Identifies a Novel Regulator of Target of Rapamycin That Mediates Hypoxia Suppression of Translation in Drosophila S2 Cells
  2131. Identification of AUF1 as a Rapamycin-responsive binding protein to the 5′-terminal oligopyrimidine element of mRNAs
  2132. Mitogen-stimulated and Rapamycin-sensitive glucose transporter 12 targeting and functional glucose transport in renal epithelial cells
  2133. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, Rapamycin and Bcl-2 inhibitor GX15-070
  2134. Modulation of the activities of AMP‐activated protein kinase, protein kinase B, and mammalian target of Rapamycin by limiting energy availability with 2‐deoxyglucose
  2135. PTEN and Rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway
  2136. Role of adenosine 5′-monophosphate-activated protein kinase subunits in skeletal muscle mammalian target of Rapamycin signaling
  2137. Pharmacokinetics of sirolimus (Rapamycin) in subjects with severe hepatic impairment
  2138. … Preconditioning Decreases Myocardial Infarction in Rabbits via Up-regulation of Hypoxia Inducible Factor 1 That Is Mediated by Mammalian Target of Rapamycin
  2139. Stress and IGF-I differentially control cell fate through mammalian target of Rapamycin (mTOR) and retinoblastoma protein (pRB)
  2140. … of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of the phosphoinositide 3‐kinase–Akt–mammalian target of Rapamycin …
  2141. Possible involvement of persistent activity of the mammalian target of Rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells
  2142. Cyclin B synthesis and Rapamycin‐sensitive regulation of protein synthesis during starfish oocyte meiotic divisions
  2143. Comparison of a polymer‐free Rapamycin‐eluting stent (YUKON) with a polymer‐based paclitaxel‐eluting stent (TAXUS) in real‐world coronary artery lesions
  2144. The Rheb switch 2 segment is critical for signaling to target of Rapamycin complex 1
  2145. Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma
  2146. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency …
  2147. Three‐year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus‐eluting stents: Insights from the Rapamycin‐eluting stent evaluated at …
  2148. Chronic alcohol consumption alters mammalian target of Rapamycin (mTOR), reduces ribosomal p70s6 kinase and p4E-BP1 levels in mouse cerebral cortex
  2149. Intrinsically lower AKT, mammalian target of Rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia …
  2150. … preclinical studies: timing of treatment, combination of a Rapamycin analog (CCI-779) and interferon-gamma, and comparison of Rapamycin to CCI-779
  2151. Rapamycin limits formation of active eukaryotic initiation factor 4F complex following meal feeding in rat hearts
  2152. CD8+ T‐Cell Depletion and Rapamycin Synergize with Combined Coreceptor/Stimulation Blockade to Induce Robust Limb Allograft Tolerance in Mice
  2153. Antineoplastic effect of Rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts
  2154. Mammalian target of Rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines
  2155. The Cairo kidney center protocol for Rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes
  2156. … of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of Rapamycin …
  2157. Total synthesis studies on macrocyclic pipecolic acid natural products: FK506, the antascomicins and Rapamycin
  2158. IGF-I receptor inhibition combined with Rapamycin or temsirolimus inhibits neuroblastoma cell growth
  2159. Chronic allograft dysfunction: can we use mammalian target of Rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
  2160. The mammalian target of Rapamycin complex 1 regulates leptin biosynthesis in adipocytes at the level of translation: the role of the 5′-untranslated region in the …
  2161. Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells.
  2162. Renal cortex neuronal nitric oxide synthase in response to Rapamycin in kidney transplantation
  2163. The MAP kinase-activated protein kinase Rck2p plays a role in Rapamycin sensitivity in Saccharomyces cerevisiae and Candida albicans
  2164. … Factor‐1 and Transforming Growth Factor‐β Controls the Quiescence/Cycling Switch of CD34+ Progenitors Through FoxO3 and Mammalian Target of Rapamycin
  2165. The effect of Rapamycin on DNA synthesis in multiple tissues from late gestation fetal and postnatal rats
  2166. Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation
  2167. Reversal of tacrolimus‐related hypertrophic cardiomyopathy after conversion to Rapamycin in a pediatric liver transplant recipient
  2168. Mechanisms of mammalian target of Rapamycin inhibition in sarcoma: present and future
  2169. siRNA targeting mammalian target of Rapamycin (mTOR) attenuates experimental proliferative vitreoretinopathy
  2170. Synthesis, characterization and antiproliferative activity of Rapamycin-loaded poly (N-isopropylacrylamide)-based nanogels in vascular smooth muscle cells
  2171. Prolongation of cardiac allograft survival by Rapamycin and the invariant natural killer T cell glycolipid agonist OCH
  2172. Rapamycin Inhibits Growth Factor-Induced Cell Cycle Regulation in Pancreatic β Cells
  2173. Molecular impacts of Rapamycin-based drug combinations: combining Rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model
  2174. Rapamycin-induced cytotoxic signal transduction pathway
  2175. Effect of rifampicin to inhibit Rapamycin-induced autophagy via the suppression of protein phosphatase 2A activity
  2176. Specific mTOR inhibitor Rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea …
  2177. Requirements of phosphatidylinositol-3 kinase and mammalian target of Rapamycin for estrogen-induced proliferation in uterine leiomyoma-and myometrium-derived …
  2178. Mass balance in Rapamycin autoxidation
  2179. Targeting the mammalian target of Rapamycin in myxoid chondrosarcoma
  2180. Acetaldehyde promotes Rapamycin-dependent activation of p70S6K and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human …
  2181. Conversion to Rapamycin immunosuppression for malignancy after kidney transplantation
  2182. Normal phase and reverse phase HPLC-UV-MS analysis of process impurities for Rapamycin analog ABT-578: Application to active pharmaceutical ingredient process …
  2183. Non-Conventional method for evaluation and optimization of medium components for Rapamycin production by Streptomyces hygroscopicus
  2184. Administration of triiodo-L-thyronine into dorsal hippocampus alters phosphorylation of Akt, mammalian target of Rapamycin, p70S6 kinase and 4E-BP1 in rats
  2185. Possible mechanism by which Rapamycin increases cyclosporine nephrotoxicity
  2186. … Extracellular Signal-regulated Kinase 1/2 and c-Jun NH2-Terminal Kinase Downstream of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin
  2187. Adverse effects of mammalian target of Rapamycin inhibitors during the postoperative period after cardiac transplantation
  2188. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with Rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft
  2189. Neointimal expression of Rapamycin receptor FK506-binding protein FKBP12: postinjury animal and human in-stent restenosis tissue characteristics
  2190. Successful treatment of post-renal transplant gastric and pulmonary Kaposi’s sarcoma with conversion to Rapamycin treatment
  2191. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer Rapamycin-eluting stent for the treatment of …
  2192. Effect of Rapamycin on hepatocyte function and proliferation induced by growth factors
  2193. Lentiviral vectors mediate nonimmunosuppressive Rapamycin analog-induced production of secreted therapeutic factors in the brain: regulation at the level of …
  2194. Rapamycin bypasses vesicle-mediated signaling events to activate Gln3 in Saccharomyces cerevisiae
  2195. Nanoparticle albumin-bound (nab) Rapamycin as an anticancer agent
  2196. Rapamycin conditionally inhibits Hsp90 but not Hsp70 mRNA translation in Drosophila: implications for the mechanisms of Hsp mRNA translation
  2197. Differential modulation of mitogen driven proliferation and homeostasis driven proliferation of T cells by Rapamycin, Ly294002 and chlorophyllin
  2198. A phase 1b study of oral Rapamycin (sirolimus) in patients with advanced malignancies
  2199. Rapamycin-loaded poly (lactic-co-glycolic) acid nanoparticles for intraarterial local drug delivery: preparation, characterization, and in vitro/in vivo release
  2200. A Combination of Donor Specific Transfusion and Rapamycin Prolonges Cardiac Allograft Survival in Mice
  2201. Immunoassay determination of Rapamycin: reliability of the method with respect to liquid chromatography mass spectrometric quantification
  2202. Thrombin induces osteoprotegerin synthesis via phosphatidylinositol 3′‐kinase/mammalian target of Rapamycin pathway in human periodontal ligament cells
  2203. Galectin-1 upregulates glucose transporter-1 expression level via protein kinase C, phosphoinositol-3 kinase, and mammalian target of Rapamycin pathways in mouse …
  2204. inhibition of the mammalian target of Rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma
  2205. Magic with Rapamycin
  2206. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity
  2207. Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy
  2208. Phorbol 12-myristate 13-acetate and serum synergize to promote Rapamycin-insensitive cell proliferation via protein kinase C-eta
  2209. A recent application of fluoro-18-deoxyglucose positron emission tomography, treatment monitoring with a mammalian target of Rapamycin inhibitor: an example …
  2210. Orally administered Rapamycin, dacarbazine or both for treatment of human melanoma evaluated in severe combined immunodeficiency mice
  2211. … /p70S6K signaling pathway constitutively activated in esophageal squamous cell carcinona cell lines and inhibition of the pathway by Rapamycin and siRNA against …
  2212. Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and Rapamycin in xenogeneic islet transplantation
  2213. Effect of chemotherapy with cisplatin and Rapamycin against Hep-2 cells in vitro
  2214. A new trick for an old drug: mTOR inhibitor Rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence
  2215. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of Rapamycin are associated with progesterone …
  2216. … MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with Rapamycin
  2217. Rapamycin, Mycophenolate Mofetil, Methylprednisolone, and Cytotoxic T-Lymphocyte–Associated Antigen 4 Immunoglobulin–Based Conditioning Regimen to Induce …
  2218. Long-term effects of Rapamycin treatment on insulin mediated phosphorylation of Akt/PKB and glycogen synthase activity
  2219. A fast and simple method to prepare the FKBP-Rapamycin binding domain of human target of Rapamycin for NMR binding assays
  2220. Dentritic cell derived IL-18 production is inhibited by Rapamycin and sanglifehrin A, but not cyclosporine A
  2221. Hypoxia-induced hypomyelination in the developing brain is mammalian target of Rapamycin-4E-binding protein-1 signaling dependent
  2222. Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM)
  2223. Effects of mTOR inhibitor Rapamycin on Smad 3 protein and collagen type I expression in rat myocardial fibroblasts infected with coxsackie virus B 3
  2224. Synergistic effect of Rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells
  2225. A phase II study of mammalian target of Rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma …
  2226. Influence of Rapamycin on rat macrophage viability and chemotaxis toward allogenic pancreatic islet supernates
  2227. Orally administered Rapamycin does not modify rat aortic vascular tone
  2228. Rapamycin inhibits the growth of cholangiocarcinoma cells in vitro
  2229. Sirolimus (Rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant
  2230. Induction effect of Rapamycin combined paclitaxel on apoptosis of ovarian cancer cell lines A2780 and SKOV3 and the molecular mechanism
  2231. Temozolomide combined with the PI3K inhibitor LY294002 or the mTOR inhibitor Rapamycin inhibits melanoma cell growth, survival and invasion
  2232. Negative inotropic effect of Rapamycin on isolated human cardiomyocytes
  2233. PDE4B Activity Controls Glucorticoid and Rapamycin Effects in DLBCL.
  2234. Effects of Rapamycin on intracellular cholesterol homeostasis of glomerular mesangial cell in the presence of interleukin-1β
  2235. TOR (target of Rapamycin) as an anti-cancer target
  2236. The expression of mammalian target of Rapamycin in Ishikawa and HEC-1A cells
  2237. Cancer and transplantation intersect at the mammalian target of Rapamycin
  2238. Expression of connective tissue growth factor in renal interstitial fibrosis after ureteral obstruction and effects of Rapamycin thereupon: experiment with rats
  2239. Rapamycin induces Balb/c murine CD4^+ CD25^+ foxp3^+ T cells proliferations
  2240. Mannan and peptidoglycan induce COX‐2 protein in human PMN via the mammalian target of Rapamycin
  2241. Establishment of a Conjugation System for the Rapamycin Producer Streptomyces hygroscopicus NRRL5491 [J]
  2242. Effeet of Rapamycin on mTOR and eIF-4E expression in coxsackievirus B3-induced rat myocardial cells [J]
  2243. Effects of Rapamycin on human hepatocellular carcinoma xenografts in nude mice [J]
  2244. Induction of PPAR gamma signaling and autophagy as a mechanism mediating acquired Rapamycin resistance in breast cancer models
  2245. A drug interaction study of sorafenib (S) and Rapamycin (R) in patients with advanced malignancies
  2246. Regression of Pulmonary Lymphangioleiomyomatosis (PLAM)-Associated Retroperitoneal Angiomyolipoma Post–Lung Transplantation With Rapamycin Treatment
  2247. Initial use of Rapamycin after kidney transplantation
  2248. Combination of CP-751871, a human monoclonal antibody against the IGF-1 receptor, with Rapamycin results in a highly effective therapy for xenografts derived from …
  2249. Rapamycin controls multiple signalling pathways involved in cancer cell survival
  2250. Phosphatidylinositol 3-kinase/mammalian target of Rapamycin pathway is critical for survival and proliferation of pancreatic cancer stem-like side population cells
  2251. Long-term limb allograft survival using a short course of anti-CD45RB monoclonal antibody, LF 15-0195, and Rapamycin in a mouse model
  2252. Resveratrol-and Rapamycin-induced Morphological Changes to Human Epithelial Colon Cancer DLD-1 Cells
  2253. Phosphoinositide 3-kinase (PI3K) and nutrient sensing mTOR (mammalian target of Rapamycin) pathways control T lymphocyte trafficking
  2254. Does the use of paclitaxel or Rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent?
  2255. Preclinical rationale for combination targeted therapy in advanced clear cell renal cell carcinoma (RCC): Abrogation of Rapamycin-mediated induction of AKT …
  2256. Effect of Rapamycin on CD4 (+) CD25 (+) regulatory T cells in allo-transplantation tolerance model
  2257. Effects of constant magnetic fields on proliferation and migration of endothelial progenitor cells under Rapamycin intervention: experiment with rats
  2258. Effect of Rapamycin on expression of origin recognition complex 1 mRNA in vascular smooth muscle cells [J]
  2259. The different effects of cyclosporin A and Rapamycin on regulatory CD4+CD25+ T cells: potential relationship with transplant tolerance induction
  2260. Experimental study of stent-based delivery of Rapamycin and tirofiban on preventing in-stent thrombosis and restenosis [J]
  2261. The clinical contrast investigation of Rapamycin eluting stent between domestic-made and imported [J]
  2262. Perivascular delivery of Rapamycin in pluronic gel inhibits neointimal hyperplasia in a rat carotid artery injury model, and the complementary role of carotid …
  2263. Effect of Rapamycin on the cell cycle arrest of T lymphocytes
  2264. mTOR kinase inhibitors exhibit properties that distinguish them from Rapamycin
  2265. … insulin-like growth factor-1 receptor (IGF-1R), enhances the anti-tumor activities of Tarceva in non-small cell lung carcinoma (NSCLC) and Rapamycin in sarcoma cell …
  2266. Conversion to Rapamycin in a renal transplant patient with von Hippel-Lindau disease: encouraging results—a case report
  2267. Rapamycin to the rescue!
  2268. Changes in FDG-PET in response to Rapamycin (R) correlated with Akt pathway inhibition and not with clinical outcome
  2269. Rapamycin inhibits proliferation of cells from TSC skin tumors.
  2270. Expression of mammalian target of Rapamycin and p70 S6 kinase in rabbit periodontal tissues remodeling during orthodontic tooth movement
  2271. Glucose transporter 12 and mammalian target of Rapamycin complex 1 signaling: a new target for diabetes-induced renal injury?
  2272. Clinical Application of Mammalian Target of Rapamycin Inhibitor in Kidney Transplantation
  2273. SYNERGISTIC EFFECT OF CYCLOSPORINE IN Rapamycin-INDUCE DIABETIC DISEASE: 1937
  2274. In Vitro Release of Rapamycin Sustained Eluting Stent Detected by a New Designed Circulating Device
  2275. Cause analysis and treatment of Rapamycin-eluting stent thrombosis [J]
  2276. Elevated phosphorylated mammalian target of Rapamycin (p-mTOR) expression in human neoplasms
  2277. Comparison between the Inhibitory and Cytotoxic Effects of Rapamycin and Paclitaxel on Endothelial Cell Proliferation
  2278. Treatment with sodium butyrate and Rapamycin inhibit growth of human cervical cancer cells
  2279. Pediatric Preclinical Testing Program (PPTP) evaluation of the mTOR inhibitor Rapamycin
  2280. The application of Rapamycin drug-eluting stents in elderly patients with acute myocardial infarction [J]
  2281. Effect of mammalian target of Rapamycin inhibitors on neuroblastoma MYCN expression and tumor growth
  2282. Efficacy and Safety Study of Rapamycin in Treating Mesangial Proliferative Glomerulonephritis: Analysis of 11 Cases
  2283. Effect of Orthodontics on Mammalian Target of Rapamycin and p70 S6 Kinase in Rabbit Periodontal Tissues [J]
  2284. Rapamycin affects eIF-4E expression in rat myocardial fibroblasts infected by Coxsackievirus B3
  2285. Local applied Rapamycin inhibits intimal hyperplasia in vein graft after CABG
  2286. Human monoclonal antibody CP751871, combined with Rapamycin is effective treatment for childhood sarcoma xenografts
  2287. P1-084: Mammalian target of Rapamycin (mTOR) inhibition by RAD001 in patients (pts) with reccurent non-small cell lung cancer (NSCLC): Use of 18F …
  2288. The application of Rapamycin drug-eluting stents in elderly patients with coronary heart disease [J]
  2289. Progress of Rapamycin in hepatocellular carcinoma
  2290. Predicting Rapamycin response using pathway profile in a population of genetically engineered hHer2 driven breast tumor model
  2291. Effect of conversion from calcineurin inhibitors to Rapamycin on chronic allograft nephropathy
  2292. The mTOR inhibitor Rapamycin demonstrates activity against AML in combination with imatinib mesylate and with 5-azacytidine.
  2293. Effeet of Rapamycin on mTOR and eIF-4E expression in coxsackievirus B3-induced rat myocardial cells
  2294. Combined regimen of Rapamycin and ciclosporin in long-term follow-up in renal allograft recipients
  2295. Rapamycin modulates the maturation of rat bone marrow-derived dendritic cells
  2296. Experimental study on Rapamycin-batroxobin eluting stent and its prevention of coronary restenosis after angiophaty [J]
  2297. Cellular differentiation of Rapamycin, PI3 kinase and TOR kinase inhibitors
  2298. Histone deacetylase inhibition with LBH589 inhibits the Rapamycin insensitive Rictor-mTOR (mTORC2) complex and translation initiation factor eIF4E activation in …
  2299. 9B-6 inhibition of Smooth Muscle Proliferation by Ultrasound-Triggered Release of Rapamycin from Microbubbles
  2300. Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor Rapamycin leads to tumor regression in the RENCA model
  2301. Toxicology and safety pharmacology of nanoparticle albumin-bound (nab) Rapamycin (ABI-009)
  2302. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.
  2303. Expression and secretion of VEGF in solid tumor cells is mediated by the mammalian target of Rapamycin (mTOR)
  2304. The design and pharmacokinetics in vivo of Rapamycin-PLGA membrane eluting stent [J]
  2305. Rapamycin combined with donor bone marrow-derived immature dendritic cells induces mouse skin allograft tolerance
  2306. Anti-Proliferative Effect of Rapamycin on Human T Cell Leukemia Cell Line Jurkat by Cell Cycle Arrest and Telomerase inhibition.
  2307. Phase I study of gefitinib and Rapamycin in adult patients with recurrent glioblastoma multiforme (GBM)
  2308. Rapamycin-induced inhibition of HTLV-I LTR activity is rescued by c-Myb
  2309. Effect of RNA interference targeting mammalian target of Rapamycin on the proliferation of vascular smooth muscle cell and the intimal hyperplasia
  2310. Anti-Cancer Effects of Rapamycin on U937 Cell Line.
  2311. Comparison of inflammatory markers and angiographic outcomes after implantation of Rapamycin and paclitaxel-eluting stents
  2312. The roles of mammalian target of Rapamycin (mTOR) and p21 in the autophagy pathway after DNA mismatch repair processing of 6-thioguanine
  2313. Molecular determinants of sensitivity to Rapamycin in NSCLC
  2314. Dasatinib and Rapamycin synergistically inhibit the proliferation of cells expressing oncogenic KIT kinase via global inhibition of AKT-dependent signaling
  2315. Anti-angiogenic activity of Rapamycin in Rapamycin-sensitive and-resistant tumor xenograft models
  2316. Mammalian target of Rapamycin impairs insulin’s ability to promote protein kinase B phosphorylation in isolated rat skeletal muscle
  2317. Dual Effects of Rapamycin on Immuno-suppression and Tumor inhibition
  2318. Rapamycin Inhibits Proliferation of Human Lung Cancer Cell Lines [J]
  2319. Combination therapy with Rapamycin and atorvastatin
  2320. PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic …
  2321. The effects of Rapamycin on body weight and insulin resistance in KKAy mice
  2322. Cell Proliferation in Multiple Rat Tissues In Vivo is Rapamycin Resistant
  2323. The Effect of Rapamycin on Repair of Liver Ischemia/Reperfusion Injury
  2324. Genetically engineered murine tumor models for drug response prediction: population based pathway profiles predict response to Rapamycin in a HER2 driven breast …
  2325. The effect of Rapamycin on PSA kinetics in men without prostate cancer
  2326. Chronic exposure to Rapamycin induces endothelial dysfunction in vitro
  2327. Antiproliferative effects of mTOR inhibition with Rapamycin (RAP) either given as a single agent or in combination with carboplatin and paclitaxel in Human Head and …
  2328. P158-M Expression of c-kit, p-mTOR and p-NFKappaB in angiolymphoid hyperplasia with eosinophilia: Potential for therapy with imitanib mesylate, Rapamycin and …
  2329. Use of Rapamycin to inhibit VEGF for the treatment of primary effusion lymphoma
  2330. Rapamycin and CCI-779 suppress the growth of hepatocellular carcinoma cells
  2331. Combined effects of Rapamycin and bicalutamide in androgen-dependent and-independent prostate cancer cells
  2332. Cholangiocarcinoma cells are selectively susceptible to Rapamycin treatment
  2333. The Mammalian Target of Rapamycin and Multiple Myeloma
  2334. Rapamycin modulates the eNOS versus shear stress relationship
  2335. Effect of Rapamycin on the Proliferation and Apoptosis of Human Leukemia Cell Line HL-60 [J]
  2336. EFFECTS OF Rapamycin COMBINED IMMUNOSUPPRESSION ON RENAL FUNCTION AFTER LIVER TRANSPLANTATION
  2337. Effects of Rapamycin on proliferation, function and cell-cycle of mouse T lymphocytes in vitro
  2338. Mammalian target of Rapamycin and leukemia treatment
  2339. Clinical utility of combined administration of Rapamycin and low dose of cyciosporin a in kidney transplantation recipients
  2340. Rapamycin Induced Transactivation of EGFR: Implications in the Regulation of Cellular Apoptosis
  2341. The mammalian target of Rapamycin (mTOR). Foreword.
  2342. Mammalian Target of Rapamycin Activation Impairs
  2343. Clinical application of Rapamycin-eluting stent in coronary artery disease
  2344. Differential response of mTORC1 and mTORC2 to Rapamycin in Rapamycin-sensitive and-resistant tumor xenograft models
  2345. Effect of IGF‐I and Rapamycin on diaphragm muscle atrogenes with malnutrition
  2346. Functional genomic identification and validation of Rapamycin response genes using high throughput RNA interference
  2347. Rapamycin increases sensitivity to cisplatin in mesothelioma cell lines
  2348. Rapamycin inhibition of cell motility is associated with its suppression of synthesis of GTPases
  2349. Yeast as a Model to Study the Immunosuppressive and Chemotherapeutic Drug Rapamycin
  2350. MANAGEMENT AND LONG-TERM OUTCOMES OF WOUND-HEALING COMPLICATIONS ASSOCIATED WITH Rapamycin: 1108
  2351. Rapamycin Augments Akt Activation in In Vitro and In Vivo Models of Cardiac Hypertrophy
  2352. The study of anti-proliferation effect of Rapamycin on human breast cancer MCF-7 cells under hypoxia [J]
  2353. Rapamycin Reduces CCR5 Density Levels
  2354. Rapamycin inhibits Stearoyl-CoA Desaturase 1 expression in breast cancer cell lines.
  2355. Overexpression analysis reveals novel growth regulators in the target of Rapamycin signaling pathway
  2356. Nutrient Stimulation of eIF4G Phosphorylation, but not PKC is Rapamycin Sensitive in Skeletal Muscle
  2357. Role of Rapamycin on cultured human Tenon′ s capsule fibroblasts
  2358. Statins and Rapamycin act synergistically to enhance vascular endothelial cytoprotection
  2359. Antitumor activity of Rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
  2360. Acute Rapamycin Treatment Does Not Improve In Vivo Insulin Action in Ob/Ob or High Fat Fed Mice
  2361. Administration of Rapamycin in vivo and in vitro prolonged allograft survival associated with iTregs
  2362. THE EFFECT OF LIVER REGENERATION ON Rapamycin PHARMACOKINETICS: 1226
  2363. The Clinical Application of Rapamycin Eluting Stent in Elderly Patients with Coronary Heart Disease.
  2364. Rapamycin induced “stunning” on FDG PET/CT in pancreatic cancer
  2365. Protective Effect of Pretreated Rapamycin on Renal Ischemia-Reperfusion Injury in Rats
  2366. Rapamycin impairs skin γδ T cell function resulting in autophagy
  2367. Rapamycin aggravates the renal damage in rats with protein overload nephropathy and the protection of losartan
  2368. Observation in Safety and Short-term Efficacy of Domestic-made Rapamycin-eluting Stent
  2369. Rapamycin Treatment Exacerbates Nutrition-Induced Diabetes in Psammomys obesus.
  2370. Rapamycin‐sensitive inhibition of Id1 and p21 in C2C12 myoblasts
  2371. Effects of Rapamycin on the Liver Regeneration after Partial Hepatectomy in Rats
  2372. Statin therapy, alone or in combination with Rapamycin, does not reverse Monocotaline Pulmonary Arterial Hypertension
  2373. Comparative study on clinical outcomes of two kinds of Chinese Rapamycin-eluting stent in patients with coronary artery disease
  2374. Rapamycin rescues lactacystin-induced dopaminergic neuron injury in vivo
  2375. Modulation of cell cycle progression by combined Rapamycin-octreotide treatment in pituitary tumor cells
  2376. Local application of Rapamycin inhibits neointimal hyperplasia in experimental vein grafts
  2377. Histologic Changes After Intravitreal Injection of Rapamycin and Bevacizumab in a Porcine Model
  2378. Bevacizumab and Rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
  2379. Study on the activation of mammalian target of Rapamycin in two endometrial carcinoma cells
  2380. Study on the changes of mammalian target of Rapamycin with aging in rat kidneys
  2381. 290: Rapamycin-generated Th2 cell therapy of established acute murine GVHD requires Th2 cell secretion of both IL-4 and IL-10
  2382. Rapamycin CAN AMELIORATE CAN IN RAT ALLOGRAFTS BY AFFECTING RHO/ROCK SIGNAL PATHWAY: 2147
  2383. Clinical study on major adverse cardiac events (MACE) rate in patients implanted with Rapamycin-eluting stents [J]
  2384. Preclinical evaluation of sorafenib in combination with Rapamycin for the treatment of acute myeloid leukemia (AML)
  2385. The Development and Molecular Expression in Mammalian Cells of an HA-Tagged Plasmid Encoding for the Target Of Rapamycin (mTOR)
  2386. The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
  2387. INFLUENCE OF Rapamycin ON RENAL TUBULAR FUNCTION IN RATS WITH OR WITHOUT CYCLOSPORINE TREATMENT: 1938
  2388. Drug eluting stents: long term results in clinical practice. Comparison between Rapamycin and paclitaxel eluting stents
  2389. Nucleophosmin Mediates Mammalian Target of Rapamycin
  2390. Rapamycin inhibits activation of Stat3 in kidney tissue of IgA nephropathy rats
  2391. Leukemia Induced by Altered TRK-Signaling Is Sensitive to Rapamycin Treatment in a Preclinical Model
  2392. Mechanisms of urokinase mediated activation of the mammalian target of Rapamycin (mTOR)
  2393. UROKINASE‐INDUCED SMOOTH MUSCLE CELL MIGRATION INVOLVES THE MAMMALIAN TARGET OF Rapamycin
  2394. Anti-inflammatory properties of Rapamycin on leukocyte-endothelial cell interactions following profound hypoperfusion
  2395. Contrasting effects of Cyclosporine and Rapamycin in de novo generation of alloantigen-specific regulatory T cells (88.45)
  2396. Combination treatment of Rapamycin and low dose irradiation causes cell death in human cancer cells cultured as 3-D spheroids
  2397. Rapamycin effects on mTOR signaling in the MCF10AT series of human breast epithelial cells: a model for proliferative breast disease and carcinoma
  2398. Anti-inflammatory drugs, sirolimus, and inhibition of target of Rapamycin and its effect on vascular diseases
  2399. Effect of Rapamycin in inducing naïve murine effector T cell convert to regulatory T cell
  2400. A high throughput assay for mammalian target of Rapamycin (mTOR) kinase activity
  2401. Rapamycin INDUCES AUTOPHAGY IN ISLETS: RELEVANCE FOR ISLETS TRANSPLANTATION: 556
  2402. Angioplasty stenting with Sirolimus (Rapamycin) eluting stents in type 2 diabetic patients
  2403. The Immunosuppressive drugs Rapamycin and FK506 decrease vasodilation by increasing PKCbetai‐mediated phosphorylation of eNOS Thr495
  2404. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A driven angiogenesis in part through the blockade of S6Kinase
  2405. Combined Rapamycin-octreotide treatment exerts its superior antiproliferative action by dramatically increasing p27/Kip1 expression
  2406. Characterisation of a novel and highly selective kinase inhibitor of the mammalian target of Rapamycin (mTOR)
  2407. ST2L upregulation promotes maturation resistance in Rapamycin‐conditioned dendritic cells
  2408. P286: Mechanisms of urokinase mediated activation of the mammalian target of Rapamycin (mTOR)
  2409. Akt phosphorylates and negatively regulates hnRNPA1-mediated control of cyclin D1 and c-myc translation in response to Rapamycin
  2410. Intravitreal Rapamycin and Bevacizumab Inhibits VEGF Expression in a Swine Model of Neovascularization
  2411. Acute activation of the mammalian target of Rapamycin complex 1 does not impair in vivo insulin action in mice
  2412. Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis
  2413. Cell cycle proteins and hTERT telomerase mRNA expression are independent targets of Rapamycin in ovarian cancer cell lines
  2414. Re-evaluating the roles of proposed modulators of mammalian target of Rapamycin complex 1 (mTORC1) signaling
  2415. P39. Rapamycin and the downstream target of mTOR, ribosomal protein L29 (RPL29), regulate prostate cancer cell growth and bone metastatic potential
  2416. Thymidine phosphorylase-related migratory effect of cancer cell is abrogated by m-TOR inhibitor Rapamycin
  2417. Curcumin inhibition of the mammalian target of Rapamycin signaling pathway
  2418. Synergistic combinations of a novel PI3 Kinase inhibitor with Erlotinib and Rapamycin and the associated effects on downstream signalling
  2419. Evaluation of the mTOT inhibitor, Rapamycin in dogs with spontaneously derived osteosarcoma: A focus on preclinical pharmacokinetics and pharmacodynamics
  2420. Activation of Mammalian Target of Rapamycin (mTOR) in Esophageal Squamous Cell Carcinona Cell Line [J]
  2421. The mammalian target of Rapamycin (mTOR) signaling in thymic lymphomagenesis in Atm-/-mice
  2422. Rapamycin-induced remission of Kaposi’s sarcoma is not associated with expansion of cytotoxic T-lymphocyte subsets
  2423. The Mammalian Target of Rapamycin Plays a Critical Role in the Development of Cardiac Hypertrophy in Spontaneously Hypertensive Rats
  2424. Inhibitory effect of Rapamycin and dexamethasone on production of IL-17 and IFN-c in Vogt–Koyanagi–Harada patients
  2425. Targeted therapy for osteosarcoma using 17AAG and Rapamycin: Identification of new targets by gene microarray profiling and miRNA
  2426. Divergent Roles of PI3K and Akt in Rapamycin-induced Cardioprotection against Ischemia-Reperfusion Injury
  2427. The Combination of the mTOR Inhibitor Rapamycin and Protein Kinase C Inhibitors Produces Marked Synergistic Anti-Myeloma Effects.
  2428. Expansion of Functional Polyclonal Human T-regulatory Cell Lines Using Artificial Antigen Presenting Cells and Rapamycin.(B159)
  2429. Sepsis associated platelet dysfunction & Rapamycin sensitive pathway of lipopolysaccharide signaling
  2430. COMPARISON OF Rapamycin VS. FK506 ON EXPRESSION OF CYTOPROTECTIVE GENES IN THE RAT-KIDNEY ALLOGRAFTS UNDERGOING CHRONIC …
  2431. Synergistic effect of Rapamycin and Casodex in inhibition of cell growth and survival as well as AR transcriptional activity in androgen dependent and independent …
  2432. Clenbuterol antagonizes Rapamycin-induced atrophy in rat soleus muscle
  2433. Ocular Toxicity and Distribution of Intravitreal and Subconjunctival Rapamycin in Horses
  2434. Rapamycin Withdrawal versus Delayed Initiation: Thrombosis vs. Suppression of Neointimal Hyperplasia after Vascular Injury
  2435. Rapamycin prevents cadmium-induced neuronal apoptosis by suppression of MAPK and mTOR pathways
  2436. Changes in gene expression profile after Rapamycin treatment of ErbB2-positive/ErbB2-negative breast carcinoma in organ culture
  2437. Dual inhibition of the Akt pathway by Rapamycin and Perifosine induces synergistic anti-tumor activity in multiple myeloma
  2438. Clinical Benefits of Rapamycin-Eluting Stent Made in China Appliance and Investigation in Patients with Acute Coronary Syndromes
  2439. Rapamycin Causes Reversible Cell Cycle Slowing, Rather Than Cell Cycle Arrest, in Myeloid and Lymphoid Cell Lines and in Acute Leukemia Cells
  2440. Effective inhibition of tumor growth in patient-derived xenografts of hepatocellular carcinoma by Rapamycin and bevacizumab
  2441. Protein kinase C (μ, θ, ϵ)-dependent Bad phosphorylation is an important signaling pathway in IGF-I rescue of sarcoma cells from Rapamycin-induced apoptosis
  2442. Enzastaurin inhibits growth of head and neck cancer cells and xenografts and synergizes with Rapamycin
  2443. Binding of novel Rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities
  2444. Combination of somatostatin analogues with Rapamycin analogues as a potential pharmaceutical treatment for non-functioning pituitary adenomas
  2445. Mammalian Target of Rapamycin (mTOR) is Essential for Murine Heart Development
  2446. A spontaneous pancreatic tumor model for monitoring pancreatic lesion and response to Rapamycin treatment through bioluminescence imaging
  2447. Targeted therapy for osteosarcoma using 17AAG and Rapamycin: Identification of new targets using Gene Microarray profiling and MiRNA
  2448. Rapamycin regulates synthesis of transforming growth factor-beta1 and extracellular matrix in arterial neointimal smooth muscle cells
  2449. Utilization of Meso Scale Discovery ELISA technology to quantitate the in vivo pharmacodynamic effects of Rapamycin treatment on the AKT pathway
  2450. Rapamycin blocks leucine‐induced protein synthesis by suppressing mTORC1 activation in skeletal muscle of neonatal pigs
  2451. Rapamycin IS LESS FIBROGENIC THAN FK506 IN RAT MODEL OF CHRONIC ALLOGRAFT NEPHROPATHY: 2144
  2452. Identification and characterization of novel positive regulators of the Target of Rapamycin (TOR) pathway in Drosophila melanogaster
  2453. The Role of Mammalian Target of Rapamycin in the Regulation of Amino Acid Transporters in the Human Placenta
  2454. Rapamycin, mTOR inhibitor, a potent inhibitor for the cell growth and proliferation by p21-dependent mitotic arrest in human gastric cancers
  2455. Role of mechanistic Target of Rapamycin (mTOR) signaling in the crustacean molting gland
  2456. … Scale Expansion of Human Dendritic Cells with Regulatory Function from Peripheral Blood Monocytes Employing Leukapheresis and Rapamycin for Clinical Trials.
  2457. Angioplasty stenting with Sirolimus (Rapamycin) eluting stents in type 2 diabetic patients Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2 …
  2458. Rapamycin prevents tobacco-carcinogen induced lung tumorigenesis and selectively reduces lung-associated Foxp3 positive cells
  2459. Clinical observation of Rapamycin Eluting Stent in acute ST-segment elevated myocardial infarction between domestic and imported product
  2460. Targeted therapy for osteosarcoma using 17AAG and Rapamycin: identification of new targets using l Gene microarray profiling and proteomics
  2461. EARLY IMMUNOSUPPRESSION WEANING AFTER CADAVER LIVER TRANSPLANTATION USING ATG INDUCTION AND Rapamycin: 358
  2462. inhibition effect of Rapamycin on acute graft-versus-host disease after allogeneic bone marrow transplantation in a murine model
  2463. Dual inhibition of phosphoinositide 3-kinase and mammalian target of Rapamycin as a novel therapeutic approach in human ovarian carcinoma
  2464. A small molecule inhibitor against kinase domain of mammalian target of Rapamycin (mTOR) causes autophagic cell death in glioblastoma
  2465. Effects of Imatinib and Rapamycin on the mTOR/S6 Signal Transduction Pathway in CD33+ Cell of CML
  2466. mTOR inhibitors Rapamycin and RAD001 (Everolimus) induce antiproliferative effects in GH3 cell line and human pituitary adenomas
  2467. PNEUMONITIS FROM INHIBITORS OF THE MAMMALIAN TARGET OF Rapamycin (mTOR) IN PATIENTS WITH METASTATIC CANCER
  2468. Targeted therapy for osteosarcoma using 17AAG and Rapamycin: Characterization of induced apoptosis and inhibition of mTOR and AKT/MAP kinase pathways
  2469. Blockage of mTOR signaling pathway by Rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains
  2470. The Yaa locus Confers Apoptosis, NF-κB and Rapamycin Signaling Resistance Through Multiple Receptors in C57BL/6J Mice (129.12)
  2471. Domestic versus foreign Rapamycin-eluting stents for emergency percutaneous coronary intervention in elder patients with acute myocardial infarction: Randomized …
  2472. Tumor suppressor gene ARHI (DIRAS3) is required for spontaneous and Rapamycin-induced autophagy in normal and ovarian cancer cells
  2473. Complete Responses in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) Using the mTOR Inhibitor Sirolimus (Rapamycin)
  2474. Signaling Downstream of Mammalian Target of Rapamycin Complex 1 (mTORC1) is Derepressed Following Treatment with L‐Asparaginase in the Liver of GCN2 …
  2475. MESENCHYMAL STEM CELLS ATTENUATE ACUTE REJECTION AND SYNERGIZE WITH Rapamycin LEADING TO CARDIAC ALLOGRAFT TOLERANCE: 382
  2476. inhibition of the mammalian target of Rapamycin (mTOR) for the chemoprevention of tobacco-carcinogen induced lung tumorigenesis
  2477. mTORC1 inhibition with Rapamycin or LY294002 alone but not in combination leads to AKT phosphorylation via mTORC2 in melanoma cells
  2478. Corrigendum to “Low-dose oral Rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis”[J …
  2479. FK506 VERSUS Rapamycin HAVE DIFFERENT EFFECTS ON EXPRESSION OF ANGIOPOIETINS1, 2 AND TIE2 IN RAT RENAL ALLOGRAFT WITH CAN: 1925
  2480. Combination Therapy Utilizing Murine Anti-Thymocyte Globulin (ATG) and Rapamycin for the Reversal of Overt Type 1 Diabetes in NOD Mice.
  2481. Rapamycin REDUCES VASCULAR INJURY BUT EXACERBATES PROTEINURIA IN ASSOCIATION WITH inhibition OF VEGF AND VEGF-R IN CHRONIC …
  2482. … Inhibitor Causes Growth inhibition, Cell Cycle Arrest, Apoptosis and Autophagic Cell Death in Mantle Cell Lymphoma Cell Lines: A Distinct Profile from Rapamycin.
  2483. Rapamycin PREFERENTIALLY BLOCKS THE EXPANSION OF POTENTIALLY TOLEROGENIC PLASMACYTOID DENDRITIC CELLS IN VIVO: 2217
  2484. Rapamycin DECREASES CHOLESTEROL EFFLUX AND ABCA1 PROTEIN EXPRESSION WITHIN THP-1 MACROPHAGES: 1931
  2485. TARGETED DELIVERY OF Rapamycin TO DENDRITIC CELLS USING BIODEGRADABLE MICROPARTICLES IS HIGHLY EFFECTIVE IN SUPPRESSING THEIR …
  2486. Mating Stimulates Protein Phosphorylation and Synthesis Via Rapamycin-and Wortmannin-Sensitive Pathways in the Male Accessory Glands of D. melanogaster
  2487. Dietary induced insulin resistance is independent of mammalian target of Rapamycin complex 1 (mTORC1) activity in skeletal muscle of mice
  2488. 191: Rapamycin inhibits endothelial cell recovery after hypoxic injury
  2489. Enhancement of Mammalian Target of Rapamycin Complex-2 (TORC2) Kinase Activity by Fructose-2, 6-Bisphosphate.
  2490. Effect of Rapamycin/Curcumin Co-Loaded Poly (Lactide-Co-Glycolide) Films on Blood Compatibility and Vascular Smooth Muscle Cell Proliferation
  2491. COMBINE TGF-BETA/FC AND Rapamycin FOR REGULATORY T CELLS GENERATION AND ALLOGRAFT TOLERANCE INDUCTION.: 728
  2492. The Wnt Agonist, SKL2020 Inhibits Neointimal Hyperplasia but Facilitates Re-Endothelialization, When Treated with Rapamycin in Porcine Coronary Artery Stent …
  2493. IL-1β-DRIVEN ST2 EXPRESSION PROMOTES MATURATION RESISTANCE IN Rapamycin-CONDITIONED DENDRITIC CELLS: 643
  2494. PRO-TOLEROGENIC PROPERTIES OF Rapamycin THAT FAVOR INDEFINITE HEART ALLOGRAFT SURVIVAL MEDIATED BY REGULATORY T CELLS.: 27
  2495. Mechanism of luteolin-induced apoptosis through suppressing p21 (WAF1/CIP1) expression with Rapamycin in HER2-overexpressing cancer cells
  2496. … ALLOGRAFT SURVIVAL IN UNMANIPULATED HOSTS BY POST-TRANSPLANT INFUSION OF DONOR-SPECIFIC REGULATORY T CELLS AND Rapamycin: 655
  2497. Role of the mammalian Target of Rapamycin (mTOR) Complex 1 signaling in beta‐adrenergic‐stimulated triacylglycerol (TAG) lipolysis and free fatty acid (FFA) …
  2498. A phase I study of the mTOR inhibitor sirolimus (Rapamycin) in combination with nanoparticle albumin-bound paclitaxel (ABI-007, abraxane) in advanced solid cancers
  2499. IMPACT OF IMMUNOSUPPRESSION ON UV-INDUCED SKIN-TUMORS IN MICE: Rapamycin IMPAIRS TUMOR OUTGROWTH AND SHIFTS THE MUTATION …
  2500. Dexamethasone represses signaling through mammalian target of Rapamycin (mTOR) in muscle cells by enhancing expression of REDD1
  2501. inhibition of mammalian target of Rapamycin (mTOR) induces phosphatidylinositol 3 kinase-dependent and Mnk-mediated eIF4E phosphorylation
  2502. Rapamycin, mTOR Inhibitor, a Potent Cell Growth and Proliferation Inhibitor by p21-Dependent Mitotic Arrest in Human Gastric Cancers
  2503. Rapamycin PROMOTES THE ENRICHMENT OF CD4+ CD25HIFOXP3+ T REGULATORY CELLS FROM NAIVE CD4+ T CELLS OF BABOON THAT SUPPRESS …
  2504. … with drug eluting stents but with significant cost saving: long term follow up results from the randomized, controlled ORAR III (Oral Rapamycin in Argentina) Study
  2505. PD2-4 Survival Advantage of Temsirolimus Validates a Role for Mammalian Target of Rapamycin (mTOR) in the Biology of Advanced Renal Cell Carcinoma
  2506. P3-026: A novel Bayesian dose-escalation Phase Ib study design investigating combination of the mammalian target of Rapamycin (mTOR) inhibitor RAD001 with …
  2507. Cell cycle arrest and suppression of the Akt/mammalian target of Rapamycin signaling mediated by yuanhuadine, a daphnane diterpenoid, isolated from Daphne …
  2508. … Smooth Muscle Cell Proliferation and Intimal Expansion by Phosphatidylinositol 3-Kinase–Dependent Mammalian Target of Rapamycin Raptor Complex 1 …
  2509. 155. Tumor Necrosis In Vivo Caused by a Novel Combination of Sorafenib and Rapamycin: Targeting the RAS and Motor Pathways ION Hepatocellular Carcinoma
  2510. 342: Rapamycin Prevents GVHD in Mouse Model through Novel Mechanism: Increase in Regulatory T cells
  2511. … downregulates acetyl-CoA carboxylase alpha and fatty acid synthase by activating AMP-activated protein kinase and suppressing the mammalian target of Rapamycin …
  2512. Glycogen Synthase Kinase-3 (GSK-3) Signaling to Mammalian Target of Rapamycin (mTOR) Regulates DNA Synthesis and Cell Cycle Progression in Rodent and …
  2513. THROMBOSPONDIN-1 (TSP-1) MEDIATES THE ANTI ANGIOGENIC AND IMMUNOMODULATORY EFFECTS OF Rapamycin ON PANCREATIC ISLET …
  2514. 53: Rapamycin Partially Overcomes the in vitro Protective Effect of M2–10B4 Mesenchymal Stromal Cells (MSC) to Murine mCGPR/+ Acute Promyelocytic Leukemic …
  2515. … CXC Chemokine Receptor 4 (CXCR4) by Hypoxia and the Phosphatidylinositol 3‐Kinase (PI‐3‐K)/Mammalian Target of Rapamycin (mTOR) Signaling Pathway
  2516. 234: Rapamycin generated donor Th2/Tc2 cells prevent graft rejection by inhibition of alloreactivity and not by deletion of alloreactive T cells
  2517. FoxP3 Mediated Induction of Pim 2 Allows T Regulatory Cells to Preferentially Expand in Rapamycin
  2518. The Novel Glycolysis Inhibitor, 3-BrOP, Has Broad Activity Against Acute Lymphoblastic Leukemias and Potentiates Methotrexate and Rapamycin.
  2519. … -selective oncolytic adenovirus OBP-405 induces autophagic cell death and enhances the antitumor effect of temozolomide and Rapamycin on glioblastoma cells in …
  2520. … regulatory (CD4+ CD25+ CD127LowFOXP3+) cells to high purity by inhibiting expansion of CD4+ CD25+ CD127HighFOXP3-conventional T cells with Rapamycin
  2521. Late stage efficacy and regulated gene expression profiles by 5-aza-dC, valproic acid, suberoylanilide hydroxamic acid, and Rapamycin in mouse lung tumorigenesis
  2522. 720: inhibition of Proliferation by Rapamycin in RAT Bladder Smooth Muscle Cells
  2523. 307: Initial selection of high affinity CD25+ cells increases the purity of CD4+ CD25+ Foxp3+ T regulatory cells expanded in medium containing Rapamycin
  2524. 518: Medium term renal function of pediatric heart transplant patients on reduced calcineurin inhibitor and Rapamycin
  2525. Automated quantitative analysis of AKT/mTOR pathway in patients treated with nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane) and (sirolimus) Rapamycin
  2526. 51: Rapamycin and its influence on arterial vascular function after short-term incubation
  2527. 336: Relative Contribution of CD127 Negative Selection, Rapamycin, and TGF-β to the Generation of Human Regulatory T Cells that Inhibit Alloreactivity via Dendritic …
  2528. An ATP-competitive mammalian target of Rapamycin inhibitor reveals Rapamycin-resistant functions of mTORC1
  2529. Rapamycin decelerates cellular senescence
  2530. Structure of the human mTOR complex I and its implications for Rapamycin inhibition
  2531. Delayed correlation of mRNA and protein expression in Rapamycin-treated cells and a role for Ggc1 in cellular sensitivity to Rapamycin
  2532. Rapamycin inhibits mTORC1, but not completely
  2533. Mammalian target of Rapamycin: discovery of Rapamycin reveals a signaling pathway important for normal and cancer cell growth
  2534. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1
  2535. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
  2536. Mechanisms of life span extension by Rapamycin in the fruit fly Drosophila melanogaster
  2537. Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson’s Disease
  2538. Targeting mTOR with Rapamycin: one dose does not fit all
  2539. The role of the mammalian target of Rapamycin (mTOR) in renal disease
  2540. Mammalian target of Rapamycin (mTOR): conducting the cellular signaling symphony
  2541. Potential use of Rapamycin in HIV infection
  2542. Targeting mTOR globally in cancer: thinking beyond Rapamycin
  2543. The complexes of mammalian target of Rapamycin
  2544. The mammalian target of Rapamycin: linking T cell differentiation, function, and metabolism
  2545. Not all substrates are treated equally: Implications for mTOR, Rapamycin-resistance, and cancer therapy
  2546. Rapamycin-induced phosphaturia
  2547. The mammalian target of Rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy
  2548. Mammalian target of Rapamycin complex 1: signalling inputs, substrates and feedback mechanisms
  2549. Rapamycin administration in humans blocks the contraction‐induced increase in skeletal muscle protein synthesis
  2550. Rapamycin extends maximal lifespan in cancer-prone mice
  2551. Active-site inhibitors of mTOR target Rapamycin-resistant outputs of mTORC1 and mTORC2
  2552. Nutrient-dependent regulation of autophagy through the target of Rapamycin pathway
  2553. Biosynthesis of Rapamycin and its regulation: past achievements and recent progress
  2554. inhibition of mTOR by Rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer’s disease
  2555. SIRT1 negatively regulates the mammalian target of Rapamycin
  2556. Targeting mammalian target of Rapamycin by Rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model
  2557. Characterization of the Rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis
  2558. Rapamycin and quasi-programmed aging: Four years later
  2559. A versatile role of mammalian target of Rapamycin in human dendritic cell function and differentiation
  2560. Autophagy is required for extension of yeast chronological life span by Rapamycin
  2561. Rapid inactivation of proteins by Rapamycin-induced rerouting to mitochondria
  2562. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of Rapamycin
  2563. Ku-0063794 is a specific inhibitor of the mammalian target of Rapamycin (mTOR)
  2564. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss
  2565. GOLPH3 modulates mTOR signalling and Rapamycin sensitivity in cancer
  2566. Molecular interplay between mammalian target of Rapamycin (mTOR), amyloid-β, and Tau: effects on cognitive impairments
  2567. A Rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states
  2568. Resveratrol and Rapamycin: are they anti‐aging drugs?
  2569. Metformin and Rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells
  2570. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of Rapamycin
  2571. Rapamycin protects against rotenone-induced apoptosis through autophagy induction
  2572. Protein synthesis is resistant to Rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
  2573. Rapamycin reduces seizure frequency in tuberous sclerosis complex
  2574. Pharmacological inhibition of the mammalian target of Rapamycin pathway suppresses acquired epilepsy
  2575. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of Rapamycin in cancer patients
  2576. TORC-specific phosphorylation of mammalian target of Rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2
  2577. Total synthesis of Rapamycin
  2578. Targeted inhibition of mammalian target of Rapamycin signaling inhibits tumorigenesis of colorectal cancer
  2579. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of Rapamycin kinase inhibitor with in vitro and in vivo antitumor activity
  2580. Tti1 and Tel2 are critical factors in mammalian target of Rapamycin complex assembly
  2581. The mTOR pathway is highly activated in diabetic nephropathy and Rapamycin has a strong therapeutic potential
  2582. Role for mammalian target of Rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders
  2583. Dual inhibition of Akt/mammalian target of Rapamycin pathway by nanoparticle albumin-bound–Rapamycin and perifosine induces antitumor activity in multiple …
  2584. Long-term Rapamycin therapy in the Han: SPRD rat model of polycystic kidney disease (PKD)
  2585. Delivery of Rapamycin to dendritic cells using degradable microparticles
  2586. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and Rapamycin in vivo
  2587. CDC25B mediates Rapamycin-induced oncogenic responses in cancer cells
  2588. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with Rapamycin
  2589. Curcumin disrupts the Mammalian target of Rapamycin-raptor complex
  2590. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and Rapamycin combination therapy
  2591. Chronic Rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose …
  2592. Recent advances in the chemistry, biosynthesis and pharmacology of Rapamycin analogs
  2593. inhibition of target of Rapamycin signaling and stress activate autophagy in Chlamydomonas reinhardtii
  2594. Akt signals through the mammalian target of Rapamycin pathway to regulate CNS myelination
  2595. Beneficial effects of Mammalian target of Rapamycin inhibition on left ventricular remodeling after myocardial infarction
  2596. Mammalian target of Rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways
  2597. Activation of the mammalian target of Rapamycin (mTOR) is essential for oligodendrocyte differentiation
  2598. The Rapamycin-sensitive phosphoproteome reveals that TOR controls protein kinase A toward some but not all substrates
  2599. Sorafenib and Rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
  2600. Mammalian target of Rapamycin: hitting the bull’s-eye for neurological disorders
  2601. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies
  2602. Mammalian target of Rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies
  2603. inhibition of the mammalian target of Rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
  2604. A pharmacodynamic study of Rapamycin in men with intermediate-to high-risk localized prostate cancer
  2605. Bone growth during Rapamycin therapy in young rats
  2606. Regulation of placental amino acid transporter activity by mammalian target of Rapamycin
  2607. Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity
  2608. Mammalian target of Rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis
  2609. Topical Rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis
  2610. New inhibitors of the mammalian target of Rapamycin signaling pathway for cancer
  2611. Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses
  2612. Mammalian target of Rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
  2613. Integration of general amino acid control and target of Rapamycin (TOR) regulatory pathways in nitrogen assimilation in yeast
  2614. Specific roles of Target of Rapamycin in the control of stem cells and their progeny in the Drosophila ovary
  2615. Down-regulation of Akt/mammalian target of Rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle
  2616. Infusion of mesenchymal stem cells and Rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance
  2617. Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia
  2618. Rapamycin inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164–Driven Angiogenesis, in Part by Blocking S6Kinase
  2619. Rapamycin Protects Against High Fat Diet–Induced Obesity in C57BL/6J Mice
  2620. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer
  2621. Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of Rapamycin in neonatal hypoxia-ischemia
  2622. Overexpression of phosphorylated mammalian target of Rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer
  2623. Mammalian target of Rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves
  2624. Rapamycin promotes β-amyloid production via ADAM-10 inhibition
  2625. Differential responses of human regulatory T cells (Treg) and effector T cells to Rapamycin
  2626. Monitoring mammalian target of Rapamycin (mTOR) activity
  2627. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with Rapamycin in renal cell carcinoma
  2628. Mammalian target of Rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive rats
  2629. Treatment with Rapamycin prevents fibrosis in tight‐skin and bleomycin‐induced mouse models of systemic sclerosis
  2630. Mammalian target of Rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage
  2631. Regulation of RNA polymerase III transcription involves SCH9-dependent and SCH9-independent branches of the target of Rapamycin (TOR) pathway
  2632. Mammalian target of Rapamycin controls dendritic cell development downstream of Flt3 ligand signaling
  2633. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of Rapamycin pathway
  2634. Long‐term administration of Rapamycin reduces adiposity, but impairs glucose tolerance in high‐fat diet‐fed KK/HlJ mice
  2635. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways
  2636. Regulation of insulin-like growth factor–mammalian target of Rapamycin signaling by microRNA in childhood adrenocortical tumors
  2637. Rapamycin prevents transforming growth factor-α–induced pulmonary fibrosis
  2638. Participation of mammalian target of Rapamycin complex 1 in Toll-like receptor 2–and 4–induced neutrophil activation and acute lung injury
  2639. Use of Rapamycin in the induction of tolerogenic dendritic cells
  2640. Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single‐blind pilot study
  2641. Insights into the domain and repeat architecture of target of Rapamycin
  2642. A novel mouse model of inflammatory bowel disease links mammalian target of Rapamycin-dependent hyperproliferation of colonic epithelium to inflammation …
  2643. Nutrient availability and lactogenic hormones regulate mammary protein synthesis through the mammalian target of Rapamycin signaling pathway
  2644. The mammalian target of Rapamycin as novel central regulator of puberty onset via modulation of hypothalamic Kiss1 system
  2645. … irinotecan and Rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of Rapamycin …
  2646. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability
  2647. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication
  2648. Mammalian target of Rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade
  2649. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of Rapamycin pathway
  2650. Critical roles for mTORC2-and Rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
  2651. inhibition of the mammalian target of Rapamycin signaling pathway suppresses dentate granule cell axon sprouting in a rodent model of temporal lobe epilepsy
  2652. Oral Rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels
  2653. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with Rapamycin
  2654. inhibition of histone deacetylase overcomes Rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
  2655. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway
  2656. Synergistic effect of Rapamycin and cisplatin in endometrial cancer cells
  2657. Activation of mammalian target of Rapamycin controls the loss of TCRζ in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation
  2658. Mammalian target of Rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice
  2659. Uremic cardiac hypertrophy is reversed by Rapamycin but not by lowering of blood pressure
  2660. Testosterone induces cardiomyocyte hypertrophy through mammalian target of Rapamycin complex 1 pathway
  2661. Rapamycin in islet transplantation: friend or foe?
  2662. Mammalian target of Rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR
  2663. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs
  2664. Mammalian target of Rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis
  2665. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage?
  2666. Distinct roles for mammalian target of Rapamycin complexes in the fibroblast response to transforming growth factor-β
  2667. Expression of an activated mammalian target of Rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors
  2668. The somatostatin analogue octreotide confers sensitivity to Rapamycin treatment on pituitary tumor cells
  2669. Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways
  2670. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis
  2671. ATP-competitive inhibitors of the mammalian target of Rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines
  2672. Gastric mammalian target of Rapamycin signaling regulates ghrelin production and food intake
  2673. The potential benefits of Rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation
  2674. Target of Rapamycin signaling in leukemia and lymphoma
  2675. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation
  2676. Targeted inhibition of mammalian target of Rapamycin for the treatment of advanced renal cell carcinoma
  2677. Target of Rapamycin (TOR) mediates the transduction of nutritional signals into juvenile hormone production
  2678. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice
  2679. Phase II trial of the oral mammalian target of Rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemia
  2680. Mammalian target of Rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma
  2681. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of Rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple …
  2682. Mammalian target of Rapamycin: biological function and target for novel anticancer agents
  2683. Mammalian target of Rapamycin signaling activation patterns in neuroendocrine tumors of the lung
  2684. inhibition of mammalian target of Rapamycin as a therapeutic strategy in the management of bladder cancer
  2685. Randomised trial of three Rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results
  2686. inhibition of mammalian target of Rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells
  2687. Perifosine inhibits mammalian target of Rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy
  2688. The effect of Rapamycin on bone growth in rabbits
  2689. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs
  2690. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with Rapamycin or cyclophosphamide
  2691. Rapamycin induces transactivation of the EGFR and increases cell survival
  2692. Mammalian target of Rapamycin inhibitors Rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro
  2693. Adiponectin modulates C-jun N-terminal kinase and mammalian target of Rapamycin and inhibits hepatocellular carcinoma
  2694. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates Rapamycin sensitivity in colorectal cancer
  2695. High entrapment efficiency of chitosan/polylactic acid/tripolyphotspate nanosized microcapsules for Rapamycin by an emulsion-evaporation approach
  2696. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of Rapamycin inhibition
  2697. Chemical genetics screen for enhancers of Rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase
  2698. Immune regulation by Rapamycin: moving beyond T cells
  2699. First report on a series of HIV patients undergoing Rapamycin monotherapy after liver transplantation
  2700. … leucine content of a complete meal directs peak activation but not duration of skeletal muscle protein synthesis and mammalian target of Rapamycin signaling in rats
  2701. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model
  2702. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer
  2703. Mammalian target of Rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock
  2704. The tuberous sclerosis proteins regulate formation of the primary cilium via a Rapamycin-insensitive and polycystin 1-independent pathway
  2705. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to Rapamycin treatment in vitro
  2706. Different effects of FK506, Rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets
  2707. Downregulation of Akt/mammalian target of Rapamycin pathway in skeletal muscle is associated with increased REDD1 expression in response to chronic hypoxia
  2708. Dual targeting of AKT and mammalian target of Rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor
  2709. Mammalian target of Rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation
  2710. Effect of Rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status
  2711. Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of Rapamycin signaling pathway
  2712. … skeletal muscle protein synthesis via an indirect mechanism involving endothelial-dependent vasodilation and mammalian target of Rapamycin complex 1 signaling
  2713. Signaling events downstream of mammalian target of Rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor …
  2714. A phase I study of the mammalian target of Rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia
  2715. Morpholine derivatives greatly enhance the selectivity of mammalian target of Rapamycin (mTOR) inhibitors
  2716. Intravesical delivery of Rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer
  2717. Complex regulation of mammalian target of Rapamycin complex 1 in the basomedial hypothalamus by leptin and nutritional status
  2718. Mammalian target of Rapamycin regulates vascular endothelial growth factor–dependent liver cyst growth in polycystin‐2–defective mice
  2719. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis
  2720. Generation of high-yield Rapamycin-producing strains through protoplasts-related techniques
  2721. An expeditious route to fluorinated Rapamycin analogues by utilising mutasynthesis
  2722. Mechanisms involved in the enhancement of mammalian target of Rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice
  2723. Mammalian target of Rapamycin and diabetes: what does the current evidence tell us?
  2724. Mammalian target of Rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients
  2725. Treatment of refractory oral erosive lichen planus with topical Rapamycin: 7 cases
  2726. Cryptotanshinone inhibits cancer cell proliferation by suppressing mammalian target of Rapamycin–mediated cyclin D1 expression and Rb phosphorylation
  2727. Tubers and tumors: Rapamycin therapy for benign and malignant tumors
  2728. The pre-clinical assessment of Rapamycin-eluting, durable polymer-free stent coating concepts
  2729. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus Rapamycin but not atorvastatin or doxycycline in tuberous …
  2730. EGFR signaling through an Akt-SREBP-1–dependent, Rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy
  2731. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents
  2732. Expansion of the target of Rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity
  2733. Long‐term blood vessel removal with combined laser and topical Rapamycin antiangiogenic therapy: Implications for effective port wine stain treatment
  2734. R1507, a fully human monoclonal antibody targeting IGF‐1R, is effective alone and in combination with Rapamycin in inhibiting growth of osteosarcoma xenografts
  2735. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of Rapamycin …
  2736. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model
  2737. Mammalian target of Rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in …
  2738. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1
  2739. Activated mammalian target of Rapamycin is a potential therapeutic target in gastric cancer
  2740. Mutual regulation of hypoxia-inducible factor and mammalian target of Rapamycin as a function of oxygen availability
  2741. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients
  2742. Rapamycin inhibits postprandial-mediated X-box-binding protein-1 splicing in rat liver
  2743. inhibition of human T-cell proliferation by mammalian target of Rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5)
  2744. Mammalian target of Rapamycin is activated in association with myometrial proliferation during pregnancy
  2745. Expression status and prognostic significance of mammalian target of Rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy
  2746. A phase 2 study of the oral mammalian target of Rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
  2747. Mammalian target of Rapamycin (mTOR) regulates TLR3 induced cytokines in human oral keratinocytes
  2748. Rapamycin-mediated FOXO1 inactivation reduces the anticancer efficacy of Rapamycin
  2749. Rapamycin for refractory acute graft-versus-host disease
  2750. Life span extension by resveratrol, Rapamycin, and metformin: The promise of dietary restriction mimetics for an healthy aging
  2751. Nucleus accumbens core mammalian target of Rapamycin signaling pathway is critical for cue-induced reinstatement of cocaine seeking in rats
  2752. New approach for local delivery of Rapamycin by bioadhesive PLGA-carbopol nanoparticles
  2753. Activation of the mammalian target of Rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics
  2754. … triterpenoid, suppresses migration and invasion of human breast cancer cells by modulating c‐Jun N‐terminal kinase, Akt and mammalian target of Rapamycin …
  2755. Rapamycin induces autophagic flux in neurons
  2756. Development and characterization of liposomal formulations for Rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells
  2757. A pilot trial of the mTOR (mammalian target of Rapamycin) inhibitor RAD001 in patients with advanced B-CLL
  2758. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of Rapamycin and epidermal growth factor …
  2759. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of Rapamycin (mTOR): Optimization of the 1-substituent
  2760. A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with Rapamycin-eluting stents
  2761. The target of Rapamycin complex 2 controls dendritic tiling of Drosophila sensory neurons through the Tricornered kinase signalling pathway
  2762. Mammalian target of Rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy
  2763. Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors
  2764. Targeted therapy of human osteosarcoma with 17AAG or Rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways
  2765. Conversion to Rapamycin immunosuppression for malignancy after kidney transplantation
  2766. cAMP-dependent activation of mammalian target of Rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4
  2767. Immunosuppression using the mammalian target of Rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement
  2768. Late progression of renal pathology and cyst enlargement is reduced by Rapamycin in a mouse model of nephronophthisis
  2769. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitors
  2770. Oral Rapamycin reduces tumour burden and vascularization in Lkb1+/− mice
  2771. Rapamycin and MPA, but not CsA, impair human NK cell cytotoxicity due to differential effects on NK cell phenotype
  2772. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
  2773. Broadening the therapeutic scope for Rapamycin treatment
  2774. Dual phosphoinositide 3-kinase/mammalian target of Rapamycin blockade is an effective radiosensitizing strategy for the treatment of non–small cell lung cancer …
  2775. Upregulation of the mammalian target of Rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic β-cells leads to increased β-cell mass and …
  2776. mTORC1 inhibition via Rapamycin promotes triacylglycerol lipolysis and release of free fatty acids in 3T3-L1 adipocytes
  2777. Mammalian target of Rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis
  2778. Effects of metformin on mammalian target of Rapamycin in a mouse model of endometrial hyperplasia
  2779. Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC Min/+ mice
  2780. Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by Rapamycin
  2781. Early and late effects of the immunosuppressants Rapamycin and mycophenolate mofetil on UV carcinogenesis
  2782. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of Rapamycin pathway activation in head and neck squamous cell carcinoma
  2783. Differing effects of systemically administered Rapamycin on consolidation and reconsolidation of context vs. cued fear memories
  2784. The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of Rapamycin signaling
  2785. Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of Rapamycin complex-2 and AKT-1
  2786. Rapamycin-induced Gln3 dephosphorylation is insufficient for nuclear localization: Sit4 and PP2A phosphatases are regulated and function differently
  2787. Melatonin attenuates methamphetamine‐induced deactivation of the mammalian target of Rapamycin signaling to induce autophagy in SK‐N‐SH cells
  2788. Monotherapy Rapamycin allows an increase of CD4+ CD25bright+ FoxP3+ T cells in renal recipients
  2789. Rapamycin: the cure for all that ails
  2790. Activation of mammalian target of Rapamycin signaling in spatial learning
  2791. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of Rapamycin in differentiated and anaplastic thyroid cancer
  2792. Comparison of radiosensitizing effects of the mammalian target of Rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell …
  2793. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling network in normal myelopoiesis and leukemogenesis
  2794. MYC activity mitigates response to Rapamycin in prostate cancer through eukaryotic initiation factor 4E–binding protein 1–mediated inhibition of autophagy
  2795. Successful control of intractable hypoglycemia using Rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases
  2796. Generation of high Rapamycin producing strain via rational metabolic pathway‐based mutagenesis and further titer improvement with fed‐batch bioprocess …
  2797. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia
  2798. Rapamycin-Insensitive Up-Regulation of MMP2 and Other Genes in Tuberous Sclerosis Complex 2–Deficient Lymphangioleiomyomatosis-Like Cells
  2799. Increasing longevity through caloric restriction or Rapamycin feeding in mammals: common mechanisms for common outcomes?
  2800. Rapamycin inhibits anal carcinogenesis in two preclinical animal models
  2801. Overexpression of the mammalian target of Rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer
  2802. Mammalian target of Rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein–protein interactions …
  2803. Downregulation of Notch pathway by a γ-secretase inhibitor attenuates AKT/mammalian target of Rapamycin signaling and glucose uptake in an ERBB2 transgenic …
  2804. A phosphatidylinositol 3-kinase/protein kinase B-independent activation of mammalian target of Rapamycin signaling is sufficient to induce skeletal muscle hypertrophy
  2805. … -1, 3, 5-triazine) derivatives: potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of Rapamycin inhibitors: discovery of …
  2806. Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-α expression in macrophages by reducing IL-10 expression
  2807. Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo
  2808. Pneumonitis associated with mammalian target of Rapamycin inhibitors in renal transplant recipients: a single-center experience
  2809. Discovery of potent and selective inhibitors of the mammalian target of Rapamycin (mTOR) kinase
  2810. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235
  2811. Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway
  2812. Mammalian target of Rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
  2813. Involvement of heterogeneous ribonucleoprotein F in the regulation of cell proliferation via the mammalian target of Rapamycin/S6 kinase 2 pathway
  2814. Treatment with Rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces …
  2815. Rapamycin and CCI‐779 inhibit the mammalian target of Rapamycin signalling in hepatocellular carcinoma
  2816. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies Rapamycin mechanism of action
  2817. Preclinical in vivo evaluation of Rapamycin in human malignant peripheral nerve sheath explant xenograft
  2818. Hypersensitivity of Ph-positive lymphoid cell lines to Rapamycin: Possible clinical application of mTOR inhibitor
  2819. Mammalian target of Rapamycin complex 1 is involved in differentiation of regenerating myofibers in vivo
  2820. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex
  2821. Treating triple-negative breast cancer by a combination of Rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study
  2822. Antitumoral activity of Rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma
  2823. Aberrant hyperactivation of akt and Mammalian target of Rapamycin complex 1 signaling in sporadic chordomas
  2824. HIV-associated nephropathy: role of mammalian target of Rapamycin pathway
  2825. The Rapamycin-regulated gene expression signature determines prognosis for breast cancer
  2826. … acid starvation of Saccharomyces cerevisiae and Candida albicans acetolactate synthase (ilv2Δ) mutants is influenced by the carbon source and Rapamycin
  2827. Combined Bcl-2/Mammalian Target of Rapamycin inhibition Leads to Enhanced Radiosensitization via Induction of Apoptosis and Autophagy in Non–Small Cell Lung …
  2828. Rapamycin down-regulates inducible nitric oxide synthase by inducing proteasomal degradation
  2829. Functional interaction of mammalian target of Rapamycin complexes in regulating mammalian cell size and cell cycle
  2830. Efficacy, tolerance, and safety of mammalian target of Rapamycin inhibitors as rescue immunosuppressants in liver transplantation
  2831. Rapamycin induces the TGFβ1/Smad signaling cascade in renal mesangial cells upstream of mTOR
  2832. … 3-kinase (PI3K) and the mammalian target of Rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin− Rapamycin conjugates
  2833. Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of Rapamycin (mTOR) pathway
  2834. Hepatitis C virus NS5A activates the mammalian target of Rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between …
  2835. Naive CD4 t cell proliferation is controlled by mammalian target of Rapamycin regulation of GRAIL expression
  2836. Activation of the mammalian target of Rapamycin signalling pathway in epidermal tumours and its correlation with cyclin‐dependent kinase 2
  2837. The effects of Rapamycin on lens epithelial cell proliferation, migration, and matrix formation: an in vitro study
  2838. Distinct phosphatase requirements and GATA factor responses to nitrogen catabolite repression and Rapamycin treatment in Saccharomyces cerevisiae
  2839. Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate
  2840. … protects mouse and human hematopoietic progenitors from γ-irradiation through extracellular signal-regulated kinase/mammalian target of Rapamycin …
  2841. Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment
  2842. Dramatic improvement in pulmonary hypertension with Rapamycin
  2843. High expression of mammalian target of Rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma
  2844. Phase Ib study of weekly mammalian target of Rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
  2845. Expression of EBV latent antigens, mammalian target of Rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic …
  2846. Identification of functional FKB protein in Echinococcus granulosus: its involvement in the protoscolicidal action of Rapamycin derivates and in calcium homeostasis
  2847. The role of phosphoinositide 3‐kinase and phosphatidic acid in the regulation of mammalian target of Rapamycin following eccentric contractions
  2848. Placental mammalian target of Rapamycin and related signaling pathways in an ovine model of intrauterine growth restriction
  2849. Rapamycin inhibits proliferation and migration of hepatoma cells in vitro
  2850. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers Rapamycin sensitivity
  2851. Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines
  2852. Activation of the AKT and mammalian target of Rapamycin pathways and the inhibitory effects of Rapamycin on those pathways in canine malignant melanoma cell lines
  2853. Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex: Case report
  2854. Rapamycin-eluting stents in the arterial duct: experimental observations in the pig model.
  2855. Device-based local delivery of siRNA against mammalian target of Rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation
  2856. mTOR inhibitor Rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
  2857. Exploring mammalian target of Rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
  2858. Target of Rapamycin (TOR)-like 1 kinase is involved in the control of polyphosphate levels and acidocalcisome maintenance in Trypanosoma brucei
  2859. Rapid modification of proteins using a Rapamycin-inducible tobacco etch virus protease system
  2860. Concurrent and sequential administration of chemotherapy and the Mammalian target of Rapamycin inhibitor temsirolimus in human cancer cells and xenografts
  2861. Mammalian target of Rapamycin complex 1 (mTORC1) signaling in energy balance and obesity
  2862. Bortezomib can suppress activation of Rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates
  2863. Rapamycin Prevents and Breaks the Anti-CD3–Induced Tolerance in NOD Mice
  2864. Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD
  2865. Polylactide-glycoli acid and Rapamycin coating intraocular lens prevent posterior capsular opacification in rabbit eyes
  2866. Regulation of cell death and epileptogenesis by the mammalian target of Rapamycin (mTOR): a double-edged sword?
  2867. Rapamycin inhibits growth of cholangiocarcinoma cells.
  2868. The Insulin-like Growth Factor-1 Receptor–Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of …
  2869. Rapamycin induces autophagy in islets: relevance in islet transplantation
  2870. Mammalian target of Rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes
  2871. Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) …
  2872. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells
  2873. Evaluation of in vivo antineoplastic effects of Rapamycin in patients with chemotherapy-refractory AML
  2874. Expression and mechanism of mammalian target of Rapamycin in age-related renal cell senescence and organ aging
  2875. Rapid improvement of nephrogenic systemic fibrosis with Rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase
  2876. Inactivation of mammalian target of Rapamycin increases STAT1 nuclear content and transcriptional activity in α4-and protein phosphatase 2A-dependent …
  2877. Testing intravitreal toxicity of Rapamycin in rabbit eyes
  2878. Antagonism of the mammalian target of Rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant …
  2879. ATP-mediated protein kinase B Akt/mammalian target of Rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes …
  2880. Delayed re-endothelialization with Rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3β inhibitor
  2881. Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR)
  2882. inhibition of mammalian target of Rapamycin signaling potentiates the effects of all‐trans retinoic acid to induce growth arrest and differentiation of human acute …
  2883. Rapamycin enhances chemotherapy‐induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells
  2884. Pilot study: Rapamycin in advanced hepatocellular carcinoma
  2885. Mammalian target of Rapamycin as a novel target in the treatment of hepatocellular carcinoma.
  2886. Mammalian target of Rapamycin: a new target in prostate cancer
  2887. MAPK, phosphatidylinositol 3-kinase, and mammalian target of Rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic …
  2888. Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage
  2889. The Rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt–mTOR–p70S6K pathway in human medullary thyroid carcinoma cells
  2890. Rapamycin and the transcription factor C/EBPβ as a switch in osteoclast differentiation: implications for lytic bone diseases
  2891. Mammalian target of Rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma …
  2892. Rapamycin inhibits lung metastasis of B16 melanoma cells through down‐regulating alphav integrin expression and up‐regulating apoptosis signaling
  2893. Mammalian target of Rapamycin (mTOR) induces proliferation and de-differentiation responses to three coordinate pathophysiologic stimuli (mechanical strain …
  2894. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) inhibitor
  2895. Effect of Rapamycin on lifespan in Drosophila
  2896. Luteinizing hormone stimulates mammalian target of Rapamycin signaling in bovine luteal cells via pathways independent of AKT and mitogen-activated protein kinase …
  2897. The effect of Rapamycin on angiogenesis in chick chorioalantoic membrane
  2898. Mammalian target of Rapamycin pathway promotes tumor-induced angiogenesis in adenoid cystic carcinoma: its suppression by isoliquiritigenin through dual …
  2899. Regulation of gastric hormones by systemic Rapamycin
  2900. Effect of combination treatment of Rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells
  2901. Distinct subsets of Sit4 holophosphatases are required for inhibition of Saccharomyces cerevisiae growth by Rapamycin and zymocin
  2902. Activation of phosphatidylinositol 3-kinase/Akt-mammalian target of Rapamycin signaling pathway in the hippocampus is essential for the acquisition of morphine …
  2903. Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and …
  2904. Critical and diverse involvement of Akt/mammalian target of Rapamycin signaling in human lung carcinomas
  2905. … yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for …
  2906. Phosphoinositide 3-kinase (PI3K) and the nutrient sensing mTOR (mammalian target of Rapamycin) pathways control T cell migration
  2907. Glycogen synthase kinase-3 and mammalian target of Rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets
  2908. Periadventitial Rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts
  2909. Inhibitory effect of Rapamycin and dexamethasone on production of IL-17 and IFN-γ in Vogt–Koyanagi–Harada patients
  2910. Rap1 promotes multiple pancreatic islet cell functions and signals through mammalian target of Rapamycin complex 1 to enhance proliferation
  2911. Novel mechanism of reducing tumourigenesis: upregulation of the DNA repair enzyme OGG1 by Rapamycin-mediated AMPK activation and mTOR inhibition
  2912. Rapamycin‐Conditioned Donor Dendritic Cells Differentiate CD4+CD25+Foxp3+ T Cells In Vitro with TGF‐β1 for Islet Transplantation
  2913. Mammalian Target of Rapamycin–Dependent Acinar Cell Neoplasia after Inactivation of Apc and Pten in the Mouse Salivary Gland: Implications for Human Acinic Cell …
  2914. The Drosophila FoxA ortholog Fork head regulates growth and gene expression downstream of Target of Rapamycin
  2915. Rescue immunosuppression with mammalian target of Rapamycin inhibitor drugs in liver transplantation
  2916. In-vitro release of Rapamycin from a thermosensitive polymer for the inhibition of vascular smooth muscle cell proliferation
  2917. Influence of combined treatment of low dose Rapamycin and cyclosporin A on corneal allograft survival
  2918. Low-dose Rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex
  2919. Rapamycin attenuates the severity of murine adriamycin nephropathy
  2920. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells
  2921. Stage 2 combination testing of Rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program
  2922. Targeting the mammalian target of Rapamycin to inhibit VEGF and cytokines for the treatment of primary effusion lymphoma
  2923. Human Protein Phosphatase PP6 Regulatory Subunits Provide Sit4-Dependent and Rapamycin–Sensitive Sap Function in Saccharomyces cerevisiae
  2924. … cell marker upregulation in normal cutaneous vessels following pulsed‐dye laser exposure and its abrogation by concurrent Rapamycin administration: implications for …
  2925. Monitoring kidney and renal cyst volumes applying MR approaches on a Rapamycin treated mouse model of ADPKD
  2926. Rapamycin promotes the expansion of CD4+ Foxp3+ regulatory T cells after liver transplantation
  2927. … cells treated with mammalian target of Rapamycin inhibitors: rationale for combined treatment with extracellular signal–regulated kinase inhibitors and Rapamycin
  2928. Effective treatment of advanced colorectal cancer by Rapamycin and 5-FU/oxaliplatin monitored by TIMP-1
  2929. Anti-CD154 mAb and Rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation
  2930. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of Rapamycin complex 2
  2931. Comparison of three Rapamycin dosing schedules in A/J Tsc2+/-mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice …
  2932. Effect of Rapamycin on cue-induced drug craving in abstinent heroin addicts
  2933. Adenosine 5′-monophosphate-activated protein kinase-mammalian target of Rapamycin cross talk regulates brown adipocyte differentiation
  2934. Intracellular parasitism with Toxoplasma gondii stimulates mammalian‐target‐of‐Rapamycin‐dependent host cell growth despite impaired signalling to S6K1 and 4E …
  2935. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of Rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia
  2936. The synergic effects of Rapamycin and extremely low frequency electromagnetic field on angiogenesis
  2937. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient
  2938. Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells
  2939. Combined inhibition of MEK and mammalian target of Rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their …
  2940. Structural basis for the association of the redox-sensitive target of Rapamycin FATC domain with membrane-mimetic micelles
  2941. NV‐128, a novel isoflavone derivative, induces caspase‐independent cell death through the Akt/mammalian target of Rapamycin pathway
  2942. Activating transcription factor 4 and CCAAT/enhancer-binding protein-β negatively regulate the mammalian target of Rapamycin via Redd1 expression in response to …
  2943. Epidermal growth factor receptor and mammalian target of Rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives
  2944. Chemopreventive efficacy of Rapamycin on Peutz–Jeghers syndrome in a mouse model
  2945. … Stents Results in Better Clinical Outcomes During 6-Year Follow-Up Than Bare-Metal Stents: An Analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At …
  2946. … repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of Rapamycin …
  2947. … of the epidermal growth factor receptor/mammalian target of Rapamycin pathway by epidermal growth factor receptor inhibitors and Rapamycin results in reduced cell …
  2948. inhibition of the mammalian target of Rapamycin promotes cyclic AMP-induced differentiation of NG108-15 cells
  2949. Human CD34-derived myeloid dendritic cell development requires intact phosphatidylinositol 3-kinase–protein kinase B–mammalian target of Rapamycin signaling
  2950. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling network in cancer stem cell biology
  2951. … -6-aryl-1H-pyrazolo[3,4-d]pyrimidines as Highly Potent and Selective ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin (mTOR): Optimization of the …
  2952. PI3K signaling regulates Rapamycin-insensitive translation initiation complex formation in vaccinia virus-infected cells
  2953. Silymarin inhibits endothelial progenitor cells’ senescence and protects against the antiproliferative activity of Rapamycin: preliminary study
  2954. inhibition of voltage-gated K+ channels in dendritic cells by Rapamycin
  2955. Phase I study of the oral mammalian target of Rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
  2956. Regulation by FK506 and Rapamycin of Ca2+ release from the sarcoplasmic reticulum in vascular smooth muscle: the role of FK506 binding proteins and mTOR
  2957. … using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at …
  2958. Rrd1 isomerizes RNA polymerase II in response to Rapamycin
  2959. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of Rapamycin activity and p27Kip1 …
  2960. Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism
  2961. If mammalian target of metformin indirectly is mammalian target of Rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in …
  2962. The transcription factor SP1 regulates centriole function and chromosomal stability through a functional interaction with the mammalian target of Rapamycin/raptor …
  2963. Involvement of autophagy via mammalian target of Rapamycin (mTOR) inhibition in tributyltin-induced neuronal cell death
  2964. Rapamycin protects heart from ischemia/reperfusion injury independent of autophagy by activating PI3 kinase-Akt pathway and mitochondria KATP channel
  2965. … peroxisome proliferator-activated receptor (PPAR) γ protein translation by suppressing the mammalian target of Rapamycin (mTOR) signaling pathway in …
  2966. SP600125 negatively regulates the mammalian target of Rapamycin via ATF4-induced Redd1 expression
  2967. … in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of Rapamycin
  2968. Rapamycin Inhibits VEGF‐Induced Microvascular Hyperpermeability In Vivo
  2969. Iron deficiency down-regulates the Akt/TSC1-TSC2/mammalian Target of Rapamycin signaling pathway in rats and in COS-1 cells
  2970. Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of Rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a …
  2971. Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by Rapamycin in human myeloma cells
  2972. Rapamycin for focal segmental glomerulosclerosis: a report of 3 cases
  2973. inhibition of mammalian target of Rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E …
  2974. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of Rapamycin
  2975. … by leucine supplementation in malnourished rats: possible involvement of the phosphatidylinositol 3-phosphate kinase/mammalian target protein of Rapamycin …
  2976. Rapamycin inhibits cholangiocyte regeneration by blocking interleukin‐6–induced activation of signal transducer and activator of transcription 3 after liver …
  2977. A role for mammalian target of Rapamycin–mTOR-pathway in non alcoholic steatohepatitis related-cirrhosis
  2978. Targeting mammalian target of Rapamycin to both downregulate and disable the P-glycoprotein pump in multidrug-resistant B-cell lymphoma cell lines
  2979. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with Rapamycin plus tacrolimus in liver transplant patient
  2980. Rapamycin promotes the enrichment of CD4+ CD25hiFoxP3+ T regulatory cells from naive CD4+ T cells of baboon that suppress antiporcine xenogenic response in …
  2981. Rapamycin, but not cyclosporine A, inhibits vascularization and incorporation of implanted surgical meshes
  2982. Rapamycin‐treated mature dendritic cells have a unique cytokine secretion profile and impaired allostimulatory capacity
  2983. Rapamycin induces autophagy and exacerbates metabolism associated complications in a mouse model of type 1 diabetes
  2984. Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by Rapamycin and bevacizumab in an intrahepatic model
  2985. Inducible somatic oocyte destruction in response to Rapamycin requires wild-type regulation of follicle cell epithelial polarity
  2986. Cutaneous T‐cell lymphoma cells are sensitive to Rapamycin
  2987. … ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase–regulated mammalian target of Rapamycin …
  2988. Mammalian target of Rapamycin (mTOR) and S6 kinase down-regulate phospholipase D2 basal expression and function
  2989. Rapamycin enhances the susceptibility of both androgen-dependent and-independent prostate carcinoma cells to docetaxel
  2990. The phosphatidylinositol 3-kinase-AKT-mammalian target of Rapamycin signaling network and the control of normal myelopoiesis
  2991. CD4+ Foxp3+ regulatory T cells converted by Rapamycin from peripheral CD4+ CD25˜. naive T cells display more potent regulatory abilityin vitro
  2992. Chemistry and pharmacology of Rapamycin and its derivatives
  2993. Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of Rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and …
  2994. Mammalian target of the Rapamycin pathway is involved in non-alcoholic fatty liver disease
  2995. Antiproliferative effects of Rapamycin and celecoxib in angiosarcoma cell lines
  2996. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of Rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung …
  2997. mTOR inhibitor Rapamycin suppresses striatal post-ischemic LTP
  2998. Ribosomal protein S6 kinase is a critical downstream effector of the target of Rapamycin complex 1 for long-term facilitation in Aplysia
  2999. FK506 and Rapamycin neuroprotect erection and involve different immunophilins in a rat model of cavernous nerve injury
  3000. Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells
  3001. MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and Rapamycin …
  3002. Lysosomal accumulation of mTOR is enhanced by Rapamycin
  3003. Systemic Rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation
  3004. Beclin 1 self‐association is independent of autophagy induction by amino acid deprivation and Rapamycin treatment
  3005. High expression levels of the mammalian target of Rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma
  3006. … of the effects of NF-κB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264. 7 cells: synergistic effects of Rapamycin on LPS-induced …
  3007. Combined administration of a mutant TGF-β1/Fc and Rapamycin promotes induction of regulatory T cells and islet allograft tolerance
  3008. Evidence for cell cycle-dependent, Rapamycin-resistant phosphorylation of ribosomal protein S6 at S240/244
  3009. Rapamycin reduces high-amplitude, mechanical stretch-induced apoptosis in pulmonary microvascular endothelial cells
  3010. Effect of low-dose Rapamycin on tumor growth in two human hepatocellular cancer cell lines
  3011. The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells
  3012. Rapamycin: could it enhance vaccine efficacy?
  3013. Rapamycin and tacrolimus differentially modulate acute graft‐versus‐host disease in rats after liver transplantation
  3014. Infarct size is increased in female post-MI rats treated with Rapamycin
  3015. Protein kinase C-δ and phosphatidylinositol 3-kinase/Akt activate mammalian target of Rapamycin to modulate NF-κB activation and intercellular adhesion …
  3016. Glutamate-dependent phosphorylation of the mammalian target of Rapamycin (mTOR) in Bergmann glial cells
  3017. Rapid regression of lymphadenopathy upon Rapamycin treatment in a child with autoimmune lymphoproliferative syndrome
  3018. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of Rapamycin inhibitors: discovery of PKI …
  3019. mTOR, the mammalian target of Rapamycin
  3020. Oral Rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice
  3021. Glucagon acts in a dominant manner to repress insulin-induced mammalian target of Rapamycin complex 1 signaling in perfused rat liver
  3022. Targeting heat‐shock protein 90 improves efficacy of Rapamycin in a model of hepatocellular carcinoma in mice
  3023. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine
  3024. inhibition of human immunodeficiency virus (HIV‐1) infection in human peripheral blood leucocytes‐SCID reconstituted mice by Rapamycin
  3025. Mammalian target of Rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells
  3026. Effects of Rapamycin on prostate cancer PC-3 cells
  3027. Five‐year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus‐eluting stents: Insights from the Rapamycin‐eluting stent evaluated at …
  3028. … of essential amino acid deficiency in the anterior piriform cortex, that requires the uncharged tRNA/GCN2 pathway, is sensitive to wortmannin but not Rapamycin
  3029. Failed rescue therapy with Rapamycin after paraquat intoxication
  3030. mTOR pathway inhibitors in cancer therapy: moving past Rapamycin
  3031. A spectrophotometric assay for routine measurement of mammalian target of Rapamycin activity in cell lysates
  3032. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and Rapamycin in a renal transplant recipient
  3033. Rapamycin in combination with donor-specific CD4+ CD25+ Treg cells amplified in vitro might be realize the immune tolerance in clinical organ transplantation
  3034. Shiga toxin 1-induced proinflammatory cytokine production is regulated by the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling pathway
  3035. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of Rapamycin (mTOR) with selectivity over PI3Kα
  3036. Timing of conversion to mammalian target of Rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation
  3037. Novel benzofuran-3-one indole inhibitors of PI3 kinase-α and the mammalian target of Rapamycin: Hit to lead studies
  3038. Fission yeast TOR and Rapamycin
  3039. Activated mammalian target of Rapamycin is associated with T regulatory cell insufficiency in nasal polyps
  3040. Rapamycin or tacrolimus alone fails to resist cardiac allograft accelerated rejection mediated by alloreactive CD4+ memory T cells in mice
  3041. A functional link between polo-like kinase 1 and the mammalian target-of-Rapamycin pathway?
  3042. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of Rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines …
  3043. Experience with everolimus (RAD001), an oral mammalian target of Rapamycin inhibitor, in patients with systemic mastocytosis
  3044. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor
  3045. Rapamycin impairs trabecular bone acquisition from high‐dose but not low‐dose intermittent parathyroid hormone treatment
  3046. Steady-state kinetic and inhibition studies of the mammalian target of Rapamycin (mTOR) kinase domain and mTOR complexes
  3047. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell …
  3048. Impact of mammalian target of Rapamycin inhibition on autosomal-dominant polycystic kidney disease
  3049. Limited utility of Rapamycin in severe, refractory Wegener’s granulomatosis
  3050. Rescuing 3T3-L1 adipocytes from insulin resistance induced by stimulation of Akt-mammalian target of Rapamycin/p70 S6 kinase (S6K1) pathway and serine …
  3051. MYC activity mitigates response to Rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy
  3052. Target of Rapamycin in the oriental fruit fly Bactrocera dorsalis (hendel): its cloning and effect on yolk protein expression
  3053. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists
  3054. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of Rapamycin
  3055. Molecular pathways involved in hair follicle tumor formation: all about mammalian target of Rapamycin?
  3056. Posttransplantation Therapeutic Rapamycin Concentration Protects Nitric Oxide–Related Vascular Endothelial Function: Comparative Effects in Rat Thoracic Aorta …
  3057. Controversies in breast cancer: the mammalian target of Rapamycin as a target for breast cancer therapy
  3058. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of Rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed …
  3059. AZD6244 (ARRY‐142886) enhances the antitumor activity of Rapamycin in mouse models of human hepatocellular carcinoma
  3060. Increased frequency of regulatory T cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with Rapamycin
  3061. Comparison of Rapamycin-and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction
  3062. Regulation of protein kinase Cδ downregulation by protein kinase Cε and mammalian target of Rapamycin complex 2
  3063. Rapamycin reduces proteinuria and renal damage in the rat remnant kidney model
  3064. How does the mammalian target of Rapamycin (mTOR) influence CD8 T-cell differentiation?
  3065. Alteration of REDD1-mediated mammalian target of Rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer
  3066. Immunohistochemical analysis of the mammalian target of Rapamycin signalling pathway in extramammary Paget’s disease
  3067. Preventing restenosis after implantation of bare stents with oral Rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow …
  3068. Rapamycin can Inhibit the Development of Chlamydia pneumoniae, which Might Partly Contribute to the Prevention of In-stent Restenosis
  3069. Depletion of mammalian target of Rapamycin (mTOR) via siRNA mediated knockdown leads to stabilization of β-catenin and elicits distinct features of …
  3070. Indirect antitumor effects of mammalian target of Rapamycin inhibitors against Kaposi sarcoma in transplant patients
  3071. … -pyrrolo [2, 3-b] pyridin-3-yl) methylene-4-hydroxybenzofuran-3 (2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of Rapamycin …
  3072. Inhibitors of the mammalian target of Rapamycin and transplant tolerance
  3073. Clinical implications of proteinuria in renal transplant recipients switching to Rapamycin for chronic allograft dysfunction
  3074. Transforming growth factor beta 1 (TGF-β1) and Rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs
  3075. Descending serotonergic facilitation mediated by spinal 5-HT3 receptors engages spinal Rapamycin-sensitive pathways in the rat
  3076. … replacement in 6-aryl-1H-pyrazolo [3, 4-d] pyrimidines and 2-arylthieno [3, 2-d] pyrimidines: ATP-competitive inhibitors of the mammalian target of Rapamycin (mTOR)
  3077. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with polycystic kidney disease
  3078. Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells
  3079. Protection from Rapamycin-induced apoptosis by insulin-like growth factor-I is partially dependent on protein kinase C signaling
  3080. Suppression of mTOR complex 2‐dependent AKT phosphorylation in melanoma cells by combined treatment with Rapamycin and LY294002
  3081. Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with Rapamycin in human orthotopic primary pancreatic cancer xenografts
  3082. Effects of delayed Rapamycin treatment on renal fibrosis and inflammation in experimental ischemia reperfusion injury
  3083. Cutting edge: Expression of the transcription factor E74-like factor 4 is regulated by the mammalian target of Rapamycin pathway in CD8+ T cells
  3084. Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of Rapamycin–dependent endometrial hyperplasia and carcinoma
  3085. Rapamycin inhibits yeast nucleotide excision repair independently of Tor kinases
  3086. ID2‐VEGF‐related Pathways in the Pathogenesis of Kaposi’s Sarcoma: A Link Disrupted by Rapamycin
  3087. Phosphorylation of translation factors in response to anoxia in turtles, Trachemys scripta elegans: role of the AMP-activated protein kinase and target of Rapamycin …
  3088. Novel mechanism of Rapamycin in GVHD: increase in interstitial regulatory T cells
  3089. Low-dose calcineurin inhibitor regimen combined with mammalian target of Rapamycin inhibitors preserves kidney functions in renal transplant recipients without …
  3090. Rapamycin for chemoprevention of upper aerodigestive tract cancers
  3091. Mutation of a phosphorylatable residue in Put3p affects the magnitude of Rapamycin-induced PUT1 activation in a Gat1p-dependent manner
  3092. Spreading of mesothelioma cells is Rapamycin‐sensitive and requires continuing translation
  3093. Rapamycin enhances platelet aggregation induced by adenosine diphosphate in vitro
  3094. Insulin resistance without elevated mammalian target of Rapamycin complex 1 activity in muscles of mice fed a high-fat diet
  3095. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of Rapamycin (mTOR)
  3096. Serine 2481-autophosphorylation of mammalian target of Rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: Confocal …
  3097. Mammalian target of Rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction
  3098. Select nutrients in the ovine uterine lumen. VI. Expression of FK506-binding protein 12-Rapamycin complex-associated protein 1 (FRAP1) and regulators and effectors …
  3099. The effect of Rapamycin liposome gutta inhibiting rat corneal neovascularization
  3100. Retracted: CCR5 blockade in combination with Rapamycin prolongs cardiac allograft survival in mice
  3101. Rapamycin joins the aging fray: maybe Ponce de Leon visited Rapa Nui, not Florida
  3102. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with Rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo
  3103. Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with Rapamycin
  3104. Rapamycin does not adversely affect intrahepatic islet engraftment in mice and improves early islet engraftment in humans
  3105. Late conversion to mammalian target of Rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years
  3106. … between a prospective randomised multicentre cutting balloon angioplasty and bare metal stent trial (REDUCE III) and the Rapamycin-Eluting Stent Evaluation At …
  3107. … growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of Rapamycin …
  3108. Rapamycin suppresses the expansion and differentiation of porcine neonatal pancreas cell clusters
  3109. The possible cellular mechanism for extending lifespan of mice with Rapamycin
  3110. Rapamycin reduces kidney volume and delays the loss of renal function in a patient with autosomal-dominant polycystic kidney disease
  3111. … posttranscriptional regulation of insulin-like growth factor-I receptor level via glycogen synthase kinase-3β and mammalian target of Rapamycin in adrenal chromaffin …
  3112. Preparation of electrospun poly (L-lactide-co-caprolactone-co-glycolide)/phospholipid polymer/Rapamycin blended fibers for vascular application
  3113. Combined effect of Rapamycin and cisplatin on survival of Hep-2 cells in vitro
  3114. Adenosine-triphosphate promoting repair of spinal cord injury by activating mammalian target of Rapamycin/signal transducers and activators of transcription 3 signal …
  3115. Mammalian target of Rapamycin complex 1 signaling opposes the effects of anchorage loss, leading to activation of Cdk4 and Cdc6 stabilization
  3116. Rapamycin for Kaposi’s sarcoma and graft-versus-host disease in bone marrow transplant recipient
  3117. Rapamycin instead of mycophenolate mofetil or azathioprine in treatment of post-renal transplantation urothelial carcinoma
  3118. First-in-man use of polymer-free valsartan-eluting stents in small coronary vessels: a comparison to polymer-free Rapamycin (2%)-eluting stents
  3119. Mammalian target of Rapamycin and autosomal dominant polycystic kidney disease
  3120. Rapamycin-induced proteinuria following allogeneic hematopoietic stem cell transplantation
  3121. Effect of Rapamycin on leukemia cell lines
  3122. inhibition of IGF-I receptor signaling in combination with Rapamycin or temsirolimus increases MYC-N phosphorylation
  3123. Role of GLUT1 in the Mammalian Target of Rapamycin Pathway: Mechanisms of Regulation.
  3124. Exendin-4 protects pancreatic beta cells from the cytotoxic effect of Rapamycin by inhibiting JNK and p38 phosphorylation
  3125. inhibition of mammalian target of Rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies
  3126. Monitoring Molecular-Specific Pharmacodynamics of Rapamycin In vivo with Inducible Gal4→ Fluc Transgenic Reporter Mice
  3127. Combination of tipifarnib and Rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling …
  3128. Pretreatment with intraluminal Rapamycin nanoparticle perfusion inhibits neointimal hyperplasia in a rabbit vein graft model
  3129. Rapamycin prevents Concanavalin A‐induced liver injury by inhibiting lymphocyte activation
  3130. Treatment algorithms in metastatic renal cell carcinoma, including the potential role of the novel oral mammalian target of Rapamycin inhibitor Everolimus
  3131. Cyclooxygenase 2 mediates the antiangiogenic effect of Rapamycin in Ewing sarcoma
  3132. Rapamycin selectively reduces the association of transcripts containing complex 5′ UTRs with ribosomes in C4‐2B prostate cancer cells
  3133. Regioselective lipase-catalyzed acylation of 41-desmethoxy-Rapamycin without vinyl esters
  3134. Rapamycin inhibits poly (ADP-ribosyl) ation in intact cells
  3135. Early loss of mammalian target of Rapamycin complex 1 (mTORC1) signalling and reduction in cell size during dominant-negative suppression of hepatic …
  3136. Combination Regimens of nab-Rapamycin (ABI-009) Effective Against MDA-MB-231 Breast-Tumor Xenografts.
  3137. Rapamycin Inhibits Activator Protein-1 But Not Nuclear Factor-κB Activity of Mature Bone Marrow-Derived Dendritic Cells
  3138. Autosomal dominant polycystic kidney disease (ADPKD): Rapamycin as a new treatment option
  3139. Synthesis of the northern sector (C8–C19) of Rapamycin via Chan rearrangement and oxidation of an α-acyloxyacetate
  3140. Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report
  3141. Effects of Rapamycin on Breast Cancer Cell Migration through the Cross-Talk of MAPK Pathway.
  3142. inhibition of mammalian target of Rapamycin: the janus face of immunosuppression?
  3143. Effect of Rapamycin on proliferated human umbilical vein endothelial cell
  3144. … 5‐(2‐chloroethyl)‐2‐acetoxy‐benzyl]‐4‐(2‐chloroethyl)‐phenyl acetate inhibits phosphoinositide 3‐kinase/Akt/mammalian target of Rapamycin signalling through JNK …
  3145. Progression of graft fibrosis under mammalian target of Rapamycin inhibitor‐based regimen
  3146. Effects of Rapamycin on the differentiation and function of macrophages in vitro
  3147. Monotherapy Rapamycin in renal transplant recipients with lymphoma successfully treated with rituximab
  3148. Rapamycin enhances lipopolysaccharide-induced apoptosis and lung injury
  3149. Rapamycin treatment suppresses epileptogenic activity in conditional Pten knockout mice
  3150. Influence of Rapamycin on autophagy and apoptosis of two lepidoptera cell lines.
  3151. Effect of Rapamycin on proliferation of acute myeloid leukemia cell lines HL-60 and HL-60/VCR
  3152. A phase II trial of a mammalian target of Rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer.
  3153. Molecular pathways in metastatic renal cell carcinoma: the evolving role of mammalian target of Rapamycin inhibitors
  3154. Anti-insulin-like growth factor-1 receptor (IGF-IR) monoclonal antibody cixutumumab plus mammalian target of Rapamycin (mTOR) inhibitor temsirolimus in metastatic …
  3155. Effect of Rapamycin and Cyclosporin A on the expression of TLR5 and Foxp3 in allorejection
  3156. Combination therapy of 5-fluorouracil with Rapamycin for hormone receptor-negative human breast cancer
  3157. … of D-cyclin translation inhibition in myeloma cells treated with mTOR inhibitors: rationale for combined treatment with ERK inhibitors and Rapamycin
  3158. Dual inhibition of Akt/mTOR pathway by nab-Rapamycin and perifosine induces anti-tumor activity in multiple myeloma
  3159. Forever young, slim and fit: Rapamycin to the rescue
  3160. Evaluation of a Rapamycin‐regulated serotype 2 adeno‐associated viral vector in macaque parotid glands
  3161. Recent developments of Rapamycin analogues
  3162. Combination of Rapamycin and IL-2 do not affect antigen presentation ability of rat B cell and could promote Tregs proliferation and inhibitory activity
  3163. Mammalian target of Rapamycin: MasTOR mediator of cellular changes in pathological states?
  3164. Use of a cocktail regimen consisting of soluble galectin-1, Rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes
  3165. Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responses to Rapamycin
  3166. Mammalian target of Rapamycin, Akt, and phosphatidylinositol 3-kinase signaling
  3167. Prevention of hepatic tumor growth and metastasis in rats with Rapamycin
  3168. Effect of Rapamycin on apoptosis in human myelodysplastic syndrome cell line MUTZ-1 and its possible mechanisms
  3169. A phase I dose-finding and pharmacodynamic study of Rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
  3170. Antitumor activity, and antiangiogenic activity of nanoparticle albumin-bound nab-Rapamycin in combination with nab-paclitaxel.
  3171. Mammalian target of Rapamycin (mTOR)-induced pneumonitis: Single-institution experience and treatment.
  3172. inhibition of cell growth by Rapamycin through targeting mammalian target of Rapamycin signaling pathway in nasopharyngeal carcinoma
  3173. Study advance of Rapamycin in the field of transplantation immunology [J]
  3174. Release test of Rapamycin in drug-eluting stents
  3175. The mechanism and influence of Rapamycin on proliferation of NIH3T3 fibroblasts transfected with mTOR gene [J]
  3176. Effects of Rapamycin on angiogenesis and tumor progression in human hepatocellular carcinoma implantation mice
  3177. Correlation factors of vascular restenosis and safety following Rapamycin drug-eluting stent implantation
  3178. Mammalian target of Rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma
  3179. Regulation of bone formation using Rapamycin-induced BMP2 expression system: influence of implanted cell number
  3180. Active-site inhibitors of mTOR target Rapamycin-resistant outputs of mTORC1 and mTORC2, PLoS Biol
  3181. Effect of Rapamycin on proliferation, apoptosis and regulation of chemokine receptor CXCR4 in RPMI8226 cells
  3182. Abstract C62: Identification of GSK2126458, a highly potent inhibitor of phosphoinositide 3‐kinase (PI3K) and the mammalian target of Rapamycin (mTOR)
  3183. Rapamycin and HIV Replication in Liver Transplant Recipients
  3184. Effects of Rapamycin-loaded poly (lactic-co-glycolic) acid nanoparticles on distribution of cell cycle, expression of p27 protein, and proliferation of human umbilical …
  3185. Rapamycin induces apoptosis of lung adenocarcinoma cell A549 under hypoxia and its molecular mechanism
  3186. A phase I study of sirolimus (Rapamycin) and bevacizumab in patients with advanced malignancies.
  3187. Effects of Rapamycin on collagen type Ⅰ expression in rat myocardial cell induced by CVB 3
  3188. Abstract C65: Enhanced antitumor effect by the combination of a PI3K inhibitor ZSTK474 with an mTOR inhibitor Rapamycin
  3189. A stimulating new role for Rapamycin
  3190. Synergistic augmentation of cisplatin-induced apoptosis in HeLa cells by Rapamycin
  3191. Evaluation for synergistic suppression of breast cancer proliferation by Chloroquine in combination with the Rapamycin derivative, Rad001
  3192. Rapamycin enhances lifespan: At last, an advantage for transplant recipients?
  3193. Rapamycin reverses glucocorticoid resistance in human T-cell acute lymphoblastic leukemia CEM-C1 cells [J]
  3194. Effects of Rapamycin on nephropathy of diabetic rats and expressions of vascular endothelial growth factor and its receptor [J]
  3195. Interference of mTOR expression enhances sensitivity of esophageal squamous cell carcinoma EC9706 cells to Rapamycin
  3196. Can phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibition ERase them all?
  3197. Tuberous Sclerosis Complex and the Mammalian Target of Rapamycin Pathways
  3198. Comparison of the MEIA and HPLC assays for the measurement of Rapamycin concentration in blood of recipients after renal transplantation [J]
  3199. Effects of simvastatin on Rapamycin-treated cardiac microvascular endothelial cells
  3200. Combined Rapamycin eye drop in nanometer vector and poly (lactic acid) wafers of cyclosporine A effectively prevents high-risk corneal allograft rejection in rabbits
  3201. Mammalian target of Rapamycin inhibitors in the treatment of malignancy after organ transplantation
  3202. Target of Rapamycin modulators of and use thereof
  3203. Essential Role of Mammalian Target of Rapamycin (mTOR) in LH-dependent Testosterone Production in Rat Leydig Cells.
  3204. Rapamycin inhibits growth and metastasis of gallbladder cancer GBC-SD cells.
  3205. Pharmacological studies of a novel inhibitor of the mammalian target of Rapamycin (mTOR) signaling pathway
  3206. Effects of Rapamycin on mTOR/p70S6K signaling pathway and tumor growth in xenografted esophageal squamous cell carcinoma.
  3207. Effect of Rapamycin (serolimus) on in vitro cultured human keratinocytes
  3208. Mesenchymal stem cells combined with Rapamycin immuno-regulates the spleniclymphocytes in allogenic mice.
  3209. Effect of Rapamycin on the interaction between Salmonella typhi plasmid pR_ (ST98) and macrophages [J]
  3210. Expression of JAK/STAT signal transduction pathway and the effects of Rapamycin in lupus nephritis-prone MRL/lpr mice
  3211. CIRCULATING CD4CD25 HIGH CD127 LOW REGULATORY T-CELLS AFTER INTRACORONARY IMPLANTATION OF Rapamycin-ELUTING STENTS: PP. 2.73
  3212. Preparation and production efficiency of Rapamycin ointment
  3213. The influence of coronary stenting with Rapamycin-eluting stents on the number of circulating CD4+ CD25high+ regulatory T-cells
  3214. Effect of Rapamycin on Phenotype of Vascular Smooth Muscle Cell and Arterial Intimal Hyperplasia in Rat Cardiac Allograft
  3215. Mammalian target of Rapamycin inhibitors in clinical practice: Case reports of everolimus in renal cell carcinoma
  3216. Application of stereocontrolled aldol coupling to synthesis of segments of immunosuppressants FK-506 and Rapamycin
  3217. Abstract C63: Biological characterization of GSK2126458, a novel and potent inhibitor of phosphoinositide 3‐kinase and the mammalian target of Rapamycin (mTOR)
  3218. Current perspectives in metastatic renal cell carcinoma treatment: the role of mammalian target of Rapamycin (mTOR) inhibition
  3219. Rapamycin decreases proinflammatory and profibrogenic gene expression in experimental NASH
  3220. Expression of mammalian target of Rapamycin and eIF4E signal pathway in cerebral glioma and its clinical significance [J]
  3221. Conditional protein stabilization via the small molecules Shld-1 and Rapamycin increases the signal-to-noise ratio with tet-inducible gene expression
  3222. A case of Kaposi’s sarcoma in the Rapamycin era
  3223. OSI-027, a potent and selective small molecule mTORC1/mTORC2 kinase Inhibitor is mechanistically distinct from Rapamycin
  3224. eIF4E Expression Predicts Apoptosis in Response to Epidermal Growth Factor Receptor inhibition and Mammalian Target of Rapamycin inhibition in Triple Negative …
  3225. Rapamycin and PD98059 collaborative inhibit mammalian target of Rapamycin pathway in the prevention and treatment of mouse colorectal cancer
  3226. Effect of Rapamycin on the growth of hepatocellular carcinoma in nude mice
  3227. Rapamycin-based GvHD prophylaxis after T-cell replete unmanipulated haploidentical peripheral stem cell transplantation for advanced leukaemias: preliminary …
  3228. Effect of Rapamycin administration in humans on the skeletal muscle protein anabolic response to essential amino acid ingestion
  3229. Differential Regulation of TLR4-Mediated TNF-a Release by Mammalian Target of Rapamycin and Glycogen Synthase Kinase-3 in Alveolar Macrophages from …
  3230. A newly developed Rapamycin-eluting stent with a biodegradable polymer reduces neointimal formation while allowing greater endothelialization
  3231. CONVERSION TO LOW DOSE TACROLIMUS OR Rapamycin 3 MONTHS AFTER KIDNEY TRANSPLANT: A PROSPECTIVE, PROTOCOL BIOPSY GUIDED STUDY …
  3232. The Effect of Rapamycin on Cardiac Allograft Vasculopathy in Rats
  3233. Abstract A94: effects of different modes of calorie restriction on mammalian target of Rapamycin (mTOR) and IGF-I signaling pathways in mammary fat pads and tumors
  3234. Rapamycin-Based GvHD Prophylaxis Is Effective in T-Cell Replete Unmanipulated Haploidentical Peripheral Stem Cell Transplantation for Advanced Haematological …
  3235. Role of Rapamycin in renal ischemia-reperfusion injury
  3236. Symbol Domestic Rapamycin-eluted stent for treatment of acute myocardial infarction in 108 cases
  3237. Rapamycin Used in Kidney Transplantation Patients in China: A Meta-analysis of Clinical Curative Effects
  3238. Conversion to Rapamycin in liver transpant recipients with renal insufficiency
  3239. Genomewide Profiling of Rapamycin Sensitivity in Saccharomyces cerevisiae on Synthetic Medium
  3240. Effect of Rapamycin (serolimus) on in vitro cultured human oral mucosa keratinocytes
  3241. Effects of Rapamycin and paclitaxel on different human prostate cancer cells and xenografts
  3242. The Generation of Novel Fluorinated Rapamycin Analogues
  3243. Treg and Rapamycin effects on humoral immunity in young and old mice (84.12)
  3244. EXPERIENCE WITH Rapamycin IN PEDIATRIC LIVER TRANSPLANTATION: 1434
  3245. Inhibitory effect of Rapamycin on proliferation of H_ (22) hepatic cancer in mice
  3246. Effect of Rapamycin on Postoperative Fibrosis After Filtration Surgery in a Rabbit Model
  3247. The mammalian target of Rapamycin in translation and folding
  3248. Effect of Rapamycin on the proliferation and apoptosis of glomerular mesangial cells
  3249. Transcriptional Profile Changes Induced by Rapamycin in Breast Cancer Maintained in Organ Culture.
  3250. Ex Vivo Manufacture of Rapamycin-Resistant Human Th1/Tc1 Cells.
  3251. Effect of Rapamycin on regulator T cells induced by TGF-β1 in vitro
  3252. Study of long-term safety and efficacy of domestic Firebird Rapamycin-eluting stent
  3253. The Role of Mammalian Target of Rapamycin in the Early Development of Mouse Zygotes
  3254. Efficacy of Rapamycin drug-eluting stents in elderly patients with coronary heart disease
  3255. Insights into hepatic carcinogenesis: The effect of Rapamycin on rat liver cell lines
  3256. Rapamycin combined with cisplatin in inhibiting the proliferation of ovarian cancer SKOV-3 cells [J]
  3257. Development of Selective Inhibitors of the Mammalian Target of Rapamycin
  3258. Rapamycin is a potent inhibitor of skin tumor promotion by TPA
  3259. Antiproliferative and antiangiogenic effect of Rapamycin on ADPKD cystic lining epithelial cells
  3260. Abstract B141: Effects of AZD8055, a novel mTOR kinase inhibitor, in human cancer cells developing resistance to Rapamycin
  3261. Abstract A41: Evaluation of maximum tolerated dose of aerosolized Rapamycin in A/J mice
  3262. Rapamycin combined with nimuatine suppresses growth and proliferation of human U87MG glioma cells
  3263. Effect of mTOR inhibition by Rapamycin on promotion of skin tumors in BK5. Aktwt transgenic mice
  3264. Characterization of the Effects and Functions of Sumoylation Through Rapamycin-Mediated Heterodimerization
  3265. Black and white: Rapamycin as a regulator of cardiac mTOR signaling
  3266. Immunomodulatory Effect of Rapamycin on Innate Immune Response Genes
  3267. Clenbuterol increases PGC1a promoter activity via a Rapamycin sensitive mechanism
  3268. Active-Site inhibition of the Mammalian Target of Rapamycin
  3269. Effect of Rapamycin on cell prolification of glomerular mesangial cells by high glucose
  3270. The role of mammalian target of Rapamycin complex 1 in hepatic physiology and disease
  3271. Anti-Leukemia Effect of Rapamycin Alone or Plus Daunorubicin on Acute Lymphoblastic Leukemia Cell Lines
  3272. Rapamycin reduces primary effusion lymphoma progression by targeting VEGF production and VEGF responses
  3273. A Combined Approach of Classical Mutagenesis and Rational Metabolic Engineering for the Improved Production of Rapamycin in Streptomyces hygroscopicus …
  3274. Rapamycin-Induced Abundance Changes in the Proteome of Budding Yeast
  3275. Inhibitory effect of Rapamycin on human renal tubular epithelial-myofibroblast transition
  3276. Rapamycin sensitizes Jurkat T-ALL cells to dexamethasone-induced apoptosis
  3277. Effects of Rapamycin on cell proliferation and apoptosis of melanoma B-16 cells
  3278. The influence of Rapamycin combined with 5-Aza-cdR to interfere in the in vitro culture of MCF-7 cell line
  3279. Mammalian Target of Rapamycin Signaling in Regulation of Aging of Human RPE
  3280. The therapeutic value of Rapamycin in a novel mouse model for tuberous scelrosis
  3281. Novel therapeutic strategy for breast cancer: mammalian target of Rapamycin inhibition
  3282. Effects of Rapamycin on growth and mTOR/4EBP1 Signalling Pathway in Xenograft of Esophageal Squamous Cell Carcinoma
  3283. Comparison of Rapamycin and Mitomycin for Reduction of Postoperative Fibrosis After Filtration Surgery in a Rabbit Model
  3284. Rapamycin enhances G protein signaling in the budding yeast Saccharomyces Cerevisiae
  3285. Pharmacokinetics characterization of Rapamycin ointment in rabbit aqueous humor
  3286. Effects of Rapamycin on nephropathy and expression of VEGF and VEGF receptors in PAN nephritic mice [J]
  3287. … Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the MammalianTarget of Rapamycin …
  3288. The Regulation of STAT1 Nuclear Content by Mammalian Target of Rapamycin
  3289. Mammalian Target of Rapamycin Regulates STAT1 Localization in Lung Epithelial Cells.
  3290. Rapamycin-Induced Allograft Tolerance: Elucidating Mechanisms and Biomarker Discovery
  3291. Rapamycin prevents the post‐exercise increase in protein synthesis and alters cell signaling in human skeletal muscle
  3292. The Rapamycin-sensitive phosphoproteome reveals that TOR controls PKA 3 toward some but not all substrates 4
  3293. CLONING AND CHARACTERIZATION OF THE PARTIAL Rapamycin-BIOSYNTHETIC GENE CLUSTER FROM ACTINOPLANES SP. N902-109
  3294. Expression of mammalian target of Rapamycin/P70S6K in pathologic scars
  3295. Rapamycin‐sensitive Co‐localization of mTOR to the Mitotic Spindle
  3296. Abstract B143: Distinct antitumor mechanisms of VEGFR inhibitor tivozanib (AV‐951) and mTOR inhibitor Rapamycin support rational combination for solid tumors to …
  3297. Effectiveness of Rapamycin drug-eluting stent (Excel stent) in treatment of patients with coronary artery disease
  3298. Defining the clinical role of the mammalian target of Rapamycin (mTOR) in lung cancer
  3299. BETA-CATENIN TARGET GENES ARE UPREGULATED DURING PARTIAL BLADDER OUTLET OBSTRUCTION AND INHIBITED BY Rapamycin
  3300. Effect of Rapamycin on TGF-β1-induced epithelial-mesenchymal transition in LoVo colonic adenocarcinoma cells
  3301. Tolerability of the mTOR inhibitor Rapamycin in cirrhotic patients with advanced hepatocellular carcinoma
  3302. Clinical Application of Domestic Rapamycin-Eluting Stent in the Emergency Intervention of Acute Coronary Syndrome (ACS)
  3303. Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss
  3304. Effect of Rapamycin on regulating Toll-like receptor-4 gene expression in rats with acute liver failure
  3305. The influence of Rapamycin on expression of CCR7 in the rats with renal fibrosis induced by adriamycin
  3306. Rapamycin induces proliferation of CD4~+ CD25~+ FoxP3~+ T regulatory cells in rats
  3307. Mammalian target of Rapamycin complex 2 regulates helper T cell differentiation and function (47.31)
  3308. BLADDER SMOOTH MUSCLE CELL GROWTH IS MEDIATED BY MAMMALIAN TARGET OF Rapamycin (mTOR)
  3309. Expression and significance of phosphorylation-mammalian target of Rapamycin in endometrial carcinoma
  3310. High Levels Of Mammalian Target Of Rapamycin (mTOR) In Pulmonary Hypertension
  3311. Transscleral Passive Delivery of Rapamycin in Rabbit Using a Visulex® Topical Application Device
  3312. Inhibitory effect of Rapamycin on connective tissue growth factor-stimulated cell proliferation and fibronectin secretion in myofibroblasts
  3313. Treatment of malignant gliomas with systemic Rapamycin and convection-enhanced delivery of nanoliposomal CPT-11
  3314. e0519 Rapamycin suppress KrÜppel-Like Factor 2 expression: mechanism of endothelial dysfunction associated with drug-eluting stents
  3315. The mammalian target of Rapamycin inhibitor RAD001 (everolimus) in early breast cancer
  3316. Mammalian target of Rapamycin inhibitors for the targeted therapy of non-small cell lung cancer
  3317. Chronic Rapamycin Therapy Ameliorates Hypertrophy and Systolic Dysfunction in Severe Chronic Heart Failure Due to Pressure Overload
  3318. Physiologic Stimulation Of Bladder Smooth Muscle Cell Growth Is Mediated By Mammalial Target Of Rapamycin (mTOR)
  3319. Treatment of Non-left Main Bifurcation Lesions Using the Rapamycin-Eluting Stent
  3320. Determination of Encapsulation Efficiency of Rapamycin-loaded Poly (lactic-co-glycolic) acid Nanoparticles by HPLC
  3321. Elucidation of chemopreventive effects of aerosolized Rapamycin and dietary myoinositol by mechanistic biomarkers in mouse lung
  3322. Expansion of CD3+/CD4+/CD25+/Foxp3+ T cells in Rapamycin-treated lupus patients (143.52)
  3323. Mammalian target of Rapamycin (mTOR) inhibitors with therapeutic potential for colitis
  3324. PATHOLOGICAL ANGIOGENESIS IN VASCULAR TUMORS IS DRIVEN BY AKT1 AND INHIBITED BY TOPICAL Rapamycin
  3325. Combination Of Simvastatin And Rapamycin Abrogates TSC2-null Tumor Growth In Nude Mice And Improves Animal Survival
  3326. Pathological angiogenesis in vascular tumors is driven by endothelial Akt1 and inhibited by Rapamycin
  3327. Effect of intravenous injection of apoptotic cells combined with Rapamycin on regulatory T cells in rhesus monkey
  3328. Rapamycin Inhibits Store-Operated Ca2+ Entry in Cells Isolated from Endarterectomized Tissues of Patients with Chronic Thromboembolic Pulmonary Hypertension.
  3329. Immune regulatory effect of Rapamycin and cyclosporine A on experimental corneal allograft survival
  3330. Effect of Rapamycin Eluting Stent for inhibition of Neointimal Hyperplasia in Diabetic Porcine Model
  3331. Supplemental Information Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster
  3332. Effects of high glucose and Rapamycin intervention on expression of type Ⅳ collagen and matrix metalloproteinase-9 in podocytes
  3333. Cigarette Smoke And Rapamycin Up-regulate Matrix Metalloproteinase-1 Expression In Endothelial Cells Through mTOR Activation
  3334. Preparation and in vitro release study of Rapamycin in poly (lactic-co-glycolic) acid microsphere for topical administration
  3335. PDGFR alpha is overexpressed in synovial sarcomas and can mediate Rapamycin induced Akt activation
  3336. Enhanced tumor cytotoxicity of a combinational therapy using liposomal copper-doxorubicin, Rapamycin, and ultrasound
  3337. Rapamycin-CONDITIONED HUMAN DENDRITIC CELLS EXHIBIT INCREASED IL-12P70 PRODUCTION UPON EXPOSURE TO PRO-INFLAMMATORY …
  3338. Rapamycin eye drops inhibit rat corneal neovascularization: Role of vascular endothelial growth factor and inflammatory factor☆
  3339. The mammalian target of Rapamycin signaling pathway in bovine mammary epithelial cells
  3340. Characterisation of the effects and mechanism of action of Rapamycin and genistein on acute myeloid leukemia using high-throughput techniques
  3341. New Drug Development in Sarcoma: Exploration of Novel Targets, Particularly the Mammalian Target of Rapamycin (mTOR) Pathway
  3342. 45A: TARGETED SITE SPECIFIC IMMUNOSUPPRESSION WITH TOPICAL Rapamycin AND MYCOPHENOLIC ACID IN COMPOSITE TISSUE …
  3343. 1, 4-phenylenebis (methylene) selenocyanate (p-XSC) inhibits mammalian target of Rapamycin complex 2 (mTORC2) signaling in prostate cancer cells
  3344. Pre-clinical and Clinical Study Results for the Coracto™ Rapamycin-eluting Stent–A New-generation Drug-eluting Stent
  3345. The Protective Effect of mammalian Target of Rapamycin (mTOR) in Cisplatin Induced Nephropathy
  3346. Contact-dependent suppression pathways in non-human primate Tregs expanded ex vivo in the presence of Rapamycin (141.36)
  3347. The effects of l-leucine, contractions, and Rapamycin on the Akt/mTOR pathway in rat skeletal muscle
  3348. Rapamycin IMPAIRS PROLIFERATION OF TRANSPLANTED ISLET BETA CELLS: 791
  3349. Rapamycin inhibits epidermal cell proliferation in a xenograft model of tuberous sclerosis skin tumors
  3350. Effect of the combination of retinoic acid and Rapamycin on cerebellar granule cell and medulloblastoma proliferation
  3351. Nutrient signaling, mammalian target of Rapamycin and ovine conceptus development
  3352. Effect of combination of CCR5 antisense peptide nucleic acid and lose-dose Rapamycin on islet allograft survival
  3353. Rapamycin inhibits cyst growth, IGF-1-mediated VEGF secretion and cell proliferation in polycystin-2 defective mice
  3354. Is Oral Rapamycin Plus Bare Metal Stents a Feasible Alternative to Drug‐Eluting Stents? Lessons Learned from Argentina Observational and Randomized Studies …
  3355. Rapamycin-Induced Autophagy Generates Anti-Apoptotic Th1/Tc1 Cells That Mediate Increased Xenogeneic Gvhd.
  3356. Rapamycin impairs metabolism-secretion coupling in rat pancreatic islets by suppressing carbohydrate metabolism in the Krebs cycle
  3357. Combination of antagonists of growth hormone-releasing hormone antagonist (GHRH) with Rapamycin as a potential therapy in human breast cancers.
  3358. Role of mammalian target of Rapamycin signalling in bone destruction by gingival squamous cell carcinoma
  3359. Rapamycin potentiates the effects of paclitaxel in uterine papillary serous carcinoma (UPSC) cells through inhibition of cell proliferation and induction of apoptosis
  3360. Symbol Effect of Rapamycin-poly (lactide-acid)/magnetic microsphere composite materials on the proliferation of vascular smooth muscle cells
  3361. Retinoblastoma Tumor Burden Control: Periocular m-TOR Inhibitor Rapamycin Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma
  3362. Effects of Mycophenolic Acid and Rapamycin on Toll-like Receptor Expression in Hypoxic Human Proximal Tubular Epithelial Cells
  3363. The Impact of Iron Deficiency During Development on Mammalian Target of Rapamycin Signaling, Neuronal Structure, and Learning and Memory Behavior
  3364. Mammalian Target of Rapamycin: A Bump in the Pathway to NF-κB Activation and ICAM-1 Expression in Endothelial Cells.
  3365. Increased Frequency Of Regulatory T-Cells And Selection Of Highly Potent CD62L+ Cells During Treatment Of Human Lung Recipients With Rapamycin
  3366. The IGF-1 receptor targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with Rapamycin in models of childhood sarcoma
  3367. Targeting mammalian target of Rapamycin (mTOR) signaling in the Han: SPRD rat, a model for polycystic kidney disease
  3368. Chemical Genetic Dissection of TOR Signaling Through Identification and Characterization of Small Molecule Enhancers of Rapamycin
  3369. Mammalian Target of Rapamycin Signaling and the Suprachiasmatic Circadian Clock
  3370. Abstract# 3712: OXA-01, a novel potent mTORC1/TORC2 inhibitor displays improved anti-tumor activity in comparison to Rapamycin, an mTORC1 selective inhibitor
  3371. inhibition of mammalian target of Rapamycin induces phenotypic reversion in three-dimensional cultures of malignant breast epithelial cells
  3372. Rapamycin mediated inhibition of mTOR prevents postprandial activation of the unfolded protein response and upregulation of fatty acid synthase
  3373. Distinct phosphatase requirements and GATA factor responses to nitrogen catabolite repression and Rapamycin treatment in S. cerevisiae
  3374. Use of Rapamycin Reveals Evidence of the Physiological Roles of FKBP12 and FKBP12. 6 In Cardiac Excitation-Contraction Coupling
  3375. e0520 Statin effects in stent thrombosis induced by Rapamycin releasing from drug-eluting stents through KrÜppel-Like Factor 2 overexpression
  3376. Rapamycin enhanced in vitro and in vivo activity of dexamethasone against acute lymphoblastic leukemia and lymphoma preclincal models via inhibition of p70S6 …
  3377. Human T Cell Rapamycin Resistance And Th1/Tc1 Polarization Augment Xenogeneic Graft-Versus-Host Disease
  3378. Abstract# 4363: inhibition of mammalian target of Rapamycin (mTOR) in advanced pancreatic cancer-the results of two prospective phase II studies.
  3379. In vitro enhancing oxidative phosphorylation by Rapamycin in proliferative CD8+ T cells during antigenic priming augments the generation of long-lived memory T cells …
  3380. Comparasion of therapeutic effects of Chinese Rapamycin-eluting stent and imported paclitaxel-eluting stent in treatment of acute myocardial infarction
  3381. Generation of tolerogenic human DC through Rapamycin conditioning and genetic modification with HLA-G.
  3382. Prolonged Exposure of Myeloid Dendritic Cells To Rapamycin enhances LPS-induced IL-12p70 production, but does not promote Th1 responses (141.29)
  3383. The mammalian target of Rapamycin mediates the angiogenic and chemotactic effects of leptin in human hepatic stellate cells.
  3384. Calorie restriction and Rapamycin, but not exercise, inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity
  3385. Abstract# LB-135: Grapefruit juice significantly increases bioavailability of weekly Rapamycin (sirolimus)-evidence of safety and activity in a phase 1 study
  3386. Mammalian Target of Rapamycin (mTOR)-mediated Effect on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  3387. Vitamin K_3 induces autophagy in HeLa cells through downregulating the mammalian target of Rapamycin (mTOR) pathway
  3388. Pharmacodynamic (PD) study of pre-prostatectomy Rapamycin in men with advanced localized prostate cancer (PC): A DOD Prostate Cancer Clinical Trials …
  3389. Effects of high-fat vs. low-fat diets on mammalian target of Rapamycin signaling and metabolic measures in spontaneously hypertensive rats
  3390. Anti-liver fibrotic effect of Salvia miltiorthiza and Shugan-Huayu powder combining with or without Rapamycin in animal models.
  3391. Rapidly Inducible Protein Modification Using Rapamycin-mediated Complementation Of Tobacco Etch Virus (TEV) Protease
  3392. Modulatory Role of Mammalian Target of Rapamycin in Regulating Endothelial ICAM‐1 Expression and Lung PMN Recruitment
  3393. Erratum: Mammalian target of Rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial …
  3394. Rapamycin AND MYCOPHENOLIC ACID, BUT NOT CYCLOSPORIN A, IMPAIR HUMAN NK CELL CYTOLYTIC ACTIVITY DUE TO DIFFERENTIAL EFFECTS ON …
  3395. 198 Modulation of CCR5 density with low doses of the transplant drug Rapamycin sensitizes Vicriviroc-resistant R5 HIV-1
  3396. Rapamycin and IL-2 Prevents Lethal Acute Graft-Versus Host Disease by Expansion of Donor Type CD4+CD25+Foxp3+ Regulatory T Cells.
  3397. Abstract# 4648: Rapamycin inhibits tube formation of lymphatic endothelial cells by targeting TORC1-mediated expression of Flt4
  3398. Abstract LB-74: A high-throughput RNAi sensitization screen of Rapamycin identifies targets for rational drug combination strategies
  3399. Abstract# 2770: Over-expression of the mammalian target of Rapamycin (mTOR): a novel biomarker for poor survival in resected early stage non-small cell lung cancer
  3400. Abstract# 2014: ATP competitive inhibitors of the mammalian target of Rapamycin (mTOR): Design and synthesis of novel, highly selective pyrazolopyrimidines with …
  3401. The Mammalian Target of Rapamycin (mTOR) Is a Novel Regulator of HMW-Hyaluronan-Mediated Pulmonary Endothelial Barrier Enhancement.
  3402. COMBINED ADMINISTRATION OF A NOVEL MUTANT TGF-β1/FC AND Rapamycin MODULATES THE IMMUNE BALANCE BETWEEN TREG AND TH17 AND …
  3403. CD28: FC AND Rapamycin CAN PREVENT TH17-MEDIATED ALLOGRAFT REJECTION IN MOUSE PANCREATIC ISLET TRANSPLANTATION MODEL: 700
  3404. Androgen receptor antagonist bicalutamide sensitizes androgen-independent prostate cancer cells to mTOR inhibitor Rapamycin by regulating phosphorylation of …
  3405. Abstract# 1735: Rapamycin inhibits hyperactivation of mTORC1 signaling in a novel xenograft model of tuberous sclerosis complex skin tumors
  3406. ET-29. ONCOLYTIC VIRUS COMBINED WITH Rapamycin TARGETING BRAIN TUMOR-INITIATING CELLS
  3407. … Multicenter phase I clinical trial of an insulin like growth factor (IGF‐R) inhibitor (IMC‐A12) in combination with a mammalian target of Rapamycin (mTOR) inhibitor (CCI …
  3408. Mouse Oocytes Promote the Mechanistic Target of Rapamycin (Serine/Threonine Kinase, mTOR) Pathway in Cumulus Cells by Suppressing the Expression of DNA …
  3409. … oral protein: time‐dependent concordance/discordance between muscle protein synthesis (MPS) and mammalian target of Rapamycin (mTOR)‐associated signaling
  3410. Relationship between expression of mutant type glutathione S-transferase theta-1 gene and reactivity of Rapamycin in myelodysplastic syndrome
  3411. Rapamycin CONDITIONED DENDRITIC CELLS FOR IN VITRO DIFFERENTIATION OF DONOR-SPECIFIC CD4+ CD25+ FOXP3+ REGULATORY T CELLS FOR …
  3412. … DEVELOPMENT OF CD8+ CD44+ CD62L+ MEMORY T CELLS PROMOTE SPECIFIC TOLERANCE TO CARDIAC ALLOGRAFTS FOLLOWING Rapamycin …
  3413. Abstract# 4050: Increased cytotoxicity with nifurtimox and Rapamycin combination therapy in neuroblastoma.
  3414. The Effect of Insulin-like Growth Factor 1 (IGF-1) and Exercise on the Protein Expression of Mammalian Target of Rapamycin (mTOR) and Androgen Receptor (AR) in …
  3415. Abstract# 3711: Superior cellular anti-tumor effects of a dual mTORC1/mTORC2 kinase inhibitor OXA-01 relative to the mTORC1 inhibitor Rapamycin
  3416. Erratum 2: Testosterone induces cardiomyocyte hypertrophy through mammalian target of Rapamycin complex 1 pathway
  3417. Erratum 2: Testosterone induces cardiomyocyte hypertrophy through mammalian target of Rapamycin complex 1 pathway (vol 202, pg 299, 2009)
  3418. Abstract# 156: Is irinotecan and Rapamycin combination, targeting mTOR/HIF-1 alpha axis, a new effective therapy in high grade brain tumors?
  3419. Intra-Nuclear Function for PP2A Phosphatase: Pph21/22 Are Required for Rapamycin-Induced GATA Factor Binding to the DAL5 Promoter in Yeast
  3420. Activating transcription factor 4 negatively regulates the mammalian target of Rapamycin via Redd1 expression in response to 2-deoxyglucose
  3421. Abstract# 5237: The combination of Rapamycin and bicalutamide induce apoptosis in prostate cancer cells by simultaneously inhibiting the mTORC1/eIF4 and AR …
  3422. TORC1/2 inhibitors have more potent anti-leukemic efficacy and are less immunosuppressive than Rapamycin
  3423. Abstract# 2824: The Src inhibitor AZD0530 enhances the anti-tumor effect of Rapamycin in hepatocellular carcinoma (HCC) cells
  3424. Abstract LB-159: An orthotopic model of head and neck squamous carcinoma reveals that mTOR inhibition with Rapamycin halts lymph node metastasis
  3425. Abstract# 3842: High expression of mTOR (mammalian target of Rapamycin) is associated with better outcome in non-small cell lung cancer
  3426. Abstract# 1079: CD133 expression is affected by Rapamycin in cancer cells.
  3427. Abstract# 2879: inhibition of mammalian target of Rapamycin as a therapeutic strategy in the management of bladder cancer
  3428. Abstract# 3757: Antiproliferative effects of Rapamycin and doxorubicin combination on human Erbb2 overexpressing breast epithelial cell lines.
  3429. Abstract# 2818: Growth inhibition of human breast cancer cells with an iron chelator and a dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor
  3430. Abstract# 2302: NVP-BEZ235 a dual inhibitor of phosphatidylinositol 3-Kinase (PI3 Kinase) and mammalian target of Rapamycin (mTOR) potently enhances the effects …
  3431. Liposomal KRN7000 (RGI-2001) Synergizes with Low-Dose Rapamycin in Preventing GvHD by promoting expansion of naturally-Occurring CD4+FOXP3+ …
  3432. Abstract P3-14-17: Trastuzumab (H) and Rapamycin (R) for Treatment of HER-2 Overexpressing Metastatic Breast Cancer (BC) with Prior Disease Progression on H …
  3433. … : HQO-0601, an amide-containing 3, 4-dihydroquinolinone derivative, against human hematologic malignancies through inhibition of mammalian target of Rapamycin …
  3434. Rapamycin slows aging in mice
  3435. Fighting neurodegeneration with Rapamycin: mechanistic insights
  3436. Target of Rapamycin (TOR) in nutrient signaling and growth control
  3437. Rapamycin and glucose-target of Rapamycin (TOR) protein signaling in plants
  3438. Rapamycin passes the torch: a new generation of mTOR inhibitors
  3439. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity
  3440. Autophagy activation by Rapamycin reduces severity of experimental osteoarthritis
  3441. Protein translocation as a tool: The current Rapamycin story
  3442. Relieving autophagy and 4EBP1 from Rapamycin resistance
  3443. Chronic inhibition of mammalian target of Rapamycin by Rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice
  3444. Paradoxical aspects of Rapamycin immunobiology in transplantation
  3445. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer
  3446. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice
  3447. TOR signaling and Rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO
  3448. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders
  3449. The mammalian target of Rapamycin regulates cholesterol biosynthetic gene expression and exhibits a Rapamycin-resistant transcriptional profile
  3450. A photocleavable Rapamycin conjugate for spatiotemporal control of small GTPase activity
  3451. Target of Rapamycin signaling regulates metabolism, growth, and life span in Arabidopsis
  3452. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice
  3453. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
  3454. Rapamycin and other longevity‐promoting compounds enhance the generation of mouse induced pluripotent stem cells
  3455. mTOR and Rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression
  3456. Inducing autophagy by Rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits
  3457. … enhances the anti-tumor activity of the mTOR inhibitor Rapamycin in multiple breast cancer cell lines mainly by suppressing Rapamycin-induced AKT signaling
  3458. Common toxicities of mammalian target of Rapamycin inhibitors
  3459. Topical Rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex
  3460. Rapamycin treatment augments motor neuron degeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis
  3461. Activating mutations of TOR (target of Rapamycin)
  3462. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells
  3463. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function
  3464. Mammalian target of Rapamycin: a signaling kinase for every aspect of cellular life
  3465. Mammalian target of Rapamycin: a central node of complex signaling cascades
  3466. Induction of tolerance to factor VIII by transient co‐administration with Rapamycin
  3467. Once again on Rapamycin-induced insulin resistance and longevity: despite of or owing to
  3468. Haploinsufficiency of target of Rapamycin attenuates cardiomyopathies in adult zebrafish
  3469. Stability of human Rapamycin-expanded CD4+ CD25+ T regulatory cells
  3470. Autophagy and cardiovascular aging: lesson learned from Rapamycin
  3471. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/− mice
  3472. A pulse Rapamycin therapy for infantile spasms and associated cognitive decline
  3473. Hyperplexing: a method for higher-order multiplexed quantitative proteomics provides a map of the dynamic response to Rapamycin in yeast
  3474. Rapamycin protects against myocardial ischemia–reperfusion injury through JAK2–STAT3 signaling pathway
  3475. Mammalian target of Rapamycin and the kidney. I. The signaling pathway
  3476. The ketogenic diet inhibits the mammalian target of Rapamycin (mTOR) pathway
  3477. Preventive and therapeutic effects of Rapamycin, a mammalian target of Rapamycin inhibitor, on food allergy in mice
  3478. Shedding new light on neurodegenerative diseases through the mammalian target of Rapamycin
  3479. Lifelong Rapamycin administration ameliorates age‐dependent cognitive deficits by reducing IL‐1β and enhancing NMDA signaling
  3480. Mammalian target of Rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth
  3481. Mammalian target of Rapamycin signaling in diabetic cardiovascular disease
  3482. Rapamycin promotes autophagy and reduces neural tissue damage and locomotor impairment after spinal cord injury in mice
  3483. Folate-conjugated Rapamycin slows progression of polycystic kidney disease
  3484. Mammalian target of Rapamycin (mTOR) signaling network in skeletal myogenesis
  3485. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy
  3486. Chronic mTOR inhibition by Rapamycin induces muscle insulin resistance despite weight loss in rats
  3487. Wound healing complications and the use of mammalian target of Rapamycin inhibitors in kidney transplantation: a critical review of the literature
  3488. Rapamycin increases oxidative stress response gene expression in adult stem cells
  3489. inhibition of mammalian target of Rapamycin reduces epileptogenesis and blood–brain barrier leakage but not microglia activation
  3490. Rapamycin As an Antiaging Therapeutic?: Targeting Mammalian Target of Rapamycin to Treat Hutchinson–Gilford Progeria and Neurodegenerative Diseases
  3491. Successful treatment of angiofibromata of tuberous sclerosis complex with Rapamycin
  3492. Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats
  3493. Rapamycin Causes Upregulation of Autophagy and Impairs Islets Function Both In Vitro and In Vivo
  3494. Therapeutic role of mammalian target of Rapamycin (mTOR) inhibition in preventing epileptogenesis
  3495. Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose Rapamycin impairs autophagic flux in …
  3496. Prevention of age-related macular degeneration–like retinopathy by Rapamycin in Rats
  3497. Mammalian target of Rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer’s disease?
  3498. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of Rapamycin (mTOR) pathway
  3499. Current and future directions in mammalian target of Rapamycin inhibitors development
  3500. Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with Rapamycin
  3501. Target of Rapamycin regulates development and ribosomal RNA expression through kinase domain in Arabidopsis
  3502. Mammalian target of Rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein synthesis by essential amino acids
  3503. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by Rapamycin
  3504. inhibition of mammalian target of Rapamycin augments lipopolysaccharide-induced lung injury and apoptosis
  3505. New nanoformulation of Rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis
  3506. Combinatorial effects of lapatinib and Rapamycin in triple-negative breast cancer cells
  3507. Phase II study of the mammalian target of Rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
  3508. Impaired autophagy in neurons after disinhibition of mammalian target of Rapamycin and its contribution to epileptogenesis
  3509. Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann–Sträussler–Scheinker disease
  3510. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of Rapamycin (mTOR) complex 2
  3511. Rapamycin reverses elevated mTORC1 signaling in lamin A/C–deficient mice, rescues cardiac and skeletal muscle function, and extends survival
  3512. Retinoic acid and Rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells
  3513. Rapamycin increases rDNA stability by enhancing association of Sir2 with rDNA in Saccharomyces cerevisiae
  3514. Review of cytomegalovirus infection findings with mammalian target of Rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients
  3515. Low‐Dose Rapamycin Treatment Increases the Ability of Human Regulatory T Cells to Inhibit Transplant Arteriosclerosis In Vivo
  3516. Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of Rapamycin on protein synthesis
  3517. Managing stomatitis in patients treated with Mammalian target of Rapamycin inhibitors.
  3518. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome–associated PTPN11 mutation
  3519. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug
  3520. inhibition of mechanistic target of Rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice
  3521. Therapeutic value of prenatal Rapamycin treatment in a mouse brain model of tuberous sclerosis complex
  3522. Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage
  3523. Rapamycin slows aging in mice
  3524. Amino acids activate mammalian target of Rapamycin complex 2 (mTORC2) via PI3K/Akt signaling
  3525. Suppression of replicative senescence by Rapamycin in rodent embryonic cells
  3526. inhibition of the mammalian target of Rapamycin blocks epilepsy progression in NS‐Pten conditional knockout mice
  3527. The mTOR inhibitor Rapamycin suppresses DNA double-strand break repair
  3528. Autophagy stimulation by Rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis
  3529. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study
  3530. Differing effects of Rapamycin or calcineurin inhibitor on T‐regulatory cells in pediatric liver and kidney transplant recipients
  3531. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by Rapamycin
  3532. Post-treatment with Rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy
  3533. Mammalian target of Rapamycin and the kidney. II. Pathophysiology and therapeutic implications
  3534. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF
  3535. Optimization of Rapamycin-loaded acetalated dextran microparticles for immunosuppression
  3536. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity
  3537. Mammalian target of Rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α
  3538. Stress-responsive sestrins link p53 with redox regulation and mammalian target of Rapamycin signaling
  3539. Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons
  3540. Oral Rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation
  3541. Oral adverse events associated with tyrosine kinase and mammalian target of Rapamycin inhibitors in renal cell carcinoma: a structured literature review
  3542. Efficacy and safety of sorafenib in combination with mammalian target of Rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation
  3543. Involvement of the mammalian target of Rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists
  3544. N‐acetylcysteine reduces disease activity by blocking mammalian target of Rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double …
  3545. … lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of Rapamycin
  3546. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG
  3547. Rapamycin-induced glucose intolerance: hunger or starvation diabetes
  3548. Induction of biogenic magnetization and redox control by a component of the target of Rapamycin complex 1 signaling pathway
  3549. Rapamycin resistance is linked to defective regulation of Skp2
  3550. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts
  3551. Roles of the mammalian target of Rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis
  3552. The mTOR inhibitor Rapamycin has limited acute anticonvulsant effects in mice
  3553. Multiple roles for mammalian target of Rapamycin signaling in both glutamatergic and GABAergic synaptic transmission
  3554. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma
  3555. Rapamycin-induced enhancement of vaccine efficacy in mice
  3556. Regulating mammalian target of Rapamycin to tune vaccination-induced CD8+ T cell responses for tumor immunity
  3557. Biosynthesis of the immunosuppressants FK506, FK520, and Rapamycin involves a previously undescribed family of enzymes acting on chorismate
  3558. A comprehensive review of everolimus clinical reports: a new mammalian target of Rapamycin inhibitor
  3559. Selective activation of Akt1 by mammalian target of Rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis
  3560. Rab5 proteins regulate activation and localization of target of Rapamycin complex 1
  3561. Mutations in the Arabidopsis homolog of LST8/GβL, a partner of the target of Rapamycin kinase, impair plant growth, flowering, and metabolic adaptation to long days
  3562. Mammalian target of Rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy
  3563. Expanding human T regulatory cells with the mTOR-inhibitor Rapamycin
  3564. Effects of Rapamycin and TOR on aging and memory: implications for Alzheimer’s disease
  3565. Naturally secreted amyloid-β increases mammalian target of Rapamycin (mTOR) activity via a PRAS40-mediated mechanism
  3566. Phospholipase D mediates nutrient input to mammalian target of Rapamycin complex 1 (mTORC1)
  3567. Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders
  3568. Plasma membrane recruitment and activation of the AGC kinase Ypk1 is mediated by target of Rapamycin complex 2 (TORC2) and its effector proteins Slm1 and Slm2
  3569. Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells
  3570. Mycobacterial induction of autophagy varies by species and occurs independently of mammalian target of Rapamycin inhibition
  3571. Third target of Rapamycin complex negatively regulates development of quiescence in Trypanosoma brucei
  3572. Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2)
  3573. Rapamycin attenuates airway hyperreactivity, goblet cells, and IgE in experimental allergic asthma
  3574. mTOR inhibition with Rapamycin causes impaired insulin signalling and glucose uptake in human subcutaneous and omental adipocytes
  3575. Progeria, Rapamycin and normal aging: recent breakthrough
  3576. Resveratrol inhibits inflammatory responses via the mammalian target of Rapamycin signaling pathway in cultured LPS-stimulated microglial cells
  3577. High-dose Rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
  3578. Systemic inhibition of the mammalian target of Rapamycin (mTOR) pathway reduces neuropathic pain in mice
  3579. The differential effects of prenatal and/or postnatal Rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis …
  3580. Induction of autophagy by palmitic acid via protein kinase C-mediated signaling pathway independent of mTOR (mammalian target of Rapamycin)
  3581. Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of Rapamycin signaling
  3582. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells
  3583. The mTOR kinase inhibitor Rapamycin decreases iNOS mRNA stability in astrocytes
  3584. Insulin-like peptides and the target of Rapamycin pathway coordinately regulate blood digestion and egg maturation in the mosquito Aedes aegypti
  3585. Heightened uterine mammalian target of Rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice
  3586. inhibition of the mammalian target of Rapamycin pathway by Rapamycin blocks cocaine-induced locomotor sensitization
  3587. Tolerance induction by exosomes from immature dendritic cells and Rapamycin in a mouse cardiac allograft model
  3588. Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate
  3589. Characterization of the metabolic phenotype of Rapamycin-treated CD8+ T cells with augmented ability to generate long-lasting memory cells
  3590. Light regulation of protein dimerization and kinase activity in living cells using photocaged Rapamycin and engineered FKBP
  3591. Mammalian target of Rapamycin signaling is a key regulator of the transit-amplifying progenitor pool in the adult and aging forebrain
  3592. Metformin promotes progesterone receptor expression via inhibition of mammalian target of Rapamycin (mTOR) in endometrial cancer cells
  3593. A critical role for non-coding RNA GAS5 in growth arrest and Rapamycin inhibition in human T-lymphocytes
  3594. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of Rapamycin complex 1 (mTORC1) signaling
  3595. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical Rapamycin: optimizing a treatment protocol
  3596. Mapping the spatio-temporal pattern of the mammalian target of Rapamycin (mTOR) activation in temporal lobe epilepsy
  3597. Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression
  3598. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of Rapamycin complex 1 activity
  3599. Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor
  3600. Mammalian target of Rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons
  3601. Mammalian target of Rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1
  3602. Proteomic identification of novel targets regulated by the mammalian target of Rapamycin pathway during oligodendrocyte differentiation
  3603. Phosphoproteomic profiling of in vivo signaling in liver by the mammalian target of Rapamycin complex 1 (mTORC1)
  3604. The influence of co-solvents on the stability and bioavailability of Rapamycin formulated in self-microemulsifying drug delivery systems
  3605. Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of Rapamycin pathway
  3606. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2
  3607. Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy
  3608. inhibition of mTOR by Rapamycin in the amygdala or hippocampus impairs formation and reconsolidation of inhibitory avoidance memory
  3609. Convergence of the mammalian target of Rapamycin complex 1-and glycogen synthase kinase 3-β–signaling pathways regulates the innate inflammatory response
  3610. Rapamycin for Treatment of Epilepsy: Antiseizure, Antiepileptogenic, Both, or Neither? Rapamycin for Treatment of Epilepsy
  3611. Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis
  3612. Stimulation of autophagy by Rapamycin protects neurons from remote degeneration after acute focal brain damage
  3613. The physiology and pathophysiology of Rapamycin resistance: implications for cancer
  3614. Combination therapy targeting Akt and mammalian target of Rapamycin improves functional outcome after controlled cortical impact in mice
  3615. Rapamycin paradox resolved
  3616. Combining mTOR inhibitors with Rapamycin-resistant T cells: a two-pronged approach to tumor elimination
  3617. Circadian regulation of mammalian target of Rapamycin signaling in the mouse suprachiasmatic nucleus
  3618. Mammalian Target of Rapamycin (mTOR) Inhibitors
  3619. Dietary restriction but not Rapamycin extends disease onset and survival of the H46R/H48Q mouse model of ALS
  3620. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study
  3621. Rapamycin reduces reactive oxygen species in cultured human corneal endothelial cells
  3622. mTOR-dependent regulation of PHLPP expression controls the Rapamycin sensitivity in cancer cells
  3623. Mammalian target of Rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells
  3624. Targeting the mammalian target of Rapamycin (mTOR) in cancer therapy: lessons from past and future perspectives
  3625. … mechanism of atorvastatin to protect mesenchymal stem cells from hypoxia and serum deprivation via AMP-activated protein kinase/mammalian target of Rapamycin …
  3626. Consolidation and reconsolidation of contextual fear memory requires mammalian target of Rapamycin-dependent translation in the dorsal hippocampus
  3627. Effects of cyclosporine, tacrolimus and Rapamycin on renal calcium transport and vitamin D metabolism
  3628. AMP-dependent kinase/mammalian target of Rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications
  3629. Ghrelin contributes to derangements of glucose metabolism induced by Rapamycin in mice
  3630. TORC1 of fission yeast is Rapamycin‐sensitive
  3631. Target-of-Rapamycin complex 1 (Torc1) signaling modulates cilia size and function through protein synthesis regulation
  3632. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of Rapamycin inhibitors
  3633. The tuberous sclerosis complex–mammalian target of Rapamycin pathway maintains the quiescence and survival of naive T cells
  3634. Low dose Rapamycin exacerbates autoimmune experimental uveitis
  3635. Rapamycin impairs proliferation of transplanted islet β cells
  3636. The role of mammalian target of Rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes
  3637. Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and Rapamycin administration
  3638. Kinome-wide selectivity profiling of ATP-competitive mammalian target of Rapamycin (mTOR) inhibitors and characterization of their binding kinetics
  3639. Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of Rapamycin complex 1 and FoxO4
  3640. Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in Rapamycin resistance in hepatocellular carcinoma
  3641. Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of Rapamycin (mTOR) pathways
  3642. Redox regulates mammalian target of Rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway
  3643. Campylobacter jejuni induces colitis through activation of mammalian target of Rapamycin signaling
  3644. Mechanistic target of Rapamycin inhibitors in solid organ transplantation: from benchside to clinical use
  3645. Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of Rapamycin …
  3646. Differing effects of Rapamycin and mTOR kinase inhibitors on protein synthesis
  3647. Coupling nutrient sensing to metabolic homoeostasis: the role of the mammalian target of Rapamycin complex 1 pathway
  3648. Impairment of object recognition memory by Rapamycin inhibition of mTOR in the amygdala or hippocampus around the time of learning or reactivation
  3649. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) kinase inhibitor (GDC-0980) …
  3650. Phosphatidic acid activates mammalian target of Rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an …
  3651. A topical combination of Rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients …
  3652. Assessing the effectiveness of Rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
  3653. Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of Rapamycin
  3654. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer
  3655. PDGF receptor alpha is an alternative mediator of Rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma
  3656. The emerging role of mammalian target of Rapamycin inhibitors in the treatment of sarcomas
  3657. Differential effects of Rapamycin on rods and cones during light-induced stress in albino mice
  3658. Evaluation of Rapamycin-induced cell death
  3659. Rapid cytoplasmic turnover of yeast ribosomes in response to Rapamycin inhibition of TOR
  3660. … mammalian target of Rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of Rapamycin …
  3661. Rapamycin attenuates the expression of cocaine‐induced place preference and behavioral sensitization
  3662. The mammalian target of Rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
  3663. L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of Rapamycin
  3664. Starvation and Rapamycin differentially regulate host cell lysosome exocytosis and invasion by Trypanosoma cruzi metacyclic forms
  3665. Paradoxical effects of Rapamycin on experimental house dust mite-induced asthma
  3666. Magnetic nanoparticles and Rapamycin encapsulated into polymeric nanocarriers
  3667. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases
  3668. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73
  3669. Rapamycin inhibits transforming growth factor β‐induced peritoneal angiogenesis by blocking the secondary hypoxic response
  3670. Calorie restriction and Rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity
  3671. Facial angiofibromas treated with topical Rapamycin: an excellent choice with fast response
  3672. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients
  3673. Regulatory T cells require mammalian target of Rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice
  3674. Spinal cord NMDA receptor-mediated activation of mammalian target of Rapamycin is required for the development and maintenance of bone cancer-induced pain …
  3675. SIRT1 is required for the effects of Rapamycin on high glucose-inducing mesangial cells senescence
  3676. The Akt/mammalian target of Rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas
  3677. inhibition of Rapamycin-induced autophagy causes necrotic cell death associated with Bax/Bad mitochondrial translocation
  3678. Emerging roles for mammalian target of Rapamycin inhibitors in the treatment of solid tumors and hematological malignancies
  3679. An increase in basal BDNF provokes hyperactivation of the Akt-mammalian target of Rapamycin pathway and deregulation of local dendritic translation in a mouse …
  3680. Novel synergistic antitumor effects of Rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model
  3681. Mammalian target of Rapamycin regulates isoliquiritigenin-induced autophagic and apoptotic cell death in adenoid cystic carcinoma cells
  3682. The mechanism of mTOR (mammalian target of Rapamycin) in a mouse model of polycystic ovary syndrome (PCOS)
  3683. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) dual inhibitors
  3684. Mammalian target of Rapamycin signaling in the podocyte
  3685. Transcriptional regulation of gene expression during osmotic stress responses by the mammalian target of Rapamycin
  3686. Mao-B elevation decreases parkin’s ability to efficiently clear damaged mitochondria: protective effects of Rapamycin
  3687. Immunoregulatory properties of Rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation
  3688. Novel feedback inhibition of surface antigen synthesis by mammalian target of Rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and …
  3689. A Hexane Fraction of Guava Leaves (Psidium guajava L.) Induces Anticancer Activity by Suppressing AKT/Mammalian Target of Rapamycin/Ribosomal p70 S6 …
  3690. Clinical activity of mammalian target of Rapamycin inhibitors in solid tumors
  3691. A novel application of topical Rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex
  3692. Targeting notch pathway enhances Rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation
  3693. Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle
  3694. Mammalian target of Rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges
  3695. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of Rapamycin inhibitors
  3696. Grape polyphenols inhibit Akt/mammalian target of Rapamycin signaling and potentiate the effects of gefitinib in breast cancer
  3697. Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro
  3698. Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive Foxp3+ regulatory cells
  3699. Effect of dietary choline on growth, intestinal enzyme activities and relative expressions of target of Rapamycin and eIF4E-binding protein2 gene in muscle …
  3700. Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of Rapamycin (mTOR)-dependent inhibition of …
  3701. Role of mammalian target of Rapamycin in hypoxic or ischemic brain injury: potential neuroprotection and limitations
  3702. Spinal phosphinositide 3-Kinase–Akt–Mammalian target of Rapamycin signaling cascades in inflammation-induced hyperalgesia
  3703. Enteric-delivered Rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence
  3704. Mechanistic or mammalian target of Rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging
  3705. Intermittent supplementation with Rapamycin as a dietary restriction mimetic
  3706. Modularity and hormone sensitivity of the Drosophila melanogaster insulin receptor/target of Rapamycin interaction proteome
  3707. The histone H3 lysine 56 acetylation pathway is regulated by target of Rapamycin (TOR) signaling and functions directly in ribosomal RNA biogenesis
  3708. TOR: target of Rapamycin
  3709. Ksp1 kinase regulates autophagy via the target of Rapamycin complex 1 (TORC1) pathway
  3710. Multiple site acetylation of Rictor stimulates mammalian target of Rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein
  3711. Clinical outcomes in kidney transplant recipients receiving long‐term therapy with inhibitors of the mammalian target of Rapamycin
  3712. Rapamycin preconditioning attenuates transient focal cerebral ischemia/reperfusion injury in mice
  3713. … of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of Rapamycin complex 1 (mTORC1) …
  3714. Mammalian target of Rapamycin and head and neck squamous cell carcinoma
  3715. Rapamycin-insensitive mTORC1 activity controls eIF4E: 4E-BP1 binding
  3716. Mammalian target of Rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN
  3717. Rapamycin suppresses axon sprouting by somatostatin interneurons in a mouse model of temporal lobe epilepsy
  3718. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of Rapamycin signaling network in cancer stem cells
  3719. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of Rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase …
  3720. Mechanistic mammalian target of Rapamycin (mTOR) cell signaling: effects of select nutrients and secreted phosphoprotein 1 on development of mammalian …
  3721. The mTOR (mammalian target of Rapamycin) kinase maintains integrity of mTOR complex 2
  3722. Rapamycin-mediated mTOR inhibition attenuates survivin and sensitizes glioblastoma cells to radiation therapy
  3723. Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a Rapamycin analogue library
  3724. Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures
  3725. A retrospective review of oral low-dose sirolimus (Rapamycin) for the treatment of active uveitis
  3726. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by Rapamycin
  3727. Drosophila insulin and target of Rapamycin (TOR) pathways regulate GSK3 beta activity to control Myc stability and determine Myc expression in vivo
  3728. Rapamycin treatment inhibits CHO cell death in a serum‐free suspension culture by autophagy induction
  3729. Mammalian target of Rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing
  3730. Rapamycin Reverses Splenomegaly and Inhibits Tumor Development in a Transgenic Model of Epstein-Barr Virus–Related Burkitt’s Lymphoma
  3731. A combined approach of classical mutagenesis and rational metabolic engineering improves Rapamycin biosynthesis and provides insights into methylmalonyl-CoA …
  3732. The risk of skin rash and stomatitis with the mammalian target of Rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis
  3733. Rapamycin reduces oxidative stress in frataxin-deficient yeast cells
  3734. Advantage of Rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single‐center trial at 10 …
  3735. Phosphorylation of Raptor by p38β participates in arsenite-induced mammalian target of Rapamycin complex 1 (mTORC1) activation
  3736. Synergistic activity of Rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis
  3737. … and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK) 1/2, and mammalian target of Rapamycin complex 1 (mTORC1) …
  3738. LST8 regulates cell growth via target-of-Rapamycin complex 2 (TORC2)
  3739. The mammalian target of Rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases
  3740. Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells
  3741. Evaluation of sphingolipid metabolism in renal cortex of rats with streptozotocin-induced diabetes and the effects of Rapamycin
  3742. Dissecting mammalian target of Rapamycin to promote longevity
  3743. Rapamycin treatment augments both protein ubiquitination and Akt activation in pressure-overloaded rat myocardium
  3744. Impact of Rapamycin on peritoneal fibrosis and transport function
  3745. Predictive biomarkers for the activity of mammalian target of Rapamycin (mTOR) inhibitors
  3746. Rapamycin‐Induced Hypophosphatemia and Insulin Resistance Are Associated With mTORC2 Activation and Klotho Expression
  3747. Phospshoinositide 3-kinase (PI3K)/mammalian target of Rapamycin (mTOR) dual inhibitors: discovery and structure–activity relationships of a series of quinoline and …
  3748. Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of Rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition
  3749. Activation of mammalian target of Rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma
  3750. Dual inhibition of phosphatidylinositol 3‐kinase/Akt and mammalian target of Rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid …
  3751. S6 kinase 1 is required for Rapamycin-sensitive liver proliferation after mouse hepatectomy
  3752. Metabolic regulation, mitochondria and the life-prolonging effect of Rapamycin: a mini-review
  3753. Induction of melanogenesis by Rapamycin in human MNT-1 melanoma cells
  3754. Calcineurin inhibitor sparing regimens using m‐target of Rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
  3755. The mammalian target of Rapamycin pathway as a therapeutic target in multiple myeloma
  3756. … and its associated cell death by “sphingolipid rheostat”: reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of Rapamycin …
  3757. Rapamycin sensitive mTOR activation mediates nerve growth factor (NGF) induced cell migration and pro-survival effects against hydrogen peroxide in retinal pigment …
  3758. Regulation of the glutamate transporter EAAT3 by mammalian target of Rapamycin mTOR
  3759. Ubiquitin-specific peptidase 9, X-linked (USP9X) modulates activity of mammalian target of Rapamycin (mTOR)
  3760. The mammalian target of Rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in …
  3761. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex …
  3762. NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitors, enhance tumor and endothelial cell …
  3763. An elaborate regulation of Mammalian target of Rapamycin activity is required for somatic cell reprogramming induced by defined transcription factors
  3764. Rapamycin-induced posterior reversible encephalopathy in a kidney transplantation patient
  3765. Mammalian target of Rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma
  3766. … secretion via down-regulation of surface expression of adrenergic α2A receptor through the mTOR (mammalian target of Rapamycin) pathway: implication in …
  3767. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation
  3768. Beta cell function during Rapamycin monotherapy in long-term type 1 diabetes
  3769. Temporal regulation of Rapamycin on memory CTL programming by IL-12
  3770. Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and-9: an in vitro study
  3771. TGFβ‐and bleomycin‐induced extracellular matrix synthesis is mediated through Akt and mammalian target of Rapamycin (mTOR)
  3772. cAMP inhibits mammalian target of Rapamycin complex-1 and-2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity
  3773. Enhanced delivery of Rapamycin by V156K-apoA-I high-density lipoprotein inhibits cellular proatherogenic effects and senescence and promotes tissue regeneration
  3774. Interpreting mammalian target of Rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes
  3775. First report of a novel abluminal groove filled biodegradable polymer Rapamycin-eluting stent in de novo coronary artery disease: results of the first in man FIREHAWK …
  3776. Autophagy induced by Rapamycin and carbon‐starvation have distinct proteome profiles in Aspergillus nidulans
  3777. An emerging role for the mammalian target of Rapamycin in “pathological” protein translation: relevance to cocaine addiction
  3778. Rapamycin-cyclodextrin complexation: improved solubility and dissolution rate
  3779. inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of Rapamycin inhibitor NVP-BEZ235
  3780. Regulation of mammalian target of Rapamycin and mitogen activated protein kinase pathways by BCR–ABL
  3781. mTOR in podocyte function: is Rapamycin good for diabetic nephropathy?
  3782. Yin Yang 1 deficiency in skeletal muscle protects against Rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling
  3783. ULK1, mammalian target of Rapamycin, and mitochondria: linking nutrient availability and autophagy
  3784. Mammalian target of Rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells
  3785. Forced degradation studies of Rapamycin: Identification of autoxidation products
  3786. Inactivation of mammalian target of Rapamycin (mTOR) by Rapamycin in a murine model of lipopolysaccharide-induced acute lung injury
  3787. Pharmacological targeting of mammalian target of Rapamycin inhibits ovarian granulosa cell tumor growth
  3788. Innovations therapy: mammalian target of Rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
  3789. Nitrogen-responsive regulation of GATA protein family activators Gln3 and Gat1 occurs by two distinct pathways, one inhibited by Rapamycin and the other by …
  3790. Myopathy caused by mammalian target of Rapamycin complex 1 (mTORC1) inactivation is not reversed by restoring mitochondrial function
  3791. Remarkable inhibition of mTOR signaling by the combination of Rapamycin and 1, 4‐phenylenebis (methylene) selenocyanate in human prostate cancer cells
  3792. Regulatory T cells expanded by Rapamycin in vitro suppress colitis in an experimental mouse model
  3793. Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or Rapamycin enhances the antitumor growth effect in neuroblastoma
  3794. Localized ultrasound enhances delivery of Rapamycin from microbubbles to prevent smooth muscle proliferation
  3795. inhibition of Akt (ser473) phosphorylation and Rapamycin-resistant cell growth by knockdown of mammalian target of Rapamycin with small interfering RNA in vascular …
Related Posts

Cryolipolysis: Freezing Fat To Death

Benefits of FASTING & CANCER

Non Opiod Analgesics

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping